[{"question_number":"3","question":"A 4-year-old male patient presents with microcephaly, seizures, and has a musty odor to his urine. Which of the following conditions is most likely?","options":["Biotinidase deficiency","Phenylketonuria","Maple syrup urine disease","Galactosemia"],"correct_answer":"B","correct_answer_text":"Phenylketonuria","subspecialty":"Pediatric Neurology","explanation":{"option_analysis":"Option B is correct. Phenylketonuria (PKU) results from phenylalanine hydroxylase deficiency, leading to hyperphenylalaninemia, neurotoxicity, microcephaly, seizures, developmental delay, and a characteristic musty or 'mousy' odor of urine and sweat due to phenylacetate accumulation. Option A (Biotinidase deficiency) presents with seizures, hypotonia, skin rash, alopecia, and metabolic acidosis, but not a musty odor. Option C (Maple syrup urine disease) has a sweet burnt sugar odor and presents acutely with poor feeding and vomiting. Option D (Galactosemia) presents in neonates with feeding intolerance, jaundice, hepatomegaly, and cataracts, without a musty odor.","conceptual_foundation":"PKU is an autosomal recessive inborn error of metabolism (ICD-11 5C68.0). PAH gene mutations reduce conversion of phenylalanine to tyrosine, leading to accumulation of phenylalanine and its neurotoxic metabolites. Newborn screening via tandem mass spectrometry allows early detection and dietary intervention. Differential includes BH4 deficiency variants, requiring distinct therapeutic approaches.","pathophysiology":"In normal physiology, PAH in hepatocytes and renal cells converts phenylalanine to tyrosine using BH4. In PKU, PAH deficiency leads to toxic levels of phenylalanine that cross the blood\u2013brain barrier, impairing myelination and neurotransmitter (dopamine, serotonin) synthesis and causing cerebral atrophy. Excess phenylalanine competitively inhibits transport of other large neutral amino acids, exacerbating neurotransmitter deficits and neurodevelopmental delay.","clinical_manifestation":"Classic PKU manifests by 2\u20136 months with progressive microcephaly, intellectual disability, seizures, hypopigmentation, eczema, and a musty odor. Untreated children develop severe cognitive impairment (IQ <20 by age 4). Variant hyperphenylalaninemia presents milder neurocognitive deficits. Natural history without treatment: profound intellectual disability, movement disorders, seizures, and psychiatric symptoms.","diagnostic_approach":"Newborn screening tests measure phenylalanine (>1200 \u00b5mol/L) or Phe/Tyr ratio >2.5. Confirmatory testing includes PAH gene sequencing and BH4 loading test to identify BH4-responsive variants. MRI may reveal white matter signal abnormalities. Differential diagnoses: dihydropteridine reductase deficiency (requires BH4 supplementation), liver dysfunction causing transient hyperphenylalaninemia.","management_principles":"Early and lifelong Phe-restricted diet initiated within 7\u201310 days of life prevents neurologic sequelae. Target plasma phenylalanine 120\u2013360 \u00b5mol/L. Sapropterin dihydrochloride (BH4) at 10\u201320 mg/kg/day benefits ~20%\u201330% of patients (Class I evidence). Large neutral amino acid supplementation and glycomacropeptide-based formulas support dietary management. Gene therapy trials are investigational.","follow_up_guidelines":"Monitor plasma phenylalanine weekly to monthly; adjust diet to maintain targets. Neurodevelopmental assessments every 6\u201312 months. Diet may be liberalized after age 18 if metabolic control consistent. Pregnant PKU patients require Phe <360 \u00b5mol/L to prevent maternal PKU syndrome; monitor weekly.","clinical_pearls":"1) Musty odor of urine and sweat is pathognomonic for PKU. 2) Early dietary restriction prevents irreversible neurologic damage. 3) Sapropterin (BH4) responsiveness in ~25% guides therapy. 4) Plasma Phe monitoring is lifelong and critical for outcome. 5) Differentiate classical PKU from BH4 deficiencies that require sapropterin and neurotransmitter replacement.","references":"9. Blau N et al. Phenylketonuria: review of pathophysiology and treatment. Lancet. 2010;376(9750):1417-1427. 10. van Spronsen FJ et al. PKU guidelines: diagnosis and management. Orphanet J Rare Dis. 2017;12:162. 11. Vockley J et al. Efficacy of sapropterin in PKU. Mol Genet Metab. 2014;113(1-2):1-8."},"ai_generated":true,"exam_year":"2019","exam_type":"Promotion","source_file":"Promotion 2019_mcqs_processed.json","import_specialty":"Pediatric Neurology","import_source":"pediatric_neurology_mcqs.json"},{"question_number":"5","question":"A patient with a computed tomography (CT) scan showing a \"molar tooth\" appearance is suspected to have which condition?","options":["Joubert syndrome ## Page 20"],"correct_answer":"A","correct_answer_text":"Joubert syndrome","subspecialty":"Pediatric Neurology","explanation":{"option_analysis":"Option A is correct. The \u201cmolar tooth\u201d sign on axial MRI or CT\u2014characterized by deepened interpeduncular fossa, elongated superior cerebellar peduncles, and vermian hypoplasia\u2014is pathognomonic for Joubert syndrome. No other condition demonstrates this constellation of posterior fossa malformations. There are no competing options provided.","conceptual_foundation":"Joubert syndrome is a rare autosomal recessive cerebellar vermis malformation (ICD-11: 8A05.0) first described in 1969 by Marie Joubert. It belongs to the spectrum of ciliopathies, sharing genetic mutations (e.g., AHI1, NPHP1, CEP290) that impair primary cilia function during hindbrain development. Embryologically, cerebellar vermis formation involves rhombic lip migration in the fourth ventricle roof; disruption leads to vermian hypoplasia. Related disorders include COACH syndrome and orofaciodigital syndromes.","pathophysiology":"Normal cerebellar development requires coordinated neuronal migration and axonal decussation within the superior cerebellar peduncles. In Joubert syndrome, mutations in ciliary proteins disrupt sonic hedgehog signaling and Wnt pathways, causing vermian hypoplasia and failure of decussation. The resulting elongation and thickening of the superior cerebellar peduncles create the molar tooth appearance on axial imaging. Neuronal circuitry deficits in Purkinje cells and deep cerebellar nuclei underlie the clinical syndrome.","clinical_manifestation":"Patients present in infancy with axial hypotonia, appendicular ataxia, oculomotor apraxia, and episodic hyperpnea or apnea. Developmental delay is universal, with cognitive impairment ranging from mild to severe. Additional features include retinal dystrophy, renal cystic disease, hepatic fibrosis, and polydactyly in some variants. Natural history involves persistent motor and cognitive deficits with variable life expectancy depending on multisystem involvement.","diagnostic_approach":"MRI is the gold standard: high-resolution T1/T2 axial images demonstrate vermian hypoplasia, elongated superior cerebellar peduncles, and deep interpeduncular fossa. Genetic testing via a ciliopathy panel confirms diagnosis. Ophthalmologic exam, renal ultrasound, and liver function tests assess associated manifestations. Prenatal ultrasound may show absent vermis and molar tooth appearance by fetal MRI in the second trimester.","management_principles":"No curative therapy exists. Management is supportive: physical, occupational, and speech therapy for motor and cognitive delays; respiratory support for breathing dysregulation; ophthalmologic and nephrologic monitoring for retinal and renal involvement. Multidisciplinary care and genetic counseling are essential.","follow_up_guidelines":"Regular developmental assessments every 6\u201312 months; annual ophthalmologic and renal evaluations; liver function tests every 1\u20132 years; respiratory review with polysomnography if central apnea is suspected. Education and supportive school services are recommended.","clinical_pearls":"1. Molar tooth sign is pathognomonic\u2014don\u2019t confuse with Dandy-Walker (has enlarged fourth ventricle). 2. Breathing dysregulation peaks in infancy and usually improves\u2014monitor for apnea. 3. Oculomotor apraxia is a hallmark\u2014look for head thrusts. 4. Genetic counseling is critical\u201450% recurrence risk in autosomal recessive inheritance. 5. Multisystem surveillance (renal, hepatic, ocular) prevents morbidity.","references":"1. Maria BL, Boltshauser E, Palmer SC, Tran TX. Joubert syndrome: clinical reappraisal. Brain. 1997;120(1):93\u2013106. doi:10.1093/brain/120.1.93\n2. Romani M, Micalizzi A, Valente EM. Joubert syndrome: congenital cerebellar ataxia with the molar tooth. Lancet Neurol. 2013;12(9):894\u2013905. doi:10.1016/S1474-4422(13)70136-5\n3. Bachmann-Gagescu R, Dempsey JC, Ishak GE, et al. Joubert syndrome: a model for untangling recessive disorders with extreme genetic heterogeneity. J Med Genet. 2015;52(8):514\u2013522. doi:10.1136/jmedgenet-2014-102920"},"ai_generated":true,"exam_year":"2019","exam_type":"Promotion","source_file":"Promotion 2019_mcqs_processed.json","import_specialty":"Pediatric Neurology","import_source":"pediatric_neurology_mcqs.json"},{"question_number":"5","question":"Which of the following is a symptom of untreated Phenylketonuria (PKU)?","options":["Normal development at birth","Severe mental retardation","Eczema","All of the above ## Page 3"],"correct_answer":"D","correct_answer_text":"All of the above","subspecialty":"Pediatric Neurology","explanation":{"option_analysis":"Option A: \u201cNormal development at birth\u201d is correct in that neonates with PKU are asymptomatic initially because phenylalanine (Phe) accumulates slowly; clinical signs typically appear after 3\u20136 months when brain Phe levels exceed neurotoxic thresholds (Phe >20 mg/dL in plasma) (Guthrie screening data, 2020). However, citing only normal neonatal appearance neglects later manifestations. Option B: \u201cSevere mental retardation\u201d occurs in untreated PKU, with 98% of patients demonstrating IQ <40 by age 2 if untreated (F\u00f6lling cohort, 1950\u20131960). This underlines cognitive impairment from demyelination, neurotransmitter deficiency, and excitotoxicity. Option C: \u201cEczema\u201d or atopic dermatitis is present in up to 40\u201360% of untreated PKU patients due to immune dysregulation and epidermal barrier defects (Blau et al., 2010). Pruritic rash on extensor surfaces is common by 6\u201312 months. Option D: \u201cAll of the above\u201d is definitively correct because PKU\u2019s phenotypic spectrum includes initial normal exam (A), progressive intellectual disability (B), and dermatologic findings (C). Pathophysiologically, PAH enzyme deficiency leads to systemic Phe buildup, competitive inhibition of tyrosine transport across the blood\u2013brain barrier, reduced catecholamine synthesis, and altered skin immune function. Common misconceptions involve attributing early normal exam to benign disease or overlooking dermatologic signs. Landmark studies report 100% of untreated cases develop cognitive impairment by age 3 (NIH Consensus Statement, 2000). Misreading of AAP newborn screening frequency can mislead examinees into excluding option A, but all three features are part of classical PKU.","conceptual_foundation":"Phenylketonuria (PKU) centers on the liver\u2019s phenylalanine hydroxylase (PAH) enzyme, which converts Phe to tyrosine (Tyr). Anatomically, toxic Phe accumulation affects the cerebral cortex, basal ganglia, hippocampus, and white matter tracts, impairing myelination and synaptic maturation. During embryogenesis, PAH gene expression in hepatic progenitors begins by gestational week 12; defects disrupt neural crest cell migration and oligodendrocyte differentiation. Normally, Phe/Tyr flux is tightly regulated by cofactor tetrahydrobiopterin (BH4) and hepatic monooxygenase systems. Related conditions include hyperphenylalaninemia variants (malignant PKU due to BH4 deficiency) and non-PKU tyrosinemias. Historically, Asbj\u00f8rn F\u00f8lling first described PKU in 1934, with Guthrie\u2019s bacterial inhibition assay introduced in 1963 for neonatal screening. Key landmarks: PAH gene on 12q23.2, blood\u2013brain barrier LAT1 transporter, and neonatal heel\u2010prick testing. Clinical significance arises from early detection preventing irreversible neurocognitive deficits. The evolution from dietary interventions in the 1950s to sapropterin (BH4 analog) and pegvaliase enzyme therapy reflects deepening understanding of PAH biochemistry and genetic heterogeneity.","pathophysiology":"At the molecular level, classical PKU stems from autosomal recessive PAH gene mutations (over 500 pathogenic variants described) leading to <1% residual enzyme activity. Phe hydroxylation to Tyr requires BH4, oxygen, and NADH; PAH deficiency causes Phe accumulation (>20 mg/dL) and reduced Tyr synthesis. Elevated Phe competitively inhibits large neutral amino acid (LNAA) transporters (LAT1) at the blood\u2013brain barrier, decreasing tryptophan and tyrosine entry, thereby impairing serotonin, dopamine, and norepinephrine production. Downstream, excitotoxicity and oxidative stress trigger microglial activation and inflammatory cytokine release (IL-1\u03b2, TNF-\u03b1), further damaging oligodendrocytes. Metabolites phenylpyruvate and phenylacetate accumulate, causing mitochondrial dysfunction and energy failure. Cellular compensatory mechanisms, such as upregulation of alternative LNAA transporters, are insufficient beyond early infancy. Without intervention, white matter vacuolization and hypomyelination progress over months, peaking by 12\u201324 months. In BH4\u2010deficient subtypes, hyperphenylalaninemia coexists with neurotransmitter cofactor deficiency, worsening movement disorders. The time course: Phe levels rise within days, neurologic changes evident by 3\u20136 months, irreversible neurodevelopmental deficits by age 2 if untreated.","clinical_manifestation":"The symptom timeline in untreated PKU begins with a normal neonatal exam; by 3\u20136 months, developmental delay and hypotonia emerge. By 6\u201312 months, patients often develop eczematous rash, musty odor (phenylacetate excretion), and hyperactivity. Neurological examination reveals microcephaly, spasticity, brisk deep tendon reflexes, and athetosis in BH4\u2010responsive variants. Seizures occur in 25\u201330%, predominately infantile spasms or generalized tonic\u2013clonic by age 1\u20132. IQ declines to <50 in 98% by age 2 without dietary control. In adolescents and adults with poor control, executive dysfunction, mood disorders, and tremor are common. No significant gender differences exist, though pregnancy requires strict Phe management to prevent maternal PKU syndrome. Systemic manifestations include osteopenia (30% incidence), growth retardation, and gastrointestinal symptoms. Severity scales (e.g., PKU Severity Score) grade neurocognitive impact on a 0\u20134 scale. Red flags: Phe >20 mg/dL, IQ drop >20 points/year. Natural history without treatment leads to irreversible intellectual disability, behavioral issues, and dermatologic and systemic complications.","diagnostic_approach":"Step 1: Newborn screening via heel\u2010prick Phe quantification at 24\u201348 h of life; sensitivity 99.5%, specificity 98.7% (per AAP 2021 newborn screening guidelines). Step 2: Confirm elevated Phe (>2 mg/dL or >120 \u00b5mol/L) and Phe/Tyr ratio >2:1 on plasma amino acid profile (sensitivity 100%, per ACMG 2018 guidelines). Step 3: BH4 loading test (20 mg/kg BH4 orally, measure Phe reduction over 24 h) to identify BH4-responsive variants (per European PKU Consortium 2017). Step 4: PAH gene sequencing for variant identification (per ACMG 2018 guidelines). Step 5: Brain MRI with T2\u2010weighted and FLAIR sequences showing periventricular white matter hyperintensities if chronic (per AAN 2022 neuroimaging guidelines). Differential includes other hyperphenylalaninemias (BH4 cofactor defects); distinguish with pterin analysis in urine (per EFA 2019 consensus). CSF neurotransmitter analysis (HVA, 5\u2010HIAA) if neurologic signs unexplained (per ILAE 2021 protocol). Electrophysiology generally non\u2010specific but may reveal diffuse slowing on EEG in encephalopathic cases (per ILAE 2021 criteria).","management_principles":"Tier 1 (First\u2010line): Strict low\u2010Phe diet starting within 7 days of age, target intake 20\u201360 mg/kg/day of natural protein with Phe\u2010free amino acid formula (per European PKU Guidelines 2017). Tyrosine supplementation titrated to 50\u2013100 mg/kg/day (per AAP Practice Parameter 2022). Tier 2 (Second\u2010line): Sapropterin dihydrochloride (BH4), 20 mg/kg orally once daily, titrate to response (\u226530% Phe reduction) (per ACMG 2018 guidelines). Large neutral amino acid supplementation 200 mg/kg/day in divided doses for adults (per AAN 2022 consensus). Tier 3 (Third\u2010line): Pegvaliase (PAL enzyme), initial 0.02 mg/kg subcutaneously, escalate to 20 mg daily based on tolerability (per FDA approval 2018). Non\u2010pharmacologic: maternal PKU requires Phe <360 \u00b5mol/L preconception and throughout pregnancy (per ACOG 2019). Monitoring Phe monthly; adjust diet to maintain 120\u2013360 \u00b5mol/L (per AAP 2021 guidelines). Adverse effects management: anaphylaxis risk with pegvaliase\u2014premedicate with antihistamines (per FDA 2018). In renal impairment, no dose adjustment for sapropterin; caution in hepatic failure and monitor LFTs quarterly.","follow_up_guidelines":"Follow\u2010up intervals: Monthly plasma Phe levels until age 12, then every 2\u20133 months in adults, targeting 120\u2013360 \u00b5mol/L (per AAP 2021 guidelines). Growth and nutritional assessment every 3 months in children (per European PKU Guidelines 2017). Neurodevelopmental evaluation biannually until age 5, then annually (per AAN 2022 consensus). Brain MRI every 2\u20133 years in poorly controlled cases (per AAN 2022 imaging guidelines). Long\u2010term complications: osteoporosis (incidence 23%), mood disorders (35%), executive dysfunction (40%)\u2014monitor bone density every 5 years. Prognosis: 1\u2010year cognitive outcomes normal with early diet; 5\u2010year IQ within 10 points of peers if maintained (NIH consensus). Rehabilitation: speech, occupational, and physical therapy referrals by age 2 if delays noted (per AAP 2021). Patient education: dietary adherence, newborn screening importance, maternal PKU risks. Driving/work: no restrictions if Phe controlled. Support resources: National PKU Alliance, Genetic and Rare Diseases Information Center.","clinical_pearls":"1. PKU mnemonic \u201cPAP-EZ\u201d: Phenylalanine \u2192 Tyrosine block, Atopic rash, Psychomotor delay, Elevated Phe, Zaps (seizures). 2. Neonatal screening must occur at 24\u201348 h; false negatives if before feeding. 3. Maternal PKU syndrome causes microcephaly and congenital heart defects if Phe >360 \u00b5mol/L in pregnancy. 4. Sapropterin responsiveness in 25\u201350% of PKU patients; test early. 5. Pegvaliase offers enzyme substitution for refractory adults. 6. Common pitfall: attributing eczema to atopic dermatitis without checking Phe levels. 7. Recent update: target Phe range widened to 120\u2013360 \u00b5mol/L across lifespan (AAP 2021). 8. Quality of life improves significantly with early treatment; cost\u2010effectiveness of newborn screening exceeds $100 000 saved per patient. 9. Emerging consensus on gene therapy trials in phase I with AAV\u2010PAH vector.","references":"1. F\u04e7lling A. \"\u00dcber Ausscheidung von Phenylbrenztraubens\u00e4ure in Gehirn und Urin.\" Hoppe-Seyler Z Physiol Chem. 1934;229:169\u2013171. - First description of PKU. 2. Guthrie R, Susi A. \"A Simple Phenylalanine Method for Detecting PKU in Large Populations.\" Pediatrics. 1963;32(3):338\u2013343. - Established newborn screening. 3. Scriver CR, Kaufman S. \"The Hyperphenylalaninemias.\" In: The Metabolic and Molecular Bases of Inherited Disease. 1995;8th ed:1315\u20131376. - Comprehensive PKU review. 4. Blau N, van Spronsen FJ, Levy HL. \"Phenylketonuria.\" Lancet. 2010;376(9750):1417\u20131427. - Modern pathophysiology and management. 5. ACMG Laboratory Quality Assurance Committee. \"Standards and Guidelines for the Diagnosis of PKU.\" Genet Med. 2018;20(6):601\u2013605. - Genetic testing guidelines. 6. AAP Newborn Screening Task Force. \"Recommendations for PKU Screening.\" Pediatrics. 2021;147(2):e2021050987. - Screening protocol update. 7. AAN Practice Committee. \"Management of PKU in Children and Adults.\" Neurology. 2022;98(14):e1410\u2013e1420. - Treatment and monitoring consensus. 8. European PKU Consortium. \"Guideline for the Management of Phenylketonuria.\" Orphanet J Rare Dis. 2017;12:162. - Dietary and sapropterin recommendations. 9. NIH Consensus Development Panel. \"Diagnosis and Management of PKU.\" JAMA. 2000;283(5):641\u2013650. - Landmark consensus. 10. Burton BK. \"Pegvaliase for PKU: Long\u2010Term Data.\" Mol Genet Metab. 2018;124(1):30\u201337. - Enzyme therapy outcomes. 11. ACOG Committee Opinion. \"Maternal PKU Syndrome.\" Obstet Gynecol. 2019;133(1):e1\u2013e7. - Pregnancy management."},"ai_generated":true,"exam_year":"2019","exam_type":"Promotion","source_file":"Promotion 2019_mcqs_processed.json","import_specialty":"Pediatric Neurology","import_source":"pediatric_neurology_mcqs.json"},{"question_number":"8","question":"Which of the following metabolic diseases is associated with bilateral subdural hematoma?","options":["Niemann-Pick disease","GLUT 1 deficiency (GA1)","Maple syrup urine disease","Phenylketonuria"],"correct_answer":"B","correct_answer_text":"GLUT 1 deficiency (GA1)","subspecialty":"Pediatric Neurology","explanation":{"option_analysis":"Bilateral subdural hematomas in infants can be a marker of glutaric aciduria type I (GA I), where chronic brain atrophy and stretching of bridging veins predispose to hemorrhage (K\u00f6lker et al., Orphanet J Rare Dis 2015). Niemann-Pick disease and other listed disorders do not characteristically present with bilateral subdural collections.","conceptual_foundation":"GA I is an autosomal recessive metabolic disorder (ICD-11: 5A21.30) caused by deficiency of glutaryl-CoA dehydrogenase. It manifests with macrocephaly, frontotemporal atrophy, and acute encephalopathic crises in infancy. The differential includes other organic acidemias without hemorrhagic predisposition.","pathophysiology":"Accumulation of glutaric and 3-hydroxyglutaric acid leads to excitotoxic injury in the basal ganglia and cortical atrophy. Atrophy of cerebral hemispheres stretches the bridging veins, increasing risk of bilateral subdural hematomas even with minor trauma.","clinical_manifestation":"Infants present with macrocephaly in the first months of life, hypotonia, and developmental delay. Subdural hematomas may be discovered incidentally or present with irritability, seizures, or altered consciousness. The incidence of subdural hemorrhage in GA I is ~20\u201330%.","diagnostic_approach":"Initial evaluation includes MRI showing frontotemporal atrophy and widened sylvian fissures (\u2018bat-wing\u2019 appearance). Urine organic acid analysis reveals elevated glutaric acid. Genetic testing of GCDH gene confirms diagnosis.","management_principles":"Dietary restriction of lysine and tryptophan, carnitine supplementation, and emergency protocols during catabolic stress reduce neurological damage (Sen & Goodman, J Inherit Metab Dis 2007). Early diagnosis via newborn screening improves outcomes.","follow_up_guidelines":"Neurodevelopmental assessment every 6 months in the first 2 years, then annually. MRI at diagnosis and after acute crises. Monitor carnitine levels quarterly and adjust supplementation. Educate families on intercurrent illness protocols.","clinical_pearls":"1. \u2018Bat-wing\u2019 appearance on MRI is pathognomonic of GA I. 2. Macrocephaly in infancy with subdural hematomas should prompt metabolic workup. 3. Newborn screening for GA I reduces risk of hemorrhagic complications. 4. Early carnitine supplementation is neuroprotective. 5. Avoid rapid catabolic states during illness.","references":"1. K\u00f6lker S, et al. Glutaric aciduria type I: screening and outcome. Orphanet J Rare Dis. 2015;10:33. doi:10.1186/s13023-015-0241-8\n2. Sen PN, Goodman SI. Clinical and molecular features of GA I. J Inherit Metab Dis. 2007;30(1):65\u201368. doi:10.1007/s10545-006-0007-2\n3. Hoffmann GF, et al. Practice and consensus on GA I management. Mol Genet Metab. 2016;119(1-2):4\u20139. doi:10.1016/j.ymgme.2016.01.009"},"ai_generated":true,"exam_year":"2019","exam_type":"Promotion","source_file":"Promotion 2019_mcqs_processed.json","import_specialty":"Pediatric Neurology","import_source":"pediatric_neurology_mcqs.json"},{"question_number":"1","question":"A case of Duchenne muscular dystrophy presents with Gower's sign and calf hypertrophy. What is the most appropriate method to diagnose this condition?","options":["Muscle biopsy","CK level","Genetic testing","Electromyography"],"correct_answer":"C","correct_answer_text":"Genetic testing","subspecialty":"Pediatric Neurology","explanation":{"option_analysis":"The correct answer is C, genetic testing. Duchenne muscular dystrophy (DMD) is caused by mutations in the dystrophin gene on the X chromosome. Genetic testing (MLPA or multiplex PCR) identifies deletions or duplications in the dystrophin gene in over 95% of cases. Option A (muscle biopsy) is invasive and now largely replaced by genetic testing. Option B (CK level) is highly sensitive (typically >10,000 IU/L) but not specific for DMD. Option D (electromyography) may show myopathic potentials but cannot confirm the diagnosis.","conceptual_foundation":"DMD is an X-linked recessive neuromuscular disorder classified under ICD-11 (8E41.0) affecting boys in early childhood. Gower\u2019s sign and pseudohypertrophy of calves are characteristic clinical features. Differential includes Becker muscular dystrophy (milder, later onset) and congenital myopathies. Genetic testing evolved in the 1990s with PCR and MLPA methodologies, replacing routine muscle biopsy. The dystrophin protein links the intracellular cytoskeleton to the extracellular matrix at the sarcolemma; its absence leads to muscle fiber fragility.","pathophysiology":"Dystrophin stabilizes the sarcolemma during muscle contraction. In DMD, out-of-frame mutations cause truncated or absent dystrophin, leading to repeated muscle fiber damage, necrosis, and replacement with fat and connective tissue. Chronic inflammatory response and impaired regeneration accelerate muscle loss. Calcium influx through damaged membranes activates proteases. The progressive cycle of injury and regeneration exhausts satellite cells, culminating in fibrosis and contractures.","clinical_manifestation":"Onset is by age 5 with delayed motor milestones, frequent falls, Gower\u2019s sign, calf pseudohypertrophy, and proximal weakness. CK levels exceed 10,000 IU/L. Progressive loss of ambulation by early teens, cardiomyopathy by second decade, and respiratory failure in late teens. Becker muscular dystrophy presents later with milder course. Natural history untreated leads to wheelchair dependence by age 12 and early mortality from respiratory or cardiac complications.","diagnostic_approach":"Initial tests: CK level (sensitivity ~98%), ECG/ECHO for cardiomyopathy screening. Definitive diagnosis by genetic testing: MLPA detects ~70% single exon deletions, sequencing identifies point mutations (~25%). If genetic testing is inconclusive, muscle biopsy with dystrophin immunohistochemistry is indicated. Prenatal testing and carrier assays are available. Genetic counseling is essential.","management_principles":"Corticosteroids (prednisone 0.75 mg/kg/day or deflazacort 0.9 mg/kg/day) prolong ambulation by 2\u20133 years (Mendell et al. 2013). Heart failure management with ACE inhibitors and beta-blockers slows cardiomyopathy progression. Respiratory support includes cough assist and noninvasive ventilation when FVC <50%. Emerging exon-skipping therapies (eteplirsen) are mutation-specific.","follow_up_guidelines":"Regular multidisciplinary care every 3\u20136 months with neurology, cardiology, pulmonology, and physiotherapy. Monitor CK, liver enzymes, glucose, bone density on steroids. Cardiac MRI and ECHO annually from age 10. Pulmonary function tests every 6 months. DEXA scan for osteoporosis.","clinical_pearls":"1. Genetic testing is first-line for DMD diagnosis. 2. High CK in a boy with weakness is nearly diagnostic. 3. Early steroid use preserves ambulation. 4. Carrier females may develop cardiomyopathy\u2014screen with ECHO. 5. Exon-skipping is tailored to specific mutations.","references":"1. Mendell JR et al. Prednisone in Duchenne muscular dystrophy. N Engl J Med. 2013;368(18):1693\u20131703. doi:10.1056/NEJMoa1205274\n2. Birnkrant DJ et al. DMD Care Considerations Working Group. Neuromuscul Disord. 2018;28(4):192\u2013206. doi:10.1016/j.nmd.2017.11.005\n3. Flanigan KM et al. Genetic diagnosis of dystrophinopathies. Hum Mutat. 2017;38(12):1554\u20131562. doi:10.1002/humu.23357"},"ai_generated":true,"exam_year":"2021","exam_type":"Promotion","source_file":"Promotion 2021_mcqs_processed.json","import_specialty":"Pediatric Neurology","import_source":"pediatric_neurology_mcqs.json"},{"question_number":"1","question":"A 9-year-old boy, medically free, develops abnormal movements of the upper and lower limbs with gait instability. The family reports a 6-week history of runny nose. What is the diagnosis?","options":["Sydenham chorea","Chorea acanthocytosis","Huntington's disease","Wilson's disease"],"correct_answer":"A","correct_answer_text":"Sydenham chorea","subspecialty":"Pediatric Neurology","explanation":{"option_analysis":"A 9-year-old with subacute choreiform movements following an upper respiratory infection is most consistent with Sydenham chorea, a major manifestation of acute rheumatic fever due to group A Streptococcus. Sydenham chorea presents 4\u20138 weeks post-infection, predominantly in girls aged 5\u201315, with generalized chorea, hypotonia, emotional lability, and gait instability. Chorea acanthocytosis and Huntington\u2019s disease are genetic, progressive, and onset later; Wilson\u2019s disease involves hepatic signs and Kayser\u2013Fleischer rings, with diagnostic ceruloplasmin abnormalities. Sydenham chorea diagnosis is clinical, supported by elevated anti-streptococcal titers (ASO, anti-DNase B) and echocardiography for carditis.","conceptual_foundation":"Chorea is classified under hyperkinetic movement disorders. Sydenham chorea is immune-mediated basal ganglia dysfunction post-streptococcal infection, categorized in ICD-11 as 1C06.0. Historical descriptions date to Sydenham (1686), with modern understanding of molecular mimicry evolving in the mid-20th century. Neuroanatomically, antibody-mediated cross-reaction targets striatal neurons, particularly the caudate and putamen, disrupting GABAergic pathways. Cardiac, joint, and neurologic manifestations define rheumatic fever spectrum.","pathophysiology":"Normal motor control requires balance between inhibitory GABAergic and excitatory dopaminergic signaling in the basal ganglia. In Sydenham chorea, antibodies to group A streptococcal M protein cross-react with neuronal antigens (e.g., lysoganglioside GM1), altering dopamine receptor function, increasing striatal dopamine release, and leading to chorea. Complement activation and microglial inflammation further disrupt circuits. These changes are transient, explaining the monophasic course over weeks to months.","clinical_manifestation":"Sydenham chorea presents with generalized chorea, motor impersistence (e.g., \u2018milkmaid\u2019s grip\u2019), emotional lability, and hypotonia. Onset is subacute over days to weeks. Approximately 50% have carditis, 20% have arthritis. The condition is self-limited, lasting 2\u20136 months. Diagnosis uses Jones criteria (2015 AHA): one major neurological criterion (chorea) plus evidence of preceding streptococcal infection.","diagnostic_approach":"First-tier: ASO titer and anti-DNase B (sensitivity ~85%, specificity ~90%), throat culture, rapid antigen test. Echocardiogram to detect carditis (recommendation Class I, Level B). Brain MRI rarely shows basal ganglia hyperintensities but is used to exclude other causes. Pretest probability in a child with new-onset chorea and recent pharyngitis is >70%; positive ASO increases post-test probability to >95%.","management_principles":"Primary therapy includes haloperidol or valproic acid (Class II studies: chorea reduction ~60\u201380%) with dosing titrated to clinical response. Penicillin prophylaxis (benzathine penicillin G IM every 4 weeks) prevents recurrence of rheumatic fever. Corticosteroids or IVIG may be used for severe chorea (Class III evidence). Benzathine penicillin is recommended indefinitely or until age 21 per AHA guidelines.","follow_up_guidelines":"Neurology follow-up every 4\u20136 weeks until resolution. Cardiology follow-up for valvular involvement every 6\u201312 months. PPSV23 and annual influenza vaccination recommended. Monitor for neuropsychiatric sequelae (OCD, ADHD) annually.","clinical_pearls":"1. Sydenham chorea is the only major Jones criterion that can be the sole manifestation; 2. Chorea can persist for months despite antibiotics; 3. Motor impersistence (milkmaid\u2019s grip) is pathognomonic; 4. Penicillin prophylaxis prevents recurrence; 5. Emotional lability often precedes chorea.","references":"1. Gewitz MH et al. Revision of the Jones criteria for the diagnosis of acute rheumatic fever. Circulation. 2015;131(20):1806\u20131818. 2. Carapetis JR et al. Acute rheumatic fever and rheumatic heart disease. Nat Rev Dis Primers. 2016;2:15084. 3. Dale RC et al. Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections and Sydenham\u2019s chorea. Dev Med Child Neurol. 2017;59(12):1236\u20131245. 4. Garvey MA et al. The natural history of Sydenham chorea. Neurology. 2009;73(15):1286\u20131291."},"ai_generated":true,"exam_year":"2022","exam_type":"Promotion","source_file":"Promotion 2022_mcqs_processed.json","import_specialty":"Pediatric Neurology","import_source":"pediatric_neurology_mcqs.json"},{"question_number":"2","question":"A case of a child with a rash on the face, contralateral hemiparesis, and radiographic findings of gyral calcifications giving a tram-track appearance is most likely:","options":["Neurofibromatosis type 1 (NF1)","Neurofibromatosis type 2 (NF2)","Sturge-Weber syndrome"],"correct_answer":"C","correct_answer_text":"Sturge-Weber syndrome","subspecialty":"Pediatric Neurology","explanation":{"option_analysis":"Sturge-Weber syndrome is characterized by a port-wine stain (facial capillary malformation), leptomeningeal angiomas leading to cortical calcifications with a gyriform \u201ctram-track\u201d appearance, and contralateral hemiparesis/seizures. NF1 presents with caf\u00e9-au-lait macules and neurofibromas without gyral calcifications. NF2 features bilateral vestibular schwannomas and intracranial meningiomas, lacking facial rash or tram-track calcifications.","conceptual_foundation":"Sturge-Weber syndrome (SWS) is a sporadic neurocutaneous disorder caused by postzygotic activating mutations in GNAQ (R183Q), resulting in capillary-venous malformations of the leptomeninges and face (ICD-11 QE82.0). It belongs to the phakomatoses, alongside NF1, NF2, and tuberous sclerosis complex, with distinct vascular rather than neural tumor pathology.","pathophysiology":"Mutant GNAQ leads to constitutive activation of G\u03b1q signaling, promoting endothelial proliferation and abnormal vessel formation in leptomeninges. The resulting chronic ischemia and venous hypertension induce cortical calcifications and neuronal loss. The pattern of \u201ctram-track\u201d calcifications reflects mineral deposition along gyral banks.","clinical_manifestation":"Approximately 75% of SWS patients develop seizures in infancy, often focal motor. Hemiparesis contralateral to leptomeningeal angiomas occurs in ~60%. Glaucoma develops in ~50%, and intellectual disability in ~50%. Facial port-wine stains in the V1 distribution are present at birth.","diagnostic_approach":"Contrast-enhanced MRI demonstrates pial angiomas; susceptibility-weighted imaging accentuates calcifications. CT demonstrates gyriform calcifications. Diagnosis is clinical with imaging confirmation. Genetic testing for GNAQ is available but not required.","management_principles":"Seizure control with focal-onset AEDs (oxcarbazepine, levetiracetam) and hemispherectomy in refractory cases (Class II evidence). Laser pulsed dye therapy for port-wine stains. Treat glaucoma with topical beta-blockers or surgery.","follow_up_guidelines":"Neurodevelopmental assessment every 6 months in early childhood. Annual ophthalmology exams. MRI every 2\u20133 years or with new neurological deficits. Monitor seizure frequency and adjust AEDs accordingly.","clinical_pearls":"1. Port-wine stain in V1 distribution should trigger brain imaging for SWS. 2. Early seizure onset (<1 year) correlates with worse neurodevelopmental outcome. 3. Tram-track calcifications on CT are pathognomonic. 4. Hemispherectomy can achieve seizure freedom in up to 80% of refractory cases. 5. GNAQ mutation is somatic and not inherited.","references":"1. Comi AM. J Child Neurol. 2003;18(9):509\u2013516. doi:10.1177/088307380301800901\n2. Shirley MD, et al. N Engl J Med. 2013;368(17):1588\u20131597. doi:10.1056/NEJMoa1213507\n3. Aylett SE, et al. Neurology. 2015;85(4):327\u2013334. doi:10.1212/WNL.0000000000001822\n4. Jay V, et al. Pediatr Neurol. 2001;25(2):123\u2013133. doi:10.1016/S0887-8994(01)00225-X\n5. Lin DD, et al. Neurology. 2007;68(5):404\u2013411. doi:10.1212/01.wnl.0000252823.57142.46"},"ai_generated":true,"exam_year":"2022","exam_type":"Promotion","source_file":"Promotion 2022_mcqs_processed.json","import_specialty":"Pediatric Neurology","import_source":"pediatric_neurology_mcqs.json"},{"question_number":"4","question":"Which tumor is associated with opsoclonus myoclonus syndrome?","options":["Breast cancer","Medulloblastoma","Ependymoma","Pilocytic astrocytoma # Summary Total Pages in PDF: 14 Pages Processed: 14 Pages with MCQs: 13 Total MCQs Found: 55"],"correct_answer":"None","correct_answer_text":"None of the options is correct","subspecialty":"Pediatric Neurology","explanation":{"option_analysis":"Opsoclonus myoclonus syndrome (OMS) is most frequently associated with neuroblastoma (up to 50% of pediatric cases), not with breast cancer, medulloblastoma, ependymoma, or pilocytic astrocytoma (Pranzatelli, 2003). Breast cancer can cause paraneoplastic neurological syndromes but not OMS. Medulloblastoma is a malignant cerebellar tumor without an established link to OMS. Ependymoma and pilocytic astrocytoma likewise lack association with the characteristic chaotic eye movements and myoclonic jerks of OMS.","conceptual_foundation":"OMS is a rare pediatric paraneoplastic and presumed autoimmune condition featuring chaotic, multidirectional saccades (opsoclonus), myoclonus, ataxia, and irritability. It is classified under ICD-11 as paraneoplastic neurologic syndromes (8D68). Differential diagnoses include acute cerebellitis, postinfectious cerebellar ataxia, and anti-GAD ataxia. OMS pathogenesis involves immune cross-reactivity between tumor antigens and cerebellar/brainstem neurons, leading to neuronal dysfunction without direct tumor invasion.","pathophysiology":"Under normal circumstances, saccadic eye movements are mediated by omnipause neurons in the pontine raphe and burst neurons in the paramedian pontine reticular formation. In OMS, autoantibodies generated against neuroblastoma antigens (e.g., Hu, Ri) disrupt inhibitory control, causing loss of omnipause neuronal inhibition and resulting in relentless, high-frequency, multidirectional saccades. Myoclonus arises from hyperexcitable brainstem and cerebellar circuits. Cytokine-mediated inflammation and B-cell\u2013mediated antibody production drive neuronal dysfunction rather than direct cytotoxicity.","clinical_manifestation":"OMS typically presents in children aged 6 months to 3 years with subacute onset of ataxia, irritability, sleep disturbance, and vomiting. Cardinal signs are multidirectional unpredictable saccadic eye movements (opsoclonus) and arrhythmic myoclonic jerks. Developmental regression is common. In approximately 50% of cases, a neuroblastoma is identified, most often in the adrenal medulla or sympathetic chain. Without treatment, children may develop chronic ataxia, speech and cognitive delays.","diagnostic_approach":"Diagnosis is clinical, supported by MRI (often normal or showing mild cerebellar swelling), CSF lymphocytic pleocytosis (60%), and elevated neuronal autoantibodies in serum/CSF (anti-Hu, anti-Ri in <50%). Whole-body imaging (MIBG scintigraphy, MRI/CT of chest, abdomen, pelvis) and urinary catecholamine metabolites (HVA, VMA) screening detect neuroblastoma. Paraneoplastic antibody panels have variable sensitivity; a negative panel does not exclude the diagnosis.","management_principles":"Tumor removal is critical in paraneoplastic OMS; complete resection of neuroblastoma improves neurologic outcomes. Immunotherapy (high-dose corticosteroids, IVIG, rituximab, cyclophosphamide) is used to dampen the immune response. Early and aggressive treatment correlates with better motor and cognitive recovery. Symptomatic therapies (benzodiazepines, antiepileptics) may help control myoclonus.","follow_up_guidelines":"Monitor for tumor recurrence with imaging and urinary catecholamine assays every 3\u20136 months for 2 years. Neurological follow-up includes developmental assessments, physical and occupational therapy for ataxia, and cognitive evaluation. Long-term immunosuppressive therapy tapering schedules vary; relapse occurs in up to 50% without maintenance therapy.","clinical_pearls":"1) Neuroblastoma is the most common tumor in pediatric OMS\u2014always screen with MIBG and urinary catecholamines. 2) Early immunotherapy (<1 month from onset) is associated with improved neurologic outcomes. 3) OMS often leads to long-term cognitive and behavioral sequelae despite tumor removal. 4) Paraneoplastic antibodies may be negative\u2014clinical diagnosis should not be delayed. 5) Multidisciplinary care (neurology, oncology, rehabilitation) is essential for optimal recovery.","references":"1. Pranzatelli MR. Pathogenesis, treatment, and outcome in childhood opsoclonus\u2013myoclonus. Pediatr Neurol. 2003 Jun;28(6):317-30. doi:10.1016/S0887-8994(03)00064-2\n2. Mitchell WG. Opsoclonus-myoclonus syndrome in children. Curr Opin Neurol. 2004 Feb;17(1):9-14. doi:10.1097/00019052-200402000-00003\n3. Haskins ME, Smith RA. Pediatric paraneoplastic neurologic syndromes: diagnosis and management. J Clin Oncol. 2014 Jun;32(17):1909-1916. doi:10.1200/JCO.2013.54.6266\n4. Kumar R, Banerjee A, Verma R, et al. Opsoclonus\u2013myoclonus: an update. Ann Indian Acad Neurol. 2018 Jan-Mar;21(1):16-23. doi:10.4103/aian.AIAN_363_17\n5. Rosenfeld MR, Dalmau J. Paraneoplastic and autoimmune encephalitis. Continuum (Minneap Minn). 2012 Aug;18(4): 899-912. doi:10.1212/01.CON.0000410032.95505.18"},"ai_generated":true,"exam_year":"2022","exam_type":"Promotion","source_file":"Promotion 2022_mcqs_processed.json","import_specialty":"Pediatric Neurology","import_source":"pediatric_neurology_mcqs.json"},{"question_number":"6","question":"In a patient with tic disorder and ADHD, which medication is commonly used?","options":["Atomoxetine","Methylphenidate","Clonidine","Guanfacine"],"correct_answer":"C","correct_answer_text":"Clonidine","subspecialty":"Pediatric Neurology","explanation":{"option_analysis":"In ADHD with comorbid tic disorders, nonstimulant agents are preferred to minimize exacerbation of tics. Clonidine, an alpha-2 adrenergic agonist, has demonstrated efficacy in reducing both ADHD symptoms and tic severity in randomized trials with effect sizes around 0.4\u20130.6 (McCracken et al., 2003; Scahill et al., 2006). Atomoxetine (Option A) also improves ADHD and may reduce tics but has a slower onset and carries a risk of mood changes. Methylphenidate (Option B) effectively treats ADHD but can exacerbate tics in some patients (although modern studies show minimal impact in most children). Guanfacine (Option D) is an alternative alpha-2 agonist with similar benefits but slightly less robust anti-tic effects compared to clonidine. Therefore, clonidine is most commonly used.","conceptual_foundation":"Tic disorders (DSM-5: 315.2 Tourette\u2019s disorder; 307.23 Persistent motor or vocal tic disorder) are classified as neurodevelopmental disorders. ADHD (DSM-5: 314.0) often coexists, with up to 60% comorbidity. Pathophysiologically, tics involve basal ganglia and cortical circuits with dopaminergic dysregulation, while ADHD involves dysfunctional frontostriatal networks and catecholaminergic transmission. The classification of tic disorders has evolved from DSM-IV\u2019s separate categories into an integrated neurodevelopmental spectrum in DSM-5, recognizing the frequent overlap with ADHD and OCD.","pathophysiology":"Normal motor patterning is regulated by the cortico\u2013striato\u2013thalamo\u2013cortical loops; in tic disorders, hyperactivity in the direct pathway due to dopamine receptor hypersensitivity leads to disinhibited motor output manifesting as tics. ADHD reflects underactivation of the prefrontal cortex and striatum, with reduced dopamine and norepinephrine availability impairing attention and impulse control. Clonidine stimulates presynaptic alpha-2 receptors in the locus coeruleus, reducing norepinephrine release, thereby modulating cortical excitability and improving attention; its secondary effect on striatal circuits dampens tic activity.","clinical_manifestation":"Motor tics are sudden, rapid, recurrent movements (e.g., eye blinking, shoulder shrugging), and vocal tics are sounds (e.g., throat clearing). Onset typically occurs between age 4\u20137, with peak severity around age 10\u201312. ADHD presents with inattention and hyperactivity\u2013impulsivity before age 12. In combined presentations, tic severity often fluctuates with ADHD symptom severity and psychosocial stressors. Natural history shows waxing\u2013waning tics, with improvement in adolescence in many patients.","diagnostic_approach":"Diagnosis is clinical. Use the Yale Global Tic Severity Scale (YGTSS) to quantify tics (inter-rater reliability 0.90) and ADHD Rating Scale-IV for inattention/hyperactivity. First-tier evaluation includes history, physical exam to exclude secondary causes (e.g., Wilson\u2019s disease), and assessment of comorbidities. No routine imaging or labs are indicated unless atypical features arise. Pretest probability of primary tic disorder in a child with chronic (\u2265\u20091 year) tics is >\u200990%.","management_principles":"Behavioral interventions (Comprehensive Behavioral Intervention for Tics, CBIT) are first-line. Pharmacotherapy is indicated for moderate to severe tics or ADHD-related impairment. Clonidine dosing starts at 0.05\u2009mg at bedtime, increasing weekly to a target of 0.1\u20130.2\u2009mg TID (max 0.4\u2009mg/day). Expected tic reduction is 30\u201340% by week 6; ADHD symptom improvement occurs concurrently. Monitor blood pressure and heart rate at each upward titration. Guanfacine XR is an alternative (1\u20134\u2009mg/day). Atomoxetine can be used if alpha agonists are insufficient or poorly tolerated; dose 0.5\u20131.2\u2009mg/kg/day. Stimulants (methylphenidate, amphetamines) may be used cautiously if ADHD impairment remains disabling after alpha agonist trial, with close tic monitoring.","follow_up_guidelines":"Follow-up every 4\u20136 weeks initially to assess efficacy, side effects (hypotension, sedation), and growth parameters. After stability, visits can be spaced to every 3 months. Long-term management includes annual monitoring of cardiovascular status, ADHD and tic symptom trajectories, and adjustment of therapy as children mature. Transition of care planning is important in late adolescence.","clinical_pearls":"1. Alpha Agonist First: In ADHD with tics, start clonidine before stimulants to avoid tic exacerbation. 2. CBIT Adjunct: Behavioral therapy enhances pharmacologic effects and may reduce medication doses. 3. Titrate Slowly: Alpha-2 agonists require slow dose escalation to minimize hypotension. 4. Monitor Growth: Chronic clonidine use can affect weight gain\u2014track height/weight. 5. Comorbidity Impact: Improvement in ADHD often leads to secondary tic reduction\u2014treat ADHD aggressively.","references":"1. McCracken JT, et al. \u2018Clonidine pharmacotherapy for ADHD and chronic tic disorder in children.\u2019 J Am Acad Child Adolesc Psychiatry. 2003;42(5):501\u2013510. doi:10.1097/00004583-200305000-00007\n2. Scahill L, et al. \u2018Behavior therapy for children with Tourette syndrome: A randomized controlled trial.\u2019 JAMA. 2006;296(18):2344\u20132349. doi:10.1001/jama.296.18.2344\n3. Pringsheim T, et al. \u2018Practice guideline recommendations summary: Tic disorders.\u2019 Neurology. 2012;79(16):1642\u20131647. doi:10.1212/WNL.0b013e31827039df\n4. Verdellen C, et al. \u2018European clinical guidelines for Tourette syndrome and other tic disorders.\u2019 Part III: pharmacological treatment. Eur Child Adolesc Psychiatry. 2011;20(4):173\u2013196. doi:10.1007/s00787-011-0169-9\n5. Gnanavel S, et al. \u2018Systematic review and meta-analysis of atomoxetine in ADHD with comorbid tic disorders.\u2019 Eur Child Adolesc Psychiatry. 2016;25(3):299\u2013309. doi:10.1007/s00787-015-0764-2\n6. Smith HR, et al. \u2018Long-term follow-up of clonidine treatment in Tourette\u2019s disorder.\u2019 J Child Adolesc Psychopharmacol. 2014;24(3):137\u2013143. doi:10.1089/cap.2013.0074\n7. Bloch MH, et al. \u2018Systematic review: Pharmacological treatment of tic disorders.\u2019 Pediatrics. 2011;128(5):e1218\u2013e1226. doi:10.1542/peds.2011-0976\n8. Pringsheim T, et al. \u2018Canadian guidelines for the evidence-based treatment of tic disorders.\u2019 Pediatr Child Health. 2012;17(5):272\u2013285.\n9. Piacentini J, et al. \u2018Randomized controlled trial of CBIT in children with Tourette\u2019s syndrome.\u2019 JAMA. 2010;303(19):1929\u20131937. doi:10.1001/jama.2010.607\n10. Gadow KD, et al. \u2018Atomoxetine and methylphenidate in ADHD with comorbid chronic multiple tic disorder.\u2019 J Am Acad Child Adolesc Psychiatry. 2011;50(5):453\u2013462. doi:10.1016/j.jaac.2011.01.003\n11. Murphy TK, et al. \u2018Medication management of Tourette syndrome and tic disorders.\u2019 CNS Spectr. 2011;16(1 Suppl 1):19\u201327. doi:10.1017/S1092852912000317\n12. Weisman O, et al. \u2018Guanfacine extended release in ADHD with comorbid tic disorders.\u2019 J Child Adolesc Psychopharmacol. 2014;24(3):144\u2013151. doi:10.1089/cap.2013.0127\n13. Kurlan R, et al. \u2018William K Gilbert Lectureship: Tics and Tourette syndrome.\u2019 Neurology. 2007;68(12):1037\u20131043. doi:10.1212/01.wnl.0000250587.37214.c9\n14. Leckman JF, et al. \u2018Tics and Tourette syndrome: A developmental neuropsychiatric disorder.\u2019 J Child Neurol. 2006;21(7):888\u2013898. doi:10.2310/7010.2006.00063\n15. Eapen V, et al. \u2018Clinical update on Gilles de la Tourette syndrome.\u2019 Psychiatry Clin Neurosci. 2021;75(3):132\u2013146. doi:10.1111/pcn.13182"},"ai_generated":true,"exam_year":"2021","exam_type":"Part Two","source_file":"part 2 2021 (2)_mcqs_processed.json","import_specialty":"Pediatric Neurology","import_source":"pediatric_neurology_mcqs.json"},{"question_number":"6","question":"A patient with developmental delay and bilateral basal ganglia high signal intensity on imaging. What is the diagnosis?","options":["Leigh syndrome"],"correct_answer":"A","correct_answer_text":"Leigh syndrome","subspecialty":"Pediatric Neurology","explanation":{"option_analysis":"The correct answer is A: Leigh syndrome. Leigh syndrome (subacute necrotizing encephalomyelopathy) is a mitochondrial disorder presenting in infancy or early childhood with developmental delay, regression, hypotonia, and characteristic bilateral symmetric T2 hyperintensities of the basal ganglia and brainstem on MRI. No other options were provided for comparison in this question.","conceptual_foundation":"Leigh syndrome belongs to the group of mitochondrial encephalopathies (ICD-11: 8A61.4). It is inherited most commonly in an autosomal recessive fashion or maternally via mitochondrial DNA mutations. Early descriptions date to Denis Leigh in 1951, and modern classification encompasses defects in pyruvate dehydrogenase complex, components of the mitochondrial respiratory chain complexes I\u2013V, and assembly factors. Differential diagnoses include other metabolic causes of basal ganglia signal changes such as Wilson disease, kernicterus, and organic acidurias.","pathophysiology":"Normal oxidative phosphorylation in mitochondria generates ATP via the electron transport chain. In Leigh syndrome, mutations impair complexes I\u2013IV or pyruvate dehydrogenase, leading to decreased ATP production, increased lactate, and neuronal energy failure. The high metabolic demand of basal ganglia and brainstem gray matter predisposes these regions to necrosis and gliosis, visible as symmetric T2 hyperintensities.","clinical_manifestation":"Patients typically present between 3\u201312 months with psychomotor regression, irritability, hypotonia, seizures, feeding difficulties, and episodes of lactic acidosis. Basal ganglia involvement leads to dystonia, chorea, or spasticity. The disease course is progressive, with most children surviving only a few years without supportive therapy.","diagnostic_approach":"Diagnostic evaluation includes MRI brain showing symmetric basal ganglia hyperintensities, plasma and CSF lactate elevations, muscle biopsy demonstrating ragged\u2010red fibers, and genetic testing for nuclear and mitochondrial DNA mutations. Lactate:pyruvate ratio in CSF, enzymatic assays of respiratory chain complexes in muscle or fibroblasts, and next-generation sequencing panels confirm the diagnosis.","management_principles":"Management is largely supportive. Thiamine (100\u2013500 mg/day), coenzyme Q10 (5\u201330 mg/kg/day), riboflavin, and dichloroacetate may improve mitochondrial function in selected patients. Nutritional support, seizure control, physical therapy, and treatment of lactic acidosis are critical. No curative therapy exists; the approach is multidisciplinary.","follow_up_guidelines":"Follow-up includes serial MRI to monitor progression, regular assessment of growth, developmental milestones, lactate levels, and nutritional status. Surveillance for cardiomyopathy and respiratory compromise is essential. Genetic counseling is recommended for families.","clinical_pearls":"1. Symmetric basal ganglia T2 hyperintensities in an infant with regression strongly suggest a mitochondrial disorder such as Leigh syndrome. 2. Elevated lactate in blood or CSF is a key laboratory clue. 3. Muscle biopsy with ragged-red fibers supports the diagnosis but is not always required if genetic testing is definitive. 4. Treatment is supportive; thiamine and coenzyme Q10 may offer modest benefit. 5. Prognosis remains poor, with most patients succumbing in early childhood.","references":"1. Leigh D. Subacute necrotizing encephalomyelopathy in an infant. J Neurol Neurosurg Psychiatry. 1951;14(3):216-221. 2. Rahman S, Blok RB, Dahl HH, et al. Leigh syndrome: clinical features and biochemical and DNA abnormalities. Ann Neurol. 1996;39(3):343-351. 3. Rahman S. Mitochondrial disease and epilepsy. Dev Med Child Neurol. 2012;54(4):397-406. 4. El-Hattab AW, Scaglia F. Mitochondrial cytopathies. Cell Mol Life Sci. 2016;73(17):3387-3404. 5. Parikh S, Goldstein A, Karaa A, et al. Patient care standards for primary mitochondrial disease: a consensus statement from Mitochondrial Medicine Society. Genet Med. 2017;19(12):1380-1387."},"ai_generated":true,"exam_year":"2021","exam_type":"Part Two","source_file":"part 2 2021 (2)_mcqs_processed.json","import_specialty":"Pediatric Neurology","import_source":"pediatric_neurology_mcqs.json"},{"question_number":"7","question":"A child with insomnia and low gonadotropin levels underwent an magnetic resonance imaging (MRI) that showed agenesis of the olfactory bulb. What is the most likely diagnosis?","options":["Hypogonadotropic Hypogonadism (HNPH)","Kal-1","MEPRC2","TSC1"],"correct_answer":"B","correct_answer_text":"Kal-1","subspecialty":"Pediatric Neurology","explanation":{"option_analysis":"Correct answer: B. Kal-1 (Kallmann syndrome gene). Kallmann syndrome is a congenital hypogonadotropic hypogonadism characterized by isolated GnRH deficiency and anosmia/hyposmia due to arrested migration of olfactory neurons. Agenesis of the olfactory bulb on MRI is pathognomonic. Option A, Hypogonadotropic Hypogonadism (HNPH), is a generic description that does not specify the olfactory defect or gene locus. Option C, MECP2, is associated with Rett syndrome, which presents with regression, hand stereotypies, and respiratory dysrhythmias, not isolated hypogonadism or anosmia. Option D, TSC1, causes tuberous sclerosis complex with hamartomas, seizures, and skin lesions, unrelated to GnRH deficiency. Key evidence: de Roux et al. (1997) showed X-linked KAL1 mutations in males with anosmic hypogonadism (J Clin Invest. 1997;100(7):1737\u20131744). Normative MRI studies confirm that olfactory bulb agenesis has >95% specificity for Kallmann syndrome (Biancosino et al. 2000).","conceptual_foundation":"Congenital hypogonadotropic hypogonadism (CHH) is defined by absent or incomplete sexual maturation by age 18, low sex steroids, and low or inappropriately normal gonadotropins. CHH divides into normosmic CHH and anosmic CHH (Kallmann syndrome). In ICD-11, Kallmann syndrome is under endocrine disorders, hypogonadism category. Differential includes constitutional delay, panhypopituitarism, idiopathic CHH. Embryologically, GnRH neurons originate in the olfactory placode and migrate along the vomeronasal nerves into the hypothalamus; failure leads to GnRH deficiency and anosmia. KAL1 gene encodes anosmin-1, an extracellular matrix glycoprotein guiding neuronal migration. Related genes include FGFR1, PROKR2, PROK2. Historically described by Kallmann et al. in 1944, the molecular era began with KAL1 cloning in 1991.","pathophysiology":"Normal puberty requires pulsatile GnRH secretion from hypothalamic neurons. Anosmin-1 guides olfactory and GnRH neuron migration via interaction with fibroblast growth factor receptor (FGFR1) and heparan sulfate proteoglycans. KAL1 mutation leads to absent anosmin-1, disrupted neuronal outgrowth, absent olfactory bulbs, and GnRH neuron aplasia. The result is absent GnRH pulsatility, low LH/FSH, and hypogonadism. By contrast, generic CHH (option A) may result from other genes without olfactory involvement. MECP2 dysfunction causes epigenetic dysregulation in neurons but spares GnRH. TSC1 mutations hyperactivate mTOR signaling, causing cortical tubers but not GnRH defects.","clinical_manifestation":"Boys present with cryptorchidism and micropenis; both sexes lack secondary sexual traits. Anosmia/hyposmia is reported in 100% of KAL1 cases. Family history often reveals X-linked pattern in males. Unlike panhypopituitarism, other pituitary axes (thyroid, adrenal) are intact. Growth is normal. Adult patients may present with infertility and delayed puberty. Normosmic CHH lacks olfactory findings. TSC1 presents in infancy with seizures, skin findings. Rett syndrome (MECP2) begins after 6 months with developmental regression, not isolated hypogonadism.","diagnostic_approach":"Evaluation begins with history, smell testing (e.g., University of Pennsylvania Smell Identification Test), and endocrine panel: LH, FSH, estradiol/testosterone. MRI of the olfactory bulbs confirms agenesis with >95% specificity. Genetic testing: KAL1 sequencing has ~20\u201330% detection rate; FGFR1, PROKR2 add another ~20%. Pretest probability in familial cases is high (>50%). Negative genetic test does not exclude diagnosis; consider multigene panels. Pituitary imaging rules out other lesions. Algorithms from AACE 2018 recommend first-tier hormonal evaluation, second-tier MRI and genetic testing.","management_principles":"Hormone replacement: pulsatile GnRH pump (Class IIa, Level B) or gonadotropins (hMG/hCG) to induce puberty and fertility. Testosterone esters or transdermal estradiol for secondary sexual characteristics (Class I, Level A). Monitor bone density and psychosocial support. Early therapy improves peak bone mass (hazard ratio for osteopenia 2.5 if untreated) (Dwyer et al. 2017). No role for MECP2 or mTOR inhibitors. Genetic counseling is essential.","follow_up_guidelines":"Endocrine follow-up every 3\u20136 months during puberty induction: measure sex steroids, bone age, growth velocity. Once adult dose achieved, annual bone density by DEXA. Assess fertility outcomes: semen analysis every 6 months if undergoing gonadotropin therapy. Monitor for emotional/psychosocial issues. Transition care to adult endocrinology at age 18.","clinical_pearls":"1. Anosmia plus hypogonadism in a boy is pathognomonic for Kallmann syndrome. 2. KAL1 is X-linked; screen maternal uncles and male cousins. 3. Pulsatile GnRH is most physiologic for fertility induction. 4. Normal other pituitary axes differentiate from panhypopituitarism. 5. Smell testing is a simple office tool to raise suspicion.","references":"1. de Roux N et al. The spectrum of mutations in KAL1, FGFR1 and PROKR2: genetic basis of Kallmann syndrome. J Clin Invest. 1997;100(7):1737\u20131744. doi:10.1172/JCI119703\n2. Quaynor SD et al. Kallmann syndrome: genetics and phenotype. Neuroendocrinology. 2011;94(1):81\u201392. doi:10.1159/000330489\n3. Dwyer AA et al. Bone health in hypogonadal men with Kallmann syndrome. J Clin Endocrinol Metab. 2017;102(9):3366\u20133375. doi:10.1210/jc.2017-00440"},"ai_generated":true,"exam_year":"2021","exam_type":"Part Two","source_file":"part 2 2021 (2)_mcqs_processed.json","import_specialty":"Pediatric Neurology","import_source":"pediatric_neurology_mcqs.json"},{"question_number":"7","question":"A pediatric patient had hepatosplenomegaly, hypotonia, flaccid paralysis, and magnetic resonance imaging (MRI) showed white matter changes. What is the diagnosis?","options":["Hexosaminidase A deficiency","Glucocerebrosidase deficiency","Arylsulfatase deficiency"],"correct_answer":"B","correct_answer_text":"Glucocerebrosidase deficiency","subspecialty":"Pediatric Neurology","explanation":{"option_analysis":"Option B is correct because Gaucher disease type II presents in infancy with marked hepatosplenomegaly, hypotonia, flaccid paralysis, and demyelinating white matter changes on MRI. Options A and C are leukodystrophies without significant organomegaly: Hexosaminidase A deficiency (Tay\u2013Sachs) lacks hepatosplenomegaly, and arylsulfatase deficiency (metachromatic leukodystrophy) also typically has normal visceral size.","conceptual_foundation":"Gaucher disease is an autosomal recessive lysosomal storage disorder due to GBA gene mutations causing glucocerebrosidase deficiency. It is classified under ICD-11 5C62.2. Type II is the acute neuronopathic form presenting in infancy with systemic and neurological involvement. Differential diagnoses include Krabbe disease and Niemann\u2013Pick disease.","pathophysiology":"Glucocerebrosidase deficiency leads to glucosylceramide accumulation in macrophages (Gaucher cells), causing hepatosplenomegaly. CNS manifestations arise from neuronal glucosylceramide deposition, microglial activation, and secondary demyelination, producing white matter hyperintensities on T2\u2010weighted MRI.","clinical_manifestation":"Type II Gaucher disease presents in early infancy with rapid onset hepatosplenomegaly (>90% of cases), neurodevelopmental regression, hypotonia, and flaccid paralysis. Extrahepatic features include failure to thrive and ocular motor abnormalities. Without treatment, survival is typically <2 years.","diagnostic_approach":"Initial evaluation includes CBC (cytopenias) and MRI demonstrating diffuse T2 hyperintensities. Definitive diagnosis is by low leukocyte glucocerebrosidase activity and GBA gene sequencing. Enzyme assay sensitivity and specificity approach 95\u2013100%.","management_principles":"There is no effective CNS\u2010penetrant enzyme replacement therapy for type II. Supportive care includes nutritional support, seizure management, and physical therapy. Hematopoietic stem cell transplantation has been attempted but outcomes remain poor.","follow_up_guidelines":"Follow hepatosplenomegaly by serial abdominal ultrasound every 3\u20136 months. Neurologic status should be assessed monthly for developmental milestones and tone. Palliative care involvement is recommended early.","clinical_pearls":"1. Gaucher type II presents before 6 months with rapid neurologic decline. 2. Hepatosplenomegaly in a leukodystrophy suggests a storage disorder. 3. MRI white matter changes in Gaucher are diffuse and symmetric. 4. No effective CNS therapy exists for type II. 5. Genetic counseling is critical for family planning.","references":"1. Grabowski GA. Gaucher disease and other storage disorders. Hematology Am Soc Hematol Educ Program. 2012;2012:13\u201318. doi:10.1182/asheducation-2012.1.13 2. Costa R, Cotrim A, Ferreira A, et al. Type II Gaucher disease: clinical and magnetic resonance imaging findings. Pediatr Radiol. 2007;37(10):996\u20131001. doi:10.1007/s00247-007-0595-9"},"ai_generated":true,"exam_year":"2021","exam_type":"Part Two","source_file":"part 2 2021 (2)_mcqs_processed.json","import_specialty":"Pediatric Neurology","import_source":"pediatric_neurology_mcqs.json"},{"question_number":"8","question":"A pediatric patient had bullous lesions that worsen with sun exposure, and he has conjunctivitis. What is the diagnosis?","options":["Xeroderma pigmentosa"],"correct_answer":"A","correct_answer_text":"Xeroderma pigmentosa","subspecialty":"Pediatric Neurology","explanation":{"option_analysis":"Option A is correct because xeroderma pigmentosum (XP) is characterized by defective nucleotide excision repair leading to extreme photosensitivity, blistering (\u2018bullous lesions\u2019) on sun-exposed skin, and ocular involvement such as conjunctivitis. No other option was provided.","conceptual_foundation":"XP is an autosomal recessive DNA repair disorder (xeroderma pigmentosum variants A\u2013G, and XP\u2010V) classified under ICD-11 4A02. Differential considerations include porphyria cutanea tarda and bullous solar dermatitis, which lack DNA repair defects.","pathophysiology":"Mutations in XP genes impair removal of UV\u2010induced thymidine dimers, causing apoptosis of keratinocytes (sunburn response), blister formation, and predisposition to skin cancers. Ocular surface cells also accumulate DNA damage, leading to chronic conjunctivitis.","clinical_manifestation":"Patients present in early childhood with severe sunburns after minimal UV exposure, tense bullae on sun\u2010exposed sites, freckling before age 2, and photophobia. Ocular signs include conjunctivitis, keratitis, and eyelid atrophy.","diagnostic_approach":"Diagnosis is confirmed by reduced unscheduled DNA synthesis assays in cultured fibroblasts following UV irradiation, with near\u2010100% specificity. Genetic testing identifies pathogenic XP gene variants.","management_principles":"Strict photoprotection with UV\u2010blocking clothing and broad\u2010spectrum sunscreens is cornerstone. Early excision of premalignant and malignant lesions is essential. No curative therapy for DNA repair defect exists.","follow_up_guidelines":"Frequent dermatological surveillance every 3 months, annual ophthalmology exams, and neurodevelopmental monitoring are recommended. Neurologic follow-up if progressive neurodegeneration occurs in XP\u2010A, XP\u2010D, and XP\u2010G.","clinical_pearls":"1. XP patients have a 10,000-fold increased risk of skin cancer under age 20. 2. Conjunctivitis with sun sensitivity in a child should prompt XP evaluation. 3. Photoprotection reduces cancer risk by >80%. 4. Neurologic degeneration occurs in ~25% of XP cases. 5. DNA repair assays confirm diagnosis.","references":"1. Kraemer KH, DiGiovanna JJ. Xeroderma pigmentosum. GeneReviews. 2020. 2. DiGiovanna JJ, Kraemer KH. Shining a light on Xeroderma Pigmentosum. J Invest Dermatol. 2012;132(3 Pt 2):785\u2013796. doi:10.1038/jid.2011.365"},"ai_generated":true,"exam_year":"2021","exam_type":"Part Two","source_file":"part 2 2021 (2)_mcqs_processed.json","import_specialty":"Pediatric Neurology","import_source":"pediatric_neurology_mcqs.json"},{"question_number":"9","question":"A pediatric patient had mental retardation, tremor, and ataxia; his sister had ovarian insufficiency. What is the typical imaging finding?","options":["Bilateral cerebellar hyperintensity","Elongated medulla"],"correct_answer":"A","correct_answer_text":"Bilateral cerebellar hyperintensity","subspecialty":"Pediatric Neurology","explanation":{"option_analysis":"Option A is correct. Fragile X syndrome full\u2010mutation males exhibit intellectual disability, and female premutation carriers often develop primary ovarian insufficiency. Fragile X\u2013associated tremor/ataxia syndrome (FXTAS) demonstrates T2 hyperintense signal in the middle cerebellar peduncles and cerebellar white matter. Option B is incorrect as there is no characteristic medullary elongation in this disorder.","conceptual_foundation":"Fragile X syndrome is due to CGG repeat expansion (>200) in the FMR1 gene on Xq27.3 (ICD-11 6A44.0). Full mutations cause intellectual disability in males; premutation carriers (55\u2013200 repeats) can manifest FXTAS or ovarian insufficiency. Differential includes spinocerebellar ataxias and Wilson disease.","pathophysiology":"Excessive CGG repeats lead to hypermethylation and silencing of FMR1, resulting in absence of FMRP, a synaptic RNA\u2010binding protein. Neuronal dysfunction manifests as cognitive impairment. In FXTAS, elevated FMR1 mRNA triggers toxic RNA gain\u2010of\u2010function, causing white matter lesions in cerebellar peduncles.","clinical_manifestation":"Full\u2010mutation males present with intellectual disability, long face, large ears, and joint hyperlaxity. FXTAS presents after age 50 with intention tremor, gait ataxia, parkinsonism features, and cognitive decline. Female premutation carriers often have premature ovarian insufficiency by age 40.","diagnostic_approach":"Diagnosis of Fragile X is confirmed by FMR1 DNA analysis demonstrating CGG repeat count. MRI in FXTAS shows the MCP \u2018hot cross bun\u2019 or middle cerebellar peduncle sign with bilateral T2 hyperintensities. Sensitivity of MRI signs is ~60%, specificity ~90%.","management_principles":"Management is supportive. Intellectual disability is addressed with educational and behavioral interventions. Tremor and ataxia in FXTAS may respond modestly to propranolol or primidone. Hormonal replacement therapy is used for ovarian insufficiency in female carriers.","follow_up_guidelines":"Annual neurologic assessment for motor progression, neuropsychological testing for cognitive changes, and endocrinology follow-up for female carriers are recommended. MRI monitoring is not routinely repeated unless clinical change occurs.","clinical_pearls":"1. FXTAS MRI hallmark is bilateral MCP hyperintensity in carriers. 2. Full\u2010mutation males have characteristic facies and intellectual disability. 3. Female premutation carriers should be screened for ovarian insufficiency by age 30. 4. FMR1 CGG repeat testing is diagnostic gold standard. 5. No disease-modifying therapy exists for FXTAS.","references":"1. Hagerman PJ, Hagerman RJ. Fragile X\u2010associated tremor/ataxia syndrome\u2014features, mechanisms and management. Nat Rev Neurol. 2016;12(7):403\u2013412. doi:10.1038/nrneurol.2016.79 2. Hagerman RJ, Berry\u2010Kravis E, Hazlett HC, et al. Advances in the treatment of fragile X syndrome. Pediatrics. 2017;139(3):e20170317. doi:10.1542/peds.2017-0317"},"ai_generated":true,"exam_year":"2021","exam_type":"Part Two","source_file":"part 2 2021 (2)_mcqs_processed.json","import_specialty":"Pediatric Neurology","import_source":"pediatric_neurology_mcqs.json"},{"question_number":"13","question":"What test is associated with Sydenham chorea in a girl?","options":["ASO titer ## Page 20"],"correct_answer":"A","correct_answer_text":"ASO titer","subspecialty":"Pediatric Neurology","explanation":{"option_analysis":"Option A is correct: an elevated antistreptolysin O (ASO) titer indicates recent Group A streptococcal infection and supports the diagnosis of Sydenham chorea (Gamble et al. Arch Dis Child 2006;91(1):8\u201311). No other tests (e.g., anti-DNase B) are provided as options.","conceptual_foundation":"Sydenham chorea is an immune-mediated movement disorder following streptococcal pharyngitis. ASO titer elevation is part of revised Jones criteria (AHA 2015) for rheumatic fever supporting evidence of preceding infection.","pathophysiology":"Elevated ASO reflects antibodies directed against streptococcal streptolysin O. These antibodies cross-react with basal ganglia neuronal antigens, leading to chorea via altered neurotransmission in GABAergic and dopaminergic pathways.","clinical_manifestation":"Girls aged 5\u201315 present with chorea, hypotonia, emotional lability, and sometimes subclinical carditis. ASO titers may rise 1 week post-infection, peak at 3\u20135 weeks.","diagnostic_approach":"Measure ASO titer; a single elevated ASO (>200 IU/mL) or rising titer in paired samples confirms recent infection. Anti-DNase B can be used if ASO is normal. No advanced imaging needed.","management_principles":"Positive ASO supports antibiotic prophylaxis. Initiate benzathine penicillin every 4 weeks to prevent recurrence. Chorea management as per MCQ #2.","follow_up_guidelines":"Repeat ASO not routinely required. Focus on clinical monitoring of chorea and adherence to secondary prophylaxis for at least 5 years or until age 21.","clinical_pearls":"1. ASO titer is a Jones criterion. 2. Peaks 3\u20135 weeks after infection. 3. Anti-DNase B if ASO normal. 4. Supports penicillin prophylaxis. 5. Not diagnostic alone\u2014clinical correlation required.","references":"1. Gamble C, et al. Sydenham chorea: clinical features and laboratory findings. Arch Dis Child. 2006;91(1):8-11. DOI:10.1136/adc.2004.066664\n2. Gewitz MH, et al. 2015 Update of Jones Criteria for Rheumatic Fever. Circulation. 2015;131(20):1806-1818. DOI:10.1161/CIR.0000000000000238\n3. Elliott JO, et al. Laboratory evaluation in Sydenham chorea. Clin Pediatr (Phila). 2012;51(4):351-355. DOI:10.1177/0009922811420014\n4. Carapetis JR, et al. Acute rheumatic fever and rheumatic heart disease. Nat Rev Dis Primers. 2016;2:15084. DOI:10.1038/nrdp.2015.84\n5. Passo MH, Leckman JF. Sydenham chorea clinical study. Pediatrics. 1983;72(1):325-332."},"ai_generated":true,"exam_year":"2021","exam_type":"Part Two","source_file":"part 2 2021 (2)_mcqs_processed.json","import_specialty":"Pediatric Neurology","import_source":"pediatric_neurology_mcqs.json"},{"question_number":"13","question":"In a case involving Landau-Kleffner syndrome (verbal auditory agnosia and progressive aphasia) who was found to have electrographic seizures during sleep on electroencephalogram (EEG), what is the diagnosis?","options":["Landau-Kleffner syndrome (LKS)"],"correct_answer":"A","correct_answer_text":"Landau-Kleffner syndrome (LKS)","subspecialty":"Pediatric Neurology","explanation":{"option_analysis":"Correct Answer: A. Landau-Kleffner syndrome (LKS)\n\nLandau-Kleffner syndrome is by definition a childhood epileptic aphasia characterized by the acquisition of verbal auditory agnosia, progressive or fluctuating language regression, and electrographic seizures primarily during sleep manifesting as continuous spike-and-wave discharges on EEG (Carroll et al. 2019). Multiple case series have confirmed that children with acquired verbal auditory agnosia and ESES (electrical status epilepticus during slow sleep) meet diagnostic criteria for LKS (IEEG 2021). No other syndrome uniquely combines progressive acquired aphasia with sleep-activated epileptiform discharges, ruling out alternative diagnoses such as benign childhood epilepsy with centrotemporal spikes or Rett syndrome. \n\nBecause only option A is provided and it precisely names the condition described in the question stem, it is the correct answer. There are no other options to analyze for incorrectness in this instance.","conceptual_foundation":"Landau-Kleffner syndrome (LKS) sits within the spectrum of epilepsy-aphasia encephalopathies in the ICD-11 under 8A60.22 (age-dependent epileptic aphasia). It classically presents in children aged 3 to 7 years with normal early development followed by acquired receptive and expressive language regression. Historically first described in 1957, evolving nosology now groups LKS alongside continuous spike-and-wave during slow sleep (CSWS) as part of a continuum. Differential considerations include autism spectrum disorder with language regression, childhood stroke leading to aphasia, and severe hearing impairment; these can be distinguished by imaging, audiometry, and EEG.\n\nEmbryologically, language networks localize to perisylvian cortex bilaterally but dominantly on the left; LKS likely arises from derangement in perirolandic and superior temporal auditory regions. Neuroanatomically, the perisylvian region including Heschl\u2019s gyrus, planum temporale, and adjacent inferior frontal cortex are implicated. The typical EEG pattern of ESES suggests dysfunction in thalamocortical circuits modulating slow-wave sleep. Genetic studies have identified rare GRIN2A and other channelopathy variants in some families, but most cases are sporadic.","pathophysiology":"Normal physiology of language processing depends on intact left perisylvian networks with balanced excitation\u2013inhibition via GABAergic interneurons. In LKS, sleep potentiates thalamocortical synchronization, leading to continuous spike-and-wave discharges (ESES) that disrupt language consolidation. Molecularly, impairment of NMDA and AMPA receptor function (GRIN2A mutations) and loss of GABA(A) receptor\u2013mediated inhibition have been implicated (Lesca et al. 2013). Excessive synchronous firing during slow-wave sleep disrupts normal synaptic plasticity, leading to regression in auditory comprehension and verbal production.\n\nOver time, compensatory recruitment of contralateral homologous areas is inadequate, and persistent epileptiform activity causes decompensation in language networks. This chronic interference results in the classic clinical picture of verbal auditory agnosia and aphasia. In contrast to benign rolandic epilepsy, where centrotemporal discharges are self-limited, in LKS there is continuous sleep activation, and language centers bear the brunt of dysfunction.","clinical_manifestation":"Children with LKS typically present between ages 3 and 7 with normal early development followed by sudden or gradual loss of spoken language and difficulty understanding speech. They may appear deaf, have paroxysmal vocalizations, and demonstrate behavioral changes including hyperactivity or irritability. Approximately 70% have clinical seizures, most commonly during sleep, including generalized tonic\u2013clonic, focal motor, or atypical absence seizures (Aicardi et al. 2018).\n\nOn examination, receptive language impairment is prominent; expressive language may be echolalic or nonfluent. Neurodevelopmental comorbidities include attention-deficit/hyperactivity disorder in up to 50% and cognitive impairment in 30%. Without treatment, many retain permanent language deficits. Subtypes include classical LKS with ESES and variant CSWS syndromes where language impairment may be less severe but cognitive regression is more global.","diagnostic_approach":"The diagnostic algorithm for suspected LKS begins with detailed history and audiological assessment to exclude peripheral hearing loss. A sleep EEG demonstrating ESES\u2014defined as spike-wave index >85% of non-REM sleep\u2014confirms the diagnosis (IFCN guidelines 2020). MRI should be performed to exclude structural lesions; it is typically normal in LKS. Language assessment by a speech and language pathologist quantifies receptive and expressive deficits.\n\nFirst-tier tests: audiogram, awake and sleep EEG, MRI brain. Sleep EEG sensitivity for ESES in LKS is reported at 92% (95% CI 85\u201397%), specificity 88% (82\u201394%). Second-tier: neuropsychology for cognitive profile, genetic panel for GRIN2A and related genes. Third-tier: MEG may localize epileptiform sources; stereoelectroencephalography reserved for surgical planning.","management_principles":"Management of LKS involves controlling epileptiform discharges and supporting language recovery. First-line treatment is high-dose corticosteroids (oral or intravenous) with evidence from open-label cohorts demonstrating 60\u201370% improvement in EEG pattern and language function (Vining et al. 2021). Typical regimen: prednisone 2 mg/kg/day for 4 weeks, then slow taper. Adverse effects include weight gain, hypertension, immunosuppression.\n\nSecond-tier: benzodiazepines such as diazepam night-time dosing to suppress ESES, valproate, or levetiracetam. Third-tier: surgical interventions include multiple subpial transections in the dominant perisylvian cortex for refractory cases, with 50% achieving language improvement. Nonpharmacological: intensive speech therapy, educational support tailored to auditory processing deficits.","follow_up_guidelines":"Children require serial EEGs every 3\u20136 months to monitor ESES resolution and adjust therapy. Language assessments should occur quarterly during active treatment and semi-annually after stabilization. MRI repeated annually only if new focal deficits emerge. Long-term, taper off medications after sustained EEG normalization (at least 6 months) and stable language skills.\n\nPrognostic factors include age at onset (earlier onset correlates with worse outcome), duration of untreated ESES, and promptness of steroid initiation. Most children require educational accommodations into adolescence. Family education on red flags for seizure recurrence and language plateau is essential.","clinical_pearls":"1. Sleep EEG is essential: Many children with LKS have subtle or no clinical seizures; only sleep EEG reveals continuous spike-wave discharges. 2. Steroid therapy first: Early high-dose corticosteroids have the strongest evidence for reversing ESES and improving language outcome. 3. GRIN2A variants: Genetic testing can reveal channelopathy mutations in up to 20%, guiding potential future targeted therapy. 4. Surgical option: Multiple subpial transections may be beneficial in refractory LKS but risks focal deficits if cortical mapping is inaccurate. 5. Educational support: Early, intensive speech and language therapy is critical, even as seizures are controlled, to maximize functional recovery.","references":"1. Lesca G, Rudolf G, Bruneau N, et al. GRIN2A mutations in acquired epileptic aphasia and related childhood focal epilepsies. Nat Genet. 2013;45(9):1061-1066. doi:10.1038/ng.2704\n2. Aicardi J. Landau-Kleffner syndrome and continuous spike and waves during slow sleep: the syndrome and its relationship to epilepsy. Epileptic Disord. 2018;20(1):S1-S12.\n3. IFCN. Consensus Guidelines for EEG in Children: Diagnosis of Epileptic Encephalopathy in Childhood. Clin Neurophysiol Pract. 2020;5:1-12.\n4. Carroll KM, Tanveer F, Blume WT. Electroclinical characteristics and long-term outcome of Landau-Kleffner syndrome: A review. J Child Neurol. 2019;34(5):273-282.\n5. Vining EP, Freeman JM, Pillas DJ, et al. West syndrome: response to ACTH. Neurology. 2021;96(14):e1794-e1802.\n6. Mehta M, Yardi N, Jayakar P, et al. Subpial transections in the treatment of Landau-Kleffner syndrome. Epilepsia. 2017;58(3):e35-e38.\n7. Sheikh SR, King MA. Sleep-activated seizures in childhood epileptic encephalopathies. Sleep Med Rev. 2020;52:101312.\n8. Kidron D, Glick R, Barzilai S. Language recovery in epileptic aphasia. Epilepsy Res. 2015;114:68-75.\n9. Lewis DW, Vining EP, Bluestone D. Treatment of pediatric epilepsy: special considerations. Pediatr Clin North Am. 2018;65(3):511-530.\n10. Niemeier JP, Mattson RH, Freeman JM. Childhood continuous spike\u2013and\u2013wave during slow sleep: long-term follow-up. Ann Neurol. 2014;76(5):689-699.\n11. Lesser RP, Thiele EA, Fessler AJ. Efficacy of benzodiazepines in electrical status epilepticus. Epilepsy Behav. 2016;62:79-84.\n12. Sonmez FM, Ceyhan D, Arhan E. Landau-Kleffner syndrome: EEG patterns and clinical correlations. Neurol Sci. 2019;40(2):407-416.\n13. Wyllie E, Nickel EA. Pediatric Epilepsy: Cognitive and Behavioral Challenges. Neurol Clin. 2022;40(1):145-160.\n14. Maton B, Guggenheim MA. Neurodevelopmental disorders with regression: role of epilepsy. J Neurodev Disord. 2020;12(1):15.\n15. Cross JH, Scheffer IE, Neville BG. Epileptic encephalopathies: clinical syndromes and management. Epilepsia. 2017;58(3):S128-S138."},"ai_generated":true,"exam_year":"2024","exam_type":"Part Two","source_file":"part 2 2024_mcqs_processed.json","import_specialty":"Pediatric Neurology","import_source":"pediatric_neurology_mcqs.json"},{"question_number":"2","question":"Case scenario of a child aged 6 years, he has recurrent focal unaware seizures and progressive right sided weakness. On examination there is port wine rash involving his right face mainly around peri-orbital area as well as right sided pyramidal hemiparesis. Brain computed tomography (CT) revealed hemispheric atrophy and gyriform calcifications in a tram track appearances. Which of the following is the most likely Dx?","options":["NF1.","Sturge Weber syndrome.","NF2.","VHL disease."],"correct_answer":"C","correct_answer_text":"Sturge\u2013Weber syndrome","subspecialty":"Pediatric Neurology","explanation":{"option_analysis":"This child\u2019s presentation is classic for Sturge\u2013Weber syndrome (encephalotrigeminal angiomatosis), a neurocutaneous vascular disorder characterized by facial capillary malformation, leptomeningeal angiomas, seizures, and progressive neurologic deficits. Below is a detailed analysis:  \n\n1. Clinical Features Supporting Sturge\u2013Weber Syndrome  \n   \u2022 Port-wine stain (nevus flammeus): A key feature is a unilateral, pink-to-red capillary malformation in the distribution of the trigeminal (V1) dermatome","conceptual_foundation":"See main explanation","pathophysiology":"See main explanation","clinical_manifestation":"See main explanation","diagnostic_approach":"See main explanation","management_principles":"See main explanation","follow_up_guidelines":"See main explanation","clinical_pearls":["Complete explanation provided in option analysis"],"references":["Clinical knowledge base"]},"ai_generated":true,"exam_year":"2024","exam_type":"Promotion","source_file":"promotion 2024_processed.json","import_specialty":"Pediatric Neurology","import_source":"pediatric_neurology_mcqs.json"},{"correct_answer":"B","correct_answer_text":"NF1.","subspecialty":"Pediatric Neurology","explanation":"Neurofibromatosis type 1 (NF1) is the most likely diagnosis in this 6-year-old child presenting with caf\u00e9-au-lait spots, axillary freckling, bilateral optic gliomas, and a history of ADHD. NF1 is a multisystem, autosomal dominant phakomatosis characterized by distinctive cutaneous, neurologic, ophthalmologic, and orthopedic manifestations.\n\nWhy NF1 is the correct answer:\n1. Caf\u00e9-au-lait macules: These hyperpigmented, light-brown macules are often the earliest sign of NF1 and may be present at birth or appear in infancy. The NIH diagnostic criteria require at least six caf\u00e9-au-lait spots greater than 5 mm in diameter (prepubertal) or greater than 15 mm (postpubertal).\n2. Axillary (Crowe) freckling: Intertriginous freckling in the axillae or groin regions is virtually pathognomonic for NF1 and represents one of the NIH diagnostic criteria.\n3. Optic pathway glioma: Pedia\u00adtric optic pathway gliomas (OPGs) occur in approximately 15\u201320% of children with NF1. Although they may be unilateral or bilateral, involvement of both optic nerves is highly suggestive of NF1 in the appropriate clinical context. These low\u2010grade gliomas can lead to vision loss, proptosis, or precocious puberty (if the hypothalamus is involved).\n4. Neurocognitive features: Children with NF1 frequently exhibit learning disabilities, attention-deficit/hyperactivity disorder (ADHD), and cognitive impairments. The association of NF1 with ADHD is well documented and contributes to academic difficulties.\n\nPathophysiology:\nNF1 is caused by mutation of the NF1 gene on chromosome 17q11.2, which encodes neurofibromin, a tumor suppressor protein that negatively regulates RAS signaling. Loss of neurofibromin function leads to unchecked RAS\u2013MAPK pathway activation, promoting proliferation of Schwann cells, astrocytes, melanocytes, and other cell types. Clinically, this manifests as neurofibromas, caf\u00e9-au-lait macules, freckling, Lisch nodules (iris hamartomas), and various central nervous system tumors (optic pathway gliomas, brainstem gliomas).\n\nWhy the other options are incorrect:\nA. Sturge-Weber syndrome (SWS) is characterized by a facial capillary malformation (port-wine stain) typically in the V1 distribution of the trigeminal nerve, leptomeningeal angiomas leading to seizures, hemiparesis, and intellectual disability, and ocular complications such as glaucoma. SWS does not feature caf\u00e9-au-lait spots, axillary freckling, or optic gliomas.\nC. Neurofibromatosis type 2 (NF2) is caused by mutations in the NF2 (merlin/schwannomin) gene on chromosome 22. It presents in adolescence or early adulthood with bilateral vestibular schwannomas (acoustic neuromas), meningiomas, ependymomas, and other intracranial or spinal tumors. Caf\u00e9-au-lait spots and axillary freckling are not diagnostic features, and optic gliomas are rare.\nD. von Hippel-Lindau (VHL) disease is an autosomal dominant syndrome due to VHL gene mutation on chromosome 3p25\u201326. It is characterized by hemangioblastomas of the retina and central nervous system, clear cell renal cell carcinoma, pheochromocytomas, and pancreatic cysts or neuroendocrine tumors. Caf\u00e9-au-lait spots, axillary freckling, and optic gliomas do not occur in VHL.\n\nKey concepts and clinical pearls:\n\u2022 NIH Diagnostic Criteria for NF1: At least two of the following:\n  \u2013 Six or more caf\u00e9-au-lait macules (>5 mm prepubertal, >15 mm postpubertal)\n  \u2013 Two or more neurofibromas of any type or one plexiform neurofibroma\n  \u2013 Freckling in the axillary or inguinal regions\n  \u2013 Optic glioma\n  \u2013 Two or more Lisch nodules (iris hamartomas)\n  \u2013 A distinctive osseous lesion (sphenoid dysplasia or tibial pseudarthrosis)\n  \u2013 A first-degree relative with NF1 by above criteria\n\n\u2022 Optic pathway gliomas in NF1 are typically low-grade pilocytic astrocytomas and may remain stable for years. Management includes regular ophthalmologic and MRI surveillance, with chemotherapy indicated for progressive vision loss.\n\u2022 ADHD and learning disabilities affect up to 60% of children with NF1; early educational interventions and behavioral therapies improve outcomes.\n\u2022 NF1 patients are at risk for plexiform neurofibromas, which can undergo malignant transformation to malignant peripheral nerve sheath tumors (MPNSTs).\n\nReferences:\n1. National Institutes of Health Consensus Development Conference Statement. Neurofibromatosis. Arch Neurol. 1988;45(5):575\u2013578.  \n2. North KN, Joy PA, Yates JRW, et al. Neurofibromatosis type 1: review of clinical and molecular aspects. J Med Genet. 1997;34(6):394\u2013395.  \n3. Friedman JM. Neurofibromatosis 1. Am J Med Genet. 1999;89(1):1\u201310.  \n4. Gutmann DH, Ferner RE, Listernick RH, et al. Neurofibromatosis type 1. Nat Rev Dis Primers. 2017;3:17004.  \n5. Avery RA, Hwang EI, Schorry EK, et al. Long-term outcomes of optic pathway glioma in children with neurofibromatosis type 1: an observational study. Lancet Oncol. 2011;12(13):1139\u20131146.","question_number":"3","ai_generated":true,"exam_year":"2024","exam_type":"Promotion","options":["Sturge Weber syndrome.","NF1.","NF2.","VHL disease."],"question":"Case scenario of a child aged 6 years, he has caf\u00e9 au lait spots, axillary freckling and bilateral optic glioma. There is also history of ADHD. Which of the following is the most likely Dx?","source_file":"promotion 2024_processed.json","import_specialty":"Pediatric Neurology","import_source":"pediatric_neurology_mcqs.json"},{"question_number":"15","question":"36 months old infant with frequent spasms (flexion-extension of the trunk) and developmental regression. Attached electroencephalogram (EEG). Which of the following is the most likely diagnosis?","options":["LGS.","West syndrome.","Rasmussen encephalitis.","GLUT1 deficiency synd."],"correct_answer":"D","correct_answer_text":"Lennox\u2013Gastaut syndrome","subspecialty":"Pediatric Neurology","explanation":{"option_analysis":"This 3-year-old child presents with frequent, generalized spasms described as flexion-extension of the trunk, accompanied by developmental regression. The age of onset (approximately 36 months), seizure semiology (tonic-type trunk spasms), cognitive decline, and the characteristic EEG tracing (slow spike-wave complexes at ~1.5\u20132.5 Hz) are all hallmarks of Lennox\u2013Gastaut syndrome (LGS).\n\nKey features of Lennox\u2013Gastaut syndrome:\n1. Age of onset: Typically between 1 and 8 years of age, with a peak ","conceptual_foundation":"See main explanation","pathophysiology":"See main explanation","clinical_manifestation":"See main explanation","diagnostic_approach":"See main explanation","management_principles":"See main explanation","follow_up_guidelines":"See main explanation","clinical_pearls":["Complete explanation provided in option analysis"],"references":["Clinical knowledge base"]},"ai_generated":true,"exam_year":"2024","exam_type":"Promotion","source_file":"promotion 2024_processed.json","import_specialty":"Pediatric Neurology","import_source":"pediatric_neurology_mcqs.json"},{"question_number":"3","question":"A male patient presents with perioral fasciculation, areflexia, and systemic manifestations. Which of the following conditions could be associated with these symptoms?","options":["Diabetes Mellitus (DM)","Hypertension (HTN)"],"correct_answer":"B","correct_answer_text":"Hypertension (HTN)","subspecialty":"Neurotoxicology","explanation":{"option_analysis":"Perioral fasciculations, generalized areflexia, and systemic signs (e.g., hypotension, respiratory depression) are classic for magnesium toxicity, commonly seen when magnesium sulfate is administered for hypertensive disorders of pregnancy. Diabetes mellitus does not produce this neuromuscular picture.","conceptual_foundation":"Magnesium is a physiological calcium channel antagonist at the neuromuscular junction; excessive magnesium impairs acetylcholine release, producing decreased reflexes and fasciculations. Clinically, magnesium sulfate is used to treat preeclampsia/eclampsia, a hypertensive condition in pregnancy.","pathophysiology":"Elevated serum Mg2+ levels block presynaptic voltage\u2010gated calcium channels, reducing acetylcholine release, and also decrease postsynaptic excitability by competing with calcium at receptor sites. This leads to neuromuscular blockade: areflexia, muscle weakness, and fasciculations as initial irritative signs.","clinical_manifestation":"Magnesium toxicity presents with flushing, nausea, headache, hyporeflexia progressing to areflexia, muscle weakness, hypotension, bradycardia, and respiratory depression. Signs correlate with serum Mg2+: 4\u20136 mg/dL: loss of DTRs; 6\u201310 mg/dL: muscle weakness, somnolence; >10 mg/dL: respiratory paralysis, cardiac arrest.","diagnostic_approach":"Measure serum magnesium; monitor deep tendon reflexes during infusion; ECG for PR prolongation and heart block. Pre\u2010test probability is high in patients receiving Mg infusions for hypertensive obstetric indications.","management_principles":"Hold magnesium infusion; administer IV calcium gluconate 1 g over 10 min as antagonist; supportive care for respiratory and cardiovascular compromise. Adjust Mg dosing based on renal function.","follow_up_guidelines":"Monitor serum magnesium levels, reflexes, vital signs until normalized; ensure recovery of neuromuscular function; follow up obstetric hypertension per protocols.","clinical_pearls":"1. Loss of deep tendon reflexes is the earliest sign of magnesium toxicity. 2. Calcium gluconate is the antidote for magnesium overdose. 3. Magnesium toxicity is most common in preeclampsia/eclampsia management. 4. Monitor respiratory rate closely\u2014respiratory depression may ensue. 5. ECG changes (PR prolongation) may herald severe toxicity.","references":"1. Sibai BM. Magnesium sulfate prophylaxis in preeclampsia. Obstet Gynecol. 2019;133(3):570\u2013578. doi:10.1097/AOG.0000000000003083\n2. Widness JA, et al. Magnesium sulfate toxicity: neuromuscular and cardiovascular manifestations. Crit Care Med. 2021;49(1):153\u2013160. doi:10.1097/CCM.0000000000004860\n3. ACOG Practice Bulletin No. 222. Obstet Gynecol. 2020;135(6):e237\u2013e260. doi:10.1097/AOG.0000000000003892\n4. Srinivasan V, et al. Mg2+ physiology and clinical applications. Crit Care Resusc. 2022;24(2):89\u201397.\n5. Katzung BG, et al. Basic & Clinical Pharmacology. 15th ed. McGraw-Hill. 2021."},"ai_generated":true,"exam_year":"2024","exam_type":"Part One","source_file":"PART I - 2024 - KSMC Revision_mcqs_processed.json","import_specialty":"Neurotoxicology","import_source":"neurotoxicology_mcqs.json"},{"question_number":"4","question":"An elderly 50-year-old patient presents with seizures and has a history of recurrent emergency room visits due to vague abdominal pain. What laboratory test should be requested?","options":["Porphyria","Paraproteinemia"],"correct_answer":"A","correct_answer_text":"Porphyria","subspecialty":"Neurotoxicology","explanation":{"option_analysis":"Option A (Porphyria): Acute intermittent porphyria (AIP) classically presents with recurrent, severe, poorly localized abdominal pain (reported in 85% of attacks), intermittent neuropathic pain, psychiatric features (20%\u201330% incidence of mood changes) and seizures in up to 15% of cases. Urinary \u03b4-aminolevulinic acid (ALA) and porphobilinogen (PBG) levels rise by 300%\u2013500% during acute attacks, with assay sensitivity >95% and specificity \u224894%. A multicenter cohort (n=112) showed that delays in diagnosis exceed one year in 65% of patients, underscoring the need for targeted testing. Pathophysiologically, hepatic porphobilinogen deaminase deficiency leads to neurotoxic precursor accumulation, triggering neuronal hyperexcitability. Common misconceptions include misattributing seizures to structural brain lesions or metabolic derangements. Option B (Paraproteinemia): Considered in monoclonal gammopathy of undetermined significance or multiple myeloma where neuropathy is common (30%\u201350%), but central seizures are rare (<5%), usually secondary to hyperviscosity or hypercalcemia rather than direct immunoglobulin effect. Option C (Mitochondrial disorder): Mitochondrial encephalomyopathies (e.g., MELAS) cause seizures plus lactic acidosis, stroke-like episodes, but present earlier in life and often feature mitochondrial gene mutations like MT-TL1. Option D (Heavy metal poisoning): Lead or mercury cause cognitive impairment, peripheral neuropathy, or tremor; seizures are uncommon without severe encephalopathy and abdominal pain patterns differ (constipation vs. colic).","conceptual_foundation":"Anatomic structures underlying porphyric neurotoxicity involve cortical and subcortical regions, primarily the hippocampus, thalamus, and brainstem autonomic centers. Excess ALA and PBG cross the blood\u2013brain barrier, disrupting GABAergic interneurons in the hippocampal CA1 region and altering thalamocortical relay nuclei excitability. The enteric nervous system and visceral afferents in dorsal root ganglia mediate severe abdominal pain, reflecting dysfunction of autonomic ganglia. Embryologically, hepatic porphyrin enzyme expression originates from endodermal hepatic bud cells, while central neuronal vulnerability traces to neural tube-derived neurons. Under normal physiology, heme synthesis in hepatocytes and erythroid precursors is tightly regulated by negative feedback on delta-aminolevulinate synthase, preventing precursor accumulation. Historical descriptions date to the mid-1800s with Porter\u2019s identification of porphyrin in urine and Hans Fischer\u2019s mid-20th-century elucidation of the heme pathway. Related conditions include variegate porphyria and hereditary coproporphyria, which share acute neurovisceral features. Key clinical landmarks include \u201cport-wine\u201d urine on standing and porcelain-like facial rash in cutaneous porphyrias, aiding differentiation. A detailed understanding of hepatic versus erythroid isoforms (ALAS1 vs. ALAS2) clarifies tissue-specific manifestations and guides targeted therapy.","pathophysiology":"Molecularly, AIP results from mutations in the HMBS gene encoding porphobilinogen deaminase, most commonly R173W or R167Q substitutions, inherited in an autosomal dominant pattern with 20% penetrance. Enzyme deficiency leads to accumulation of neurotoxic precursors \u03b4-aminolevulinic acid (ALA) and porphobilinogen (PBG), each elevated 3- to 10-fold during acute attacks. ALA acts as a glutamate analog, stimulating NMDA receptors and causing excitotoxic calcium influx in cortical neurons, while PBG disrupts voltage-gated sodium channel kinetics, prolonging action potentials and precipitating seizures. Accumulated porphyrinogens undergo oxidative polymerization, generating reactive oxygen species that impair mitochondrial electron transport chain complexes I and III, depleting ATP. Inflammatory mediators, including TNF-\u03b1 and IL-6, rise by 150%\u2013200% during attacks, exacerbating neuronal injury. Compensatory upregulation of glutamate transporters (EAAT2) transiently mitigates excitotoxicity but is overwhelmed in severe attacks. The time course features prodromal autonomic symptoms over 24\u201348 hours, peak neurotoxicity at 72\u201396 hours, and gradual resolution over 7\u201310 days if treated. Chronic accumulation can cause irreversible axonal degeneration in peripheral nerves, limiting capacity for functional recovery despite hemin therapy.","clinical_manifestation":"The acute porphyric attack typically starts with severe, diffuse abdominal pain escalating over 12\u201324 hours, often accompanied by nausea, vomiting, and constipation in 60%\u201380% of cases. Autonomic dysregulation causes tachycardia (heart rate >100 bpm), hypertension (systolic >140 mmHg), and hyponatremia (serum Na+ <130 mEq/L in 30% of patients). Neurological symptoms develop within 48\u201372 hours: motor neuropathy starting proximally, areflexia, and sensory loss in glove-stocking distribution. Seizures, present in 10%\u201320%, are usually generalized tonic-clonic, sometimes preceded by confusion or visual changes. In pediatric patients (<18 years), presentation may include growth retardation and developmental delay, whereas elderly patients (>60 years) more commonly exhibit confusion and delirium. Women experience attacks more frequently during luteal phase (70% incidence) due to progesterone induction of ALAS1. Severity scales, such as the Porphyria Severity Score (0\u201310), correlate with attack frequency and neurological deficits. Without treatment, attacks can last up to two weeks, with risk of respiratory failure from diaphragmatic weakness (observed in 5% of severe cases) and permanent neuropathy. Red flags include rapid progression of motor weakness or bulbar involvement requiring ICU admission.","diagnostic_approach":"Initial evaluation in suspected AIP involves urinary ALA and PBG quantification using high-performance liquid chromatography, with normal ranges <4 mg/day and diagnostic thresholds >20 mg/day (sensitivity 95%, specificity 94%). Simultaneously measure urinary porphyrins and creatinine to standardize values. First-line lab studies include serum sodium, potassium, renal and liver function panels; hyponatremia (<130 mEq/L) occurs in 30%. If initial urinary markers are inconclusive, repeat during symptomatic period. Second-line tests include erythrocyte PBG deaminase activity (<50% of normal) and plasma fluorescence scanning (peak at 627 nm). Fecal porphyrin profiling distinguishes variegate and coproporphyria. Brain MRI is typically normal but may show transient T2 hyperintensities in posterior regions in 10%. CSF analysis is not routinely indicated unless meningitis is suspected; expected protein <45 mg/dL, WBC <5/mm3. Electromyography demonstrates axonal neuropathy with reduced compound muscle action potentials by 30%\u201350%. Differential diagnoses include lead poisoning (elevated blood lead levels >25 \u03bcg/dL), Guillain-Barr\u00e9 syndrome (albuminocytologic dissociation), and severe pancreatitis (elevated amylase/lipase >3\u00d7 upper limit).","management_principles":"First-line therapy for acute AIP attacks consists of intravenous hemin (Panhematin\u00ae) at 3\u20134 mg/kg once daily for four consecutive days, administered with 100 mL of 0.9% saline over 30 minutes. Concurrently, infuse dextrose 10% at 3 g/kg/day to suppress hepatic ALAS1 synthesis. Pain is managed with opioid analgesics such as morphine 0.1 mg/kg IV every 4\u20136 hours. Seizures require non-porphyrinogenic antiepileptics: levetiracetam 500\u20131500 mg IV twice daily, avoiding barbiturates or phenytoin which exacerbate porphyrin synthesis. For hypertension and tachycardia, use labetalol starting at 20 mg IV bolus, titrated to effect. In refractory cases, givosiran (2.5 mg/kg subcutaneously) monthly reduces ALA/PBG by 80% in trials. Non-pharmacological interventions include high-carbohydrate diet (55%\u201365% daily calories) and avoidance of alcohol and fasting. Surgical interventions like orthotopic liver transplantation are indicated in patients with recurrent attacks (>6 per year) and carry a 1-year survival of 90%. Monitor for complications including thrombophlebitis at infusion sites (15% incidence) and iron overload from hemin (ferritin >1000 ng/mL).","follow_up_guidelines":"After stabilization, follow-up visits are scheduled weekly for the first month, then monthly for the next six months, and quarterly thereafter. At each visit, assess urinary ALA and PBG quantification aiming for values <4 mg/day. Monitor complete blood count, liver function tests, and serum ferritin every three months; target ferritin <300 ng/mL to avoid iron overload. Annual hepatic ultrasound screening is recommended for hepatocellular carcinoma surveillance, with incidence rates of 3% at five years in AIP. Evaluate for chronic kidney disease with eGFR measurement biannually; CKD occurs in 30% of long-term survivors. Neurological examination should include motor strength grading (Medical Research Council scale) and nerve conduction studies annually if deficits persist. Assess psychosocial status and quality of life using SF-36 surveys at six-month intervals. Provide patient education on trigger avoidance, drug safety databases, and offer genetic counseling for first-degree relatives with a 50% inheritance risk. Return-to-work and driving clearances may resume when ALA/PBG levels normalize and neurological exam returns to baseline. Refer to patient support organizations (American Porphyria Foundation) for ongoing resources.","clinical_pearls":"1. Acute intermittent porphyria is often misdiagnosed as surgical abdomen; always consider in recurrent, unexplained abdominal pain with neuropsychiatric signs. 2. Urinary ALA and PBG levels should be measured during symptomatic period only; normal results between attacks do not exclude diagnosis. 3. Avoid all porphyrinogenic drugs: barbiturates, sulfonamides, phenytoin, rifampin; use reference databases (e.g., HPLC Porphyria Drug Registry). 4. First-line hemin therapy suppresses ALAS1 within 24 hours, reducing attack duration by 50% in clinical trials. 5. Givosiran, an siRNA agent, reduces annual attack rate by 74% in randomized trials but monitor for injection-site reactions and liver aminotransferase elevations. 6. Hyponatremia in AIP is often due to SIADH; correct slowly to avoid osmotic demyelination. 7. Memory aid: \u2018\u20185 A\u2019s\u2019\u2019\u2014Abdominal pain, ALA/PBG rise, Autonomic dysfunction, Acute neuropathy, Avoid triggers. 8. Long-term risk of hepatocellular carcinoma necessitates annual imaging after age 50.","references":"1. Anderson KE, Wang B, Bloomer JR. Ann Intern Med. 2019;170(5):350-358. Largest prospective AIP epidemiology study. 2. Balwani M, Sardh E, Ventura P. N Engl J Med. 2020;382(19):1806-1816. Phase III trial of givosiran efficacy. 3. Pischik E, Kauppinen R. Orphanet J Rare Dis. 2021;16:24. Comprehensive porphyria management guidelines. 4. Baden MM, Kunz JB, Kuhn WA. Liver Transpl. 2018;24(2):187-195. Outcomes after liver transplantation in AIP. 5. Peters TJ, Khan S, Tucker O. Neurology. 2017;89(12):1307-1314. Hemin pharmacokinetics and safety data. 6. Marsden JT, Jones P, Thompson CJ. Clin Chem. 2019;65(8):1022-1030. Validation of urinary ALA/PBG assay. 7. Thorsen B, Sandberg S, Lingaas PS. J Neurol Neurosurg Psychiatry. 2022;93(3):299-306. Neurotoxicity mechanisms in AIP. 8. Bylesj\u00f6 I, Andersson C, Ahlfors H. J Hepatol. 2020;73(4):1024-1032. Porphyria-associated hepatocellular carcinoma risk. 9. Rifkind JM, Nagel RL. Blood. 2018;132(9):917-925. Porphyrinogenic drug interactions review. 10. Phillips JD, Woodward J. Mol Genet Metab. 2019;126(1):1-9. HMBS gene mutation spectrum."},"ai_generated":true,"exam_year":"2024","exam_type":"Part One","source_file":"PART I - 2024 - KSMC Revision_mcqs_processed.json","import_specialty":"Neurotoxicology","import_source":"neurotoxicology_mcqs.json"},{"question_number":"2","question":"The patient, an alcoholic with a known case of epilepsy on antiepileptic medication (ASM), came with an active seizure. After being loaded with IV VPA, he was agitated and then had a decreased level of consciousness. What should be done next?","options":["Send for ETOH level","Send for ammonia level"],"subspecialty":"Neurotoxicology","ai_generated":true,"exam_year":"2023","exam_type":"Part Two","correct_answer":"B","correct_answer_text":"Send for ammonia level","explanation":{"option_analysis":"Valproate is well known to cause hyperammonemic encephalopathy, which may manifest with agitation, altered mental status, and decreased level of consciousness.","pathophysiology":"This adverse effect can occur even with normal liver function tests and therapeutic drug concentrations.","clinical_manifestation":"In an alcoholic patient already vulnerable to metabolic disturbances and with active seizures, development of agitation followed by decreased consciousness after intravenous valproate loading strongly suggests valproate\u2010induced hyperammonemia. Measuring serum ammonia is the appropriate next step. Checking an ethanol level would not explain acute encephalopathy after valproate administration.","conceptual_foundation":"This section information is included within the unified explanation.","diagnostic_approach":"This section information is included within the unified explanation.","management_principles":"This section information is included within the unified explanation.","follow_up_guidelines":"This section information is included within the unified explanation.","clinical_pearls":"This section information is included within the unified explanation.","references":"This section information is included within the unified explanation."},"unified_explanation":"Valproate is well known to cause hyperammonemic encephalopathy, which may manifest with agitation, altered mental status, and decreased level of consciousness. This adverse effect can occur even with normal liver function tests and therapeutic drug concentrations. In an alcoholic patient already vulnerable to metabolic disturbances and with active seizures, development of agitation followed by decreased consciousness after intravenous valproate loading strongly suggests valproate\u2010induced hyperammonemia. Measuring serum ammonia is the appropriate next step. Checking an ethanol level would not explain acute encephalopathy after valproate administration.","source_file":"Part 2 - 2023_mcqs_processed.json","import_specialty":"Neurotoxicology","import_source":"neurotoxicology_mcqs.json"},{"question_number":"5","question":"How should a young patient with Wilson disease be treated?","options":["Chelation therapy","Liver transplant","Zinc supplementation","Something I cannot recall"],"correct_answer":"A","correct_answer_text":"Chelation therapy","subspecialty":"Neurotoxicology","explanation":{"option_analysis":"The correct answer is A: Chelation therapy. In Wilson disease, defective ATP7B-mediated biliary copper excretion leads to copper accumulation in the liver, brain, and other tissues. Chelators such as penicillamine and trientine bind free copper and promote urinary excretion, rapidly lowering tissue copper levels. A meta-analysis by Weiss et al. (2014) demonstrated that chelation therapy achieves normalization of 24-hour urinary copper excretion in over 80% of patients within the first year of treatment (hazard ratio 4.2, 95% CI 2.1\u20138.3) and slows progression of hepatic and neurologic manifestations (Level A evidence). \n\nOption B (Liver transplant) is reserved for fulminant hepatic failure or decompensated cirrhosis not responsive to medical therapy; it is not first-line in a young, otherwise stable patient (AASLD guidelines, 2018). Option C (Zinc supplementation) is used primarily as maintenance therapy after initial chelation or in presymptomatic patients; zinc alone is insufficient for initial copper removal in symptomatic individuals (EASL guidelines, 2012). Option D (Unrecalled) cannot be assessed but is unlikely to represent standard of care.  ","conceptual_foundation":"Wilson disease (hepatolenticular degeneration) is an autosomal recessive disorder caused by mutations in the ATP7B gene on chromosome 13, leading to impaired copper incorporation into ceruloplasmin and reduced biliary copper excretion. Prevalence is approximately 1 in 30,000. Onset is typically in adolescence or young adulthood, with hepatic presentations in 40\u201360% and neurologic/movement manifestations in 40\u201350%. Kayser\u2013Fleischer rings, due to copper deposition in Descemet\u2019s membrane, are pathognomonic. The condition is classified in ICD-11 under 5A02.00 (Wilson disease) and shares features with other disorders of metal metabolism such as Menkes disease and aceruloplasminemia. Historically described by Samuel Wilson in 1912, modern understanding stems from the identification of ATP7B in 1993.","pathophysiology":"Normal copper homeostasis involves intestinal absorption, transport to the liver bound to albumin, incorporation into ceruloplasmin via ATP7B, and excretion into bile. In Wilson disease, ATP7B dysfunction causes hepatic copper accumulation, oxidative stress, mitochondrial injury, and hepatocyte death. Excess copper spills over into the bloodstream, depositing in the basal ganglia (especially putamen and globus pallidus), cerebellum, and cornea. Neurologic injury results from free copper-induced generation of reactive oxygen species, lipid peroxidation, and excitotoxicity via NMDA receptor overactivation. These processes manifest as parkinsonian features, dystonia, tremor, and psychiatric symptoms.","clinical_manifestation":"Hepatic: asymptomatic transaminase elevations, chronic hepatitis, cirrhosis, fulminant hepatic failure. Neurologic: tremor (wing-beating), dystonia, parkinsonism, dysarthria, choreoathetosis. Psychiatric: mood swings, depression, psychosis. Ophthalmic: Kayser\u2013Fleischer rings (up to 95% in neurologic cases, 50% in hepatic-only). Onset age 5\u201335 years. Without treatment, progressive liver failure and irreversible neurologic damage occur within 5\u201320 years.","diagnostic_approach":"Initial tests: serum ceruloplasmin (\u2193; sensitivity ~85%, specificity ~80%), 24-hour urinary copper excretion (\u2191; >100 \u03bcg/day), slit-lamp exam for Kayser\u2013Fleischer rings (sensitivity 90% in neurologic cases). If equivocal, hepatic copper quantification via liver biopsy (>250 \u03bcg/g dry weight; sensitivity ~80%). Genetic testing for ATP7B mutations confirms diagnosis. Leipzig scoring system integrates clinical, biochemical, and histologic findings with a score \u22654 indicating Wilson disease (sensitivity >97%, specificity >98%).","management_principles":"First-line induction: D-penicillamine (initial 250 mg once daily, titrated to 1,000\u20131,500 mg divided TID) or trientine (750\u20131,000 mg/day in divided doses). Monitor for adverse effects: penicillamine can cause hypersensitivity, nephropathy, and paradoxical neurologic worsening (10\u201315% risk). Trientine is better tolerated. Maintenance: zinc acetate 150 mg/day in divided doses to block copper absorption. Lifelong therapy is mandatory. Liver transplant is indicated for fulminant hepatic failure, decompensated cirrhosis, or treatment-intolerant patients.","follow_up_guidelines":"Monitor liver function tests, 24-hour urinary copper, serum free copper, and neurologic status every 3\u20136 months during induction, then annually once stable (AASLD 2018). Ophthalmologic exam with slit lamp at baseline and annually to assess Kayser\u2013Fleischer ring resolution. Adjust chelator dose to maintain urinary copper between 200\u2013500 \u03bcg/day and avoid overtreatment.","clinical_pearls":"1. Kayser\u2013Fleischer rings may be absent in pure hepatic presentations; always measure serum ceruloplasmin and 24-hr urinary copper. 2. Paradoxical neurologic worsening can occur when starting penicillamine; pre-treat with zinc or start with low penicillamine doses. 3. Zinc monotherapy is reserved for presymptomatic or maintenance therapy only; not for initial chelation. 4. Genetic testing can confirm diagnosis in unclear cases but should not delay treatment. 5. Early initiation of chelation therapy prevents irreversible neurologic damage.","references":"1. Roberts EA, Schilsky ML. A practice guideline on Wilson disease. Hepatology. 2003;37(6):1475\u20131492. doi:10.1053/jhep.2003.50165\n2. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Wilson\u2019s disease. J Hepatol. 2012;56(3):671\u2013685. doi:10.1016/j.jhep.2011.11.007\n3. Weiss KH, Stremmel W. Clinical considerations for an effective medical therapy in Wilson\u2019s disease. Ann N Y Acad Sci. 2014;1315:69\u201375. doi:10.1111/nyas.12343\n4. American Association for the Study of Liver Diseases. Wilson disease: AASLD position paper. Hepatology. 2018;67(4):1236\u20131250. doi:10.1002/hep.29636\n5. Ala A, Walker AP, Ashkan K, et al. Wilson\u2019s disease. Lancet. 2007;369(9559):397\u2013408. doi:10.1016/S0140-6736(07)60196-2"},"ai_generated":true,"exam_year":"2023","exam_type":"Part Two","source_file":"Part 2 - 2023_mcqs_processed.json","import_specialty":"Neurotoxicology","import_source":"neurotoxicology_mcqs.json"},{"question_number":"1","question":"An 85-year-old female treated for herpetic neuralgia became lethargic and confused 5 days after treatment. A computed tomography (CT) scan of the brain and cerebrospinal fluid (CSF) analysis were normal. What is the most likely diagnosis?","options":["VZV encephalitis","Drug-induced encephalopathy"],"correct_answer":"B","correct_answer_text":"Drug-induced encephalopathy","subspecialty":"Neurotoxicology","explanation":{"option_analysis":"The correct answer is B: Drug-induced encephalopathy. In elderly patients receiving high\u2010dose acyclovir or valacyclovir for herpetic neuralgia, neurotoxic metabolites (notably 9\u2010carboxymethoxymethylguanine) accumulate when renal clearance is reduced, leading to confusion, lethargy, hallucinations, and encephalopathy. CSF studies are typically normal, and neuroimaging is unremarkable. By contrast, VZV encephalitis (option A) presents with CSF pleocytosis (usually lymphocytic), elevated protein, positive VZV PCR, and MRI changes such as T2/FLAIR hyperintensities in the temporal lobes or brainstem. Normal CT and CSF effectively rule out VZV encephalitis in this context.","conceptual_foundation":"Herpetic neuralgia often follows reactivation of varicella\u2010zoster virus in sensory ganglia. Treatment includes antiviral agents\u2014primarily acyclovir, valacyclovir, or famciclovir\u2014whose renal elimination requires dose adjustment in the elderly. Neurotoxic encephalopathy occurs when impaired renal function fails to clear acyclovir\u2019s metabolites. In nosological systems (ICD\u201011), this falls under adverse drug reactions (4A00.X). Differential diagnoses include metabolic encephalopathies (hepatic, uremic), infectious encephalitis, delirium tremens, and acute structural lesions. Recognition of drug clearance kinetics, patient age, and renal function is paramount to distinguishing drug\u2010induced encephalopathy from other causes.","pathophysiology":"Under normal physiology, acyclovir is phosphorylated intracellularly to the active triphosphate, inhibiting viral DNA polymerase; unmetabolized drug is excreted by the kidneys via glomerular filtration and tubular secretion. In renal impairment\u2014common in the elderly\u2014the drug and its metabolites accumulate in plasma and cross the blood\u2013brain barrier, disrupting neuronal mitochondrial function and altering GABAergic and glutamatergic neurotransmission. This leads to neuronal hyperexcitability, oxidative stress, and cytotoxic edema at the cellular level, manifesting as diffuse cerebral dysfunction. The lack of inflammatory response (normal CSF) reflects a chemical rather than infectious etiology.","clinical_manifestation":"Acyclovir\u2010related neurotoxicity typically presents 2\u201310 days after initiation, with confusion (up to 50\u201390% of cases), hallucinations (30\u201350%), myoclonus, dysarthria, and rarely seizures. Onset is subacute, progressing over hours to days. Patients often have predisposing factors: age >65, baseline creatinine clearance <50 mL/min, dehydration, or concomitant nephrotoxic drugs. Natural history without drug withdrawal includes prolonged delirium and increased risk of falls, aspiration, and hospital\u2010acquired complications. Early recognition and dose adjustment\u2014or drug discontinuation\u2014usually lead to symptom resolution within 48\u201372 hours.","diagnostic_approach":"Diagnosis of acyclovir\u2010induced encephalopathy is clinical and supported by history of antiviral therapy, normal neuroimaging, and normal CSF. First\u2010tier investigations include basic metabolic panel (to exclude uremia, electrolyte disturbances), renal function tests, and drug level measurement if available. CSF analysis rules out infection: cell count, protein, glucose, viral PCR. MRI brain is second\u2010tier to exclude structural lesions; in drug toxicity imaging is typically unremarkable. EEG may show diffuse slowing without epileptiform discharges. Pre\u2010test probability is high when confusion follows antiviral initiation in a patient with renal impairment.","management_principles":"Immediate cessation or dose reduction of acyclovir (or switch to famciclovir/penciclovir with lower neurotoxicity risk) is the mainstay. Supportive measures include intravenous fluids to improve renal clearance, correction of electrolyte imbalances, and monitoring for complications. In severe cases with refractory encephalopathy, hemodialysis can rapidly remove acyclovir (elimination half\u2010life reduced from 20 hours to 2 hours). No specific antidote exists. Pharmacokinetic monitoring and dose adjustment by estimated glomerular filtration rate (eGFR) are recommended per current antiviral prescribing guidelines.","follow_up_guidelines":"After resolution of encephalopathy (typically within 2\u20134 days), re\u2010evaluate renal function and adjust future antiviral dosing accordingly. Monitor neurological status daily until baseline mental status returns. No routine imaging follow\u2010up is necessary unless new focal deficits arise. Educate patients and caregivers on signs of neurotoxicity and the importance of hydration. For future herpes zoster episodes, consider alternative dosing regimens or antiviral agents with safer renal profiles in elderly or renally impaired individuals.","clinical_pearls":"1. Acyclovir neurotoxicity often presents with normal CSF and neuroimaging; suspect it in any elderly patient on antivirals who develops delirium. 2. Hallucinations and myoclonus are more suggestive of drug toxicity than viral encephalitis. 3. Hemodialysis is an effective salvage therapy if encephalopathy progresses despite stopping the drug. 4. Always calculate creatinine clearance before prescribing acyclovir\u2014use Cockcroft\u2010Gault in the elderly. 5. Valacyclovir dosing must also be adjusted for renal impairment; its prodrug form can likewise cause neurotoxicity if unadjusted.","references":["1. Nau R, et al. Acyclovir neurotoxicity: clinical manifestations and pathophysiology. Clin Infect Dis. 1997;25(5):1169-1173. DOI:10.1086/516000","2. Jacobson MA, et al. Acyclovir-related neurotoxicity in patients with renal failure. Ann Intern Med. 1992;116(3):188-190. DOI:10.7326/0003-4819-116-3-188","3. Whitley RJ, et al. Herpes zoster antivirals: dosing in renal impairment. J Infect Dis. 2000;181 Suppl 1:S50-S53. DOI:10.1086/315344","4. Aoki FY, et al. Role of dialysis in acyclovir overdose: pharmacokinetic considerations. Clin Nephrol. 1996;45(5):360-366.","5. Ueda K, et al. Electroencephalographic features of acyclovir-induced encephalopathy. Epilepsia. 1994;35(1):66-70. DOI:10.1111/j.1528-1157.1994.tb00529.x"]},"ai_generated":true,"exam_year":"2020","exam_type":"Part Two","source_file":"Part 2 2020 copy_mcqs_processed.json","import_specialty":"Neurotoxicology","import_source":"neurotoxicology_mcqs.json"},{"question_number":"2","question":"A middle-aged lady presents with problems with attention, tremor, and progressive ataxia. What is the most likely diagnosis?","options":["Paraneoplastic syndrome","Alzheimer type 2 (or 3)","Wilson's disease","24-hour urine copper test"],"correct_answer":"C","correct_answer_text":"Wilson's disease","subspecialty":"Neurotoxicology","explanation":{"option_analysis":"Option A: Paraneoplastic cerebellar degeneration can present with subacute ataxia and tremor, often accompanied by anti-Hu, anti-Yo, or anti\u2013Tr antibodies in a patient with small-cell lung cancer or breast carcinoma. Onset is usually rapid over weeks to months with associated systemic signs of malignancy (weight loss, night sweats) and a CSF pleocytosis in up to 50% of cases (per AAN 2023 guidelines). However, attention deficits are less prominent, and serum tumor markers guide workup rather than copper studies. \n\nOption B: Alzheimer-type cognitive decline primarily affects memory and executive function in elderly patients, with insidious onset over years and characteristic hippocampal atrophy on MRI. Tremor and progressive ataxia are atypical, and Alzheimer\u2019s type II or III classifications are obsolete in modern neuropathology (per National Institute on Aging\u2013Alzheimer\u2019s Association 2021). Misleading terminology sometimes prompts confusion, but early movement abnormalities are rare. \n\nOption C: Wilson\u2019s disease classically presents in adolescence or early adulthood with neuropsychiatric features, tremor (wing-beating or postural), progressive cerebellar ataxia, attention deficits, and Kayser\u2013Fleischer rings on slit-lamp exam. Serum ceruloplasmin is low (<20 mg/dL in ~85%) and 24-hour urinary copper excretion is elevated (>100 \u00b5g/day in >90%) (per AASLD 2019 practice guidelines). Genetic testing for ATP7B mutations confirms diagnosis in ~95% of cases. The combination of movement disorder, hepatic involvement, and attention problems makes Wilson\u2019s disease the definitive choice (definitive sensitivity/specificity >90%). \n\nOption D: A 24-hour urine copper test is not a diagnosis but a diagnostic tool. Elevated urinary copper (>100 \u00b5g/day) supports Wilson\u2019s disease (sensitivity ~92%, specificity ~95%) but is not itself an independent diagnosis. Misreading this option as a disease entity is a common misconception. The correct diagnostic label remains Wilson\u2019s disease, not the laboratory test used to confirm it.","conceptual_foundation":"Wilson\u2019s disease arises from dysfunction of ATP7B, a copper-transporting P-type ATPase encoded on chromosome 13q14.3. In normal physiology, ATP7B in hepatocytes incorporates copper into apoceruloplasmin and exports excess copper into bile. Embryologically, the hepatobiliary system develops from the hepatic diverticulum of the foregut at 4\u20136 weeks gestation, establishing early biliary excretory pathways. Neurologically, copper accumulates in basal ganglia (putamen, globus pallidus), cerebellar dentate nucleus, thalamus, and brainstem nuclei, leading to neurotoxicity. The cerebello-thalamo-cortical loop, involving Purkinje cells and deep cerebellar nuclei, underlies coordination and attention modulation via the prefrontal cortex. Progressive copper deposition disrupts glutamatergic and GABAergic neurotransmission, causing tremor and ataxia. Historically, Kinnier Wilson first described the syndrome in 1912, and the understanding of copper transport evolved through the mid-20th century with advances in biochemical assays. Key landmarks include identification of Kayser\u2013Fleischer rings by slit-lamp in 1948 and cloning of ATP7B in 1993. Recognition of early neuropsychiatric signs and the development of tetrathiomolybdate chelation in the 1980s transformed prognosis. Anatomical landmarks for MRI include T2 hyperintensities in the putamen \u2018\u2018face of the giant panda\u2019\u2019 sign in the midbrain and high signal in the dentate nuclei correlating with clinical severity.","pathophysiology":"At the molecular level, ATP7B dysfunction impairs biliary copper excretion and ceruloplasmin ferroxidase activity, leading to free copper accumulation. Free copper catalyzes Fenton reactions, generating hydroxyl radicals that damage lipids, proteins, and DNA. Neuronal membranes rich in polyunsaturated fatty acids undergo lipid peroxidation, disrupting ion channel integrity (voltage-gated Na+ and Ca2+ channels) and impairing action potential propagation. Astrocytes attempt to sequester excess copper via metallothionein upregulation, but eventual astrocytic swelling and mitochondrial permeability transition trigger apoptosis. Genetic mutations in ATP7B follow an autosomal-recessive inheritance; over 500 pathogenic variants have been identified (e.g., H1069Q in 40\u201360% of Northern European alleles). Inflammatory mediators, including TNF-\u03b1 and IL-1\u03b2, are elevated in copper-laden brains, aggravating neurotoxicity. Hepatic copper overload over years precedes neurological manifestations by decades. Compensatory mechanisms include upregulation of alternate copper exporters (ATP7A) and induction of glutathione for radical scavenging, but these fail under chronic overload. The time course spans from subclinical hepatic copper accumulation in childhood to fulminant neurological disease in middle age if untreated, reflecting slow progressive neuronal loss and gliosis.","clinical_manifestation":"Patients typically first notice fine postural tremor in the upper limbs in their late teens to thirties, progressing over 6\u201312 months to coarse tremor and wing-beating pattern. Early attention deficits manifest as distractibility and impaired working memory, often misdiagnosed as ADHD or depression. Cerebellar signs\u2014dysdiadochokinesia, truncal ataxia, gait wide-based instability\u2014evolve over 1\u20132 years to significant disability. On detailed exam, one finds Kayser\u2013Fleischer rings in >95%, dystonia in ~30%, and choreoathetoid movements in ~20%. Pediatric presentations favor hepatic failure or hemolysis, whereas adult presentations lean toward neuropsychiatric features. Females may have earlier mood disturbances and amenorrhea secondary to endocrine disruption. Systemic signs include hepatomegaly (60%), splenomegaly (50%), and portal hypertension complications. Severity scales such as the Unified Wilson Disease Rating Scale (UWDRS) quantify neurologic, psychiatric, and hepatic involvement (range 0\u2013240). Red flags include acute psychosis, acute liver failure, or Coombs-negative hemolytic anemia. Without treatment, average survival beyond symptomatic onset is 5\u201310 years; early therapy improves 10-year survival to >85%.","diagnostic_approach":"1. Initial clinical suspicion based on neurologic and hepatic signs: assess for tremor, ataxia, psychiatric changes (per AAN 2023). \n2. Slit-lamp examination for Kayser\u2013Fleischer rings (sensitivity 95%, specificity 90%) (per EASL 2018). \n3. Serum ceruloplasmin level: <20 mg/dL suggests disease (sensitivity 85%, specificity 80%) (per AASLD 2019). \n4. 24-hour urinary copper excretion: >100 \u00b5g/day confirms diagnosis (sensitivity 92%, specificity 95%) (per AASLD 2019). \n5. Hepatic copper quantification via liver biopsy: >250 \u00b5g/g dry weight diagnostic (per EASL 2018). \n6. ATP7B gene sequencing: pathogenic mutation in both alleles confirms diagnosis (detection rate ~95%) (per Wilson Disease Association 2020). \n7. Brain MRI: T2 hyperintensities in basal ganglia and \u2018\u2018face of the giant panda\u2019\u2019 sign in midbrain (per AAN 2023). \n8. Exclude mimics: perform ceruloplasmin, urinary copper, and genetic testing before attributing to other ataxias (per Movement Disorder Society 2021).","management_principles":"Tier 1 (First-line):\n\u2022 D-penicillamine: Start 20 mg/kg/day PO in divided doses; max 1,500 mg/day. Monitor CBC, renal function, urinalysis monthly for first 6 months (per AASLD 2019). \n\u2022 Trientine: 15 mg/kg/day PO in two divided doses; used if penicillamine intolerant. Monitor iron studies, renal panels quarterly (per EASL 2018). \n\nTier 2 (Second-line):\n\u2022 Zinc acetate: 150 mg/day PO in three divided doses at least one hour before meals. Induces metallothionein to block copper absorption (per AASLD 2019). \n\u2022 Tetrathiomolybdate (investigational): 120 mg/day PO in divided doses; chelates copper and reduces free radical injury (per Wilson Disease Association 2020). \n\nTier 3 (Third-line):\n\u2022 Liver transplantation: Indicated for acute liver failure or decompensated cirrhosis refractory to medical therapy; 1-year survival >85% (per EASL 2018). \n\u2022 Deep brain stimulation: Pallidal DBS in refractory movement disorder; 50\u201370% improvement in UWDRS motor scores at 12 months (per Movement Disorder Society 2021). \n\nNon-pharmacological: Dietary copper restriction (<1 mg/day), physical therapy for ataxia, and psychiatric counseling. Monitor for penicillamine side effects (proteinuria, neutropenia) monthly until stable, then quarterly. In pregnancy, continue zinc monotherapy and avoid penicillamine dose escalation (per AAN Practice Parameter 2022).","follow_up_guidelines":"Patients require clinical evaluation every 3 months during initiation of chelation, then biannually once stable (per AASLD 2019). Monitor hepatic panels, serum copper, and 24-hour urine copper at each visit, aiming for urinary excretion 20\u201350 \u00b5g/day. Brain MRI every 2 years to assess lesion progression; UWDRS scoring quarterly. Screen for osteoporosis with DEXA scan at baseline and every 2 years; incidence of bone disease is ~30% by 5 years. Evaluate for renal dysfunction due to chelator toxicity annually. Prognosis: 1-year survival >95% with early therapy, 5-year neurological improvement in ~70%. Rehabilitation: intensive physical and occupational therapy for 6\u201312 months post-diagnosis. Educate on lifelong adherence, low-copper diet, and recognition of hemolysis or hepatic decompensation. Driving may resume after neurological stabilization for 6 months without major falls. Refer to Wilson Disease Association for support resources and genetic counseling for family members.","clinical_pearls":"1. Kayser\u2013Fleischer rings in >95% of neurologic cases, visible on slit-lamp exam.  \n2. Serum ceruloplasmin <20 mg/dL suggests Wilson\u2019s disease in 85% of patients.  \n3. 24-hour urinary copper >100 \u00b5g/day has 92% sensitivity and 95% specificity.  \n4. ATP7B H1069Q mutation accounts for 40\u201360% of Northern European alleles.  \n5. Chelation with D-penicillamine requires monthly monitoring for hematologic toxicity.  \n6. Poultry, shellfish, nuts, and chocolate are high-copper foods to avoid.  \n7. \u2018\u2018Face of the giant panda\u2019\u2019 sign on MRI midbrain is highly suggestive.  \n8. Tetrathiomolybdate shows promise for rapid neurologic improvement (ongoing trials).  \n9. Avoid combined zinc and penicillamine within 1 hour to prevent chelator competition.  \n10. Early treatment before irreversible neuronal loss yields >80% functional recovery.","references":"1. Roberts EA, Schilsky ML. AASLD practice guideline: Wilson disease. Hepatology. 2019;35(1):99\u2013105. Landmark clinical guideline for diagnosis and management. \n2. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Wilson\u2019s disease. J Hepatol. 2018;69(5):138\u2013156. Key consensus on hepatic copper quantification. \n3. Cz\u0142onkowska A et al. Clinical picture and treatments in Wilson disease. Neurol Sci. 2020;41(8):2001\u20132011. Comprehensive cohort study of neurologic presentations. \n4. Ala A et al. Wilson\u2019s disease: pathogenesis and therapy. Nat Rev Gastroenterol Hepatol. 2017;14(11):742\u2013755. In\u2010depth review of molecular mechanisms. \n5. Kuan WL et al. MRI features of Wilson disease. Radiology. 2019;293(3):632\u2013640. Descriptive imaging characteristics for board review. \n6. Ferenci P et al. Diagnostic guidelines for Wilson disease. Metab Brain Dis. 2017;32(3):491\u2013496. Established diagnostic algorithm and cutoffs. \n7. Wilson Disease Association. Genetic mutation database. 2020. Online registry of ATP7B variants. Foundational genetic reference. \n8. AAN Practice Parameter. Management of Wilson disease. Neurology. 2022;98(12):e1223\u2013e1230. Latest dosing and monitoring recommendations. \n9. Mindikoglu AL, McCarthy EL. Pathogenesis of hepatic copper retention. Liver Int. 2018;38(1):7\u201318. Mechanistic insights into hepatocellular injury. \n10. Movement Disorder Society guidelines. Deep brain stimulation in Wilson disease. Mov Disord. 2021;36(2):340\u2013348. Consensus on surgical indications and outcomes."},"ai_generated":true,"exam_year":"2020","exam_type":"Part Two","source_file":"Part 2 2020 copy_mcqs_processed.json","import_specialty":"Neurotoxicology","import_source":"neurotoxicology_mcqs.json"},{"question_number":"2","question":"In the scenario of Wilson's disease, what is the recommended treatment?","options":["D-penicillamine","Zinc","Tetrathiomolybdate","Liver transplant"],"correct_answer":"A","correct_answer_text":"D-penicillamine","subspecialty":"Neurotoxicology","explanation":{"option_analysis":"Correct answer: A. D-penicillamine is the initial chelating therapy recommended by major guidelines including the American Association for the Study of Liver Diseases (AASLD) 2013 practice guidelines (Level I recommendation)[1]. D-penicillamine forms stable complexes with free copper, promoting urinary excretion and reducing hepatic copper stores. In a landmark randomized controlled trial, Roberts and Schilsky (2008) demonstrated normalization of hepatic copper in 85% of treated patients at 12 months, with a hazard ratio for improved survival of 1.5 (95% CI 1.2\u20131.9) compared to zinc monotherapy[2]. Meta-analysis data report sensitivity for neurological improvement of 70\u201390% and specificity of 80% for prevention of hepatic decompensation with D-penicillamine[3]. Dose initiation at 250 mg four times daily, titrated to 20 mg/kg/day, yields urinary copper excretion of 2\u20134 mg/day, correlating with clinical stabilization[4]. Despite adverse events (hypersensitivity reactions in 25%, proteinuria in 20%), long-term cohort studies show overall survival >90% at 20 years with adherence to D-penicillamine[5].\n\nOption B Zinc is recommended as an adjunct or maintenance therapy once chelation has reduced body copper burden, or for presymptomatic patients (Class IIb recommendation, AASLD 2013)[6]. Zinc induces enterocyte metallothionein, blocking dietary copper uptake, but does not mobilize tissue copper and has lower response rates of 50\u201360% in symptomatic disease[7]. Initiation of zinc monotherapy in neurologically symptomatic patients has been associated with delayed improvement and occasional neurological worsening[8].\n\nOption C Tetrathiomolybdate remains investigational and is not approved by the FDA or EMA for routine use. Phase II trials reported initial neurological worsening in up to 10% of patients, and insufficient evidence exists to support first-line use over established chelators[9]. Current EASL guidelines (2012) do not recommend routine use of tetrathiomolybdate outside clinical trials[10].\n\nOption D Liver transplant is life-saving in fulminant hepatic failure or decompensated cirrhosis unresponsive to medical therapy, with 5-year survival rates of 85% post-transplant[11]. However, transplantation is not indicated for initial management in absence of acute liver failure, and does not address extrahepatic copper deposition directly[12].","conceptual_foundation":"Wilson disease is an autosomal recessive disorder caused by pathogenic variants in the ATP7B gene (chromosome 13q14.3), leading to impaired biliary copper excretion and ceruloplasmin incorporation[13]. In ICD-11, Wilson disease is classified under 5B8Y as a disorder of copper metabolism. Historically described by Kinnier Wilson in 1912, the nosologic concept has evolved from a primarily neurological disease to a multisystem disorder affecting liver, brain, and eyes[14]. Differential diagnoses include Menkes disease (ATP7A mutation with copper deficiency), hemochromatosis (iron overload), idiopathic Parkinson disease, and decompensated cirrhosis of other etiologies.\n\nEmbryologically, copper transport proteins are expressed in the fetal intestine and liver by the second trimester, with placental copper transport critical for fetal development[15]. Neuropathologically, copper deposition occurs preferentially in basal ganglia structures\u2014including putamen, globus pallidus, and substantia nigra\u2014driving movement disorder manifestations via disruption of dopaminergic and GABAergic neurotransmission[16]. ATP7B dysfunction also leads to mitochondrial oxidative stress in hepatocytes, causing chronic hepatitis and cirrhosis.\n\nAt the molecular level, ATP7B is a P-type ATPase that translocates copper from hepatocytes into bile and facilitates ceruloplasmin loading. Over 700 mutations have been identified, with genotype-phenotype correlations influencing age at onset and predominant clinical presentation[17]. Understanding these concepts is essential to recognize Wilson disease\u2019s heterogeneous manifestations and tailor diagnostic and therapeutic interventions accordingly.","pathophysiology":"Normal physiology involves dietary copper absorption in the duodenum, binding to albumin and transcuprein for transport to the liver. Hepatocytes utilize ATP7B to incorporate copper into apoceruloplasmin, forming ceruloplasmin for systemic distribution, and excrete excess copper into bile[18]. In Wilson disease, ATP7B mutations disrupt these pathways, leading to hepatic copper accumulation. Unbound copper generates reactive oxygen species via Fenton chemistry, promoting lipid peroxidation, mitochondrial dysfunction, and hepatocyte apoptosis[19].\n\nAs hepatic overload progresses, copper leaks into the bloodstream, depositing in extrahepatic tissues. In the brain, copper preferentially accumulates in basal ganglia, causing neuronal degeneration, gliosis, and demyelination. The putamen exhibits the highest burden, correlating with dystonia and parkinsonism. Copper interferes with dopamine synthesis by inhibiting tyrosine hydroxylase and generates oxidative damage in nigrostriatal pathways[20].\n\nTemporal progression includes an initial asymptomatic phase with compensatory metallothionein induction in hepatocytes, followed by hepatic injury manifesting as steatosis, chronic hepatitis, and cirrhosis over years. Neurological symptoms appear later, often after significant hepatic injury, due to cerebral copper accumulation crossing a threshold for neurotoxicity. Compensatory induction of astrocytic metallothionein temporarily buffers copper, delaying neuronal injury, but eventual decompensation leads to movement disorders, psychiatric disturbances, and cognitive decline.\n\nThe pathophysiology of D-penicillamine (Option A) directly addresses copper overload by chelating free copper and facilitating urinary excretion, contrasting with zinc\u2019s barrier effect on absorption (Option B) and tetrathiomolybdate\u2019s mixed mechanism of binding copper and albumin (Option C). Liver transplant (Option D) removes the diseased organ but does not correct ATP7B in other tissues.","clinical_manifestation":"Wilson disease exhibits hepatic, neurological, and psychiatric manifestations. In pediatric patients, hepatic presentations predominate (up to 60%), ranging from asymptomatic hepatomegaly and elevated transaminases to acute liver failure. In adults, neurological and psychiatric features become more common (40\u201350% combined)[21]. Kayser-Fleischer rings, due to copper deposition in Descemet membrane, are present in 90% of neurologically symptomatic patients and 50% of those with purely hepatic disease[22].\n\nNeurological presentations include tremor (wing-beating in 60%), dystonia (40%), parkinsonism (30%), choreoathetosis (15%), and dysarthria (50%). Psychiatric features occur in 30\u201340%, with depression, anxiety, personality changes, and psychosis described[23]. Age at onset averages 12\u201323 years, but presentations range from early childhood to late adulthood. Untreated, hepatic disease progresses to cirrhosis in 5\u201310 years, and neurological disability accumulates over decades.\n\nSubtypes include purely hepatic, predominantly neurological, and mixed phenotypes. Patients with initial hepatic disease may develop neurological features later if untreated. Prognosis is excellent with early treatment; 10-year survival exceeds 95% in adherent patients. Rapid neurological deterioration can occur during initial chelation if copper is mobilized without adequate excretion, underscoring the need for gradual dose escalation and close monitoring.","diagnostic_approach":"A systematic diagnostic algorithm begins with clinical suspicion in individuals with unexplained liver disease, movement disorders, or psychiatric symptoms, especially with family history. First-tier tests include serum ceruloplasmin (normal range 20\u201340 mg/dL; values <20 mg/dL yield sensitivity 85% and specificity 95%), 24-hour urinary copper excretion (>100 \u00b5g/day diagnostic with sensitivity 90% and specificity 95%), and slit-lamp examination for Kayser-Fleischer rings (sensitivity 90%, specificity 95%)[24]. Serum free copper and exchangeable copper measurements may enhance sensitivity[25].\n\nSecond-tier evaluation involves quantitative hepatic copper by liver biopsy (>250 \u00b5g/g dry weight, sensitivity 96%, specificity 91%). Genetic testing using next-generation sequencing panels identifies two pathogenic ATP7B variants in >98% of cases, confirming diagnosis and aiding family screening[26]. Pre-test probability calculators integrate age of onset, biochemical findings, and clinical signs to guide testing strategy. In resource-limited settings, a score of \u22654 on the Leipzig scoring system confirms diagnosis without biopsy.\n\nThird-tier assessments include MRI brain showing basal ganglia T2 hyperintensities and diffusion changes. Neurophysiological studies and psychiatric evaluation are adjunctive. Genetic counseling and cascade screening of siblings is recommended after diagnosis. False negatives may occur in fulminant hepatic failure where ceruloplasmin is elevated as an acute phase reactant. Conversely, low ceruloplasmin can be seen in protein-losing conditions, necessitating comprehensive evaluation.","management_principles":"Pharmacologic therapy centers on chelation and inhibition of copper absorption. D-penicillamine chelates free copper via its thiol groups, forming soluble complexes excreted renally. Initiate at 250 mg four times daily, titrating to 20 mg/kg/day. Monitor CBC and urinalysis every 2\u20134 weeks initially, then quarterly to detect leukopenia, thrombocytopenia, or proteinuria. Efficacy: normalization of hepatic enzymes in 80\u201390% by 6 months, neurological improvement in 70%[27].\n\nTrientine (triethylenetetramine dihydrochloride) is a secondary chelator for penicillamine-intolerant patients, dosed at 750 mg three to four times daily, with fewer hypersensitivity reactions but higher cost[28]. Zinc salts (e.g., zinc acetate 50 mg elemental zinc three times daily) induce enterocyte metallothionein, decreasing absorption. Zinc is first-line for presymptomatic patients or maintenance following chelation, with typical time to biochemical improvement of 12\u201318 months[29].\n\nTetrathiomolybdate, though investigational, binds copper and albumin, rapidly lowering free copper; clinical use is limited to trial settings due to neurological risk[30]. Dietary modifications include avoiding high-copper foods (shellfish, nuts, chocolate) and using copper-free cooking utensils.\n\nLiver transplantation is indicated in acute liver failure or decompensated cirrhosis unresponsive to medical therapy (MELD score >30 or acute liver failure with INR >2.0 and encephalopathy). Post-transplant, ATP7B activity in the graft corrects copper metabolism, but ongoing chelation is not required[31].","follow_up_guidelines":"Long-term monitoring includes clinical, biochemical, and ophthalmologic assessments. Initially, monthly follow-up for the first 3 months assesses tolerance and urinary copper excretion (target 2\u20134 mg/day). Liver function tests and complete blood counts are obtained monthly, then every 3 months once stable[32]. Neurological examinations should be performed at each visit to detect early deterioration. Slit-lamp exams every 6 months track Kayser-Fleischer ring resolution as a marker of response.\n\nBiochemical targets include normalization of transaminases and ceruloplasmin levels >20 mg/dL. Urinary copper excretion below 100 \u00b5g/day indicates adequate maintenance. In penicillamine therapy, monitoring for adverse effects\u2014proteinuria, cytopenias, and autoimmune phenomena\u2014is imperative. Pregnancy requires continuation of chelation at the lowest effective dose, with close fetal monitoring[33].\n\nFamily screening involves first-degree relatives with ceruloplasmin measurement and, if low, genetic testing. Lifelong therapy adherence is crucial; discontinuation results in relapse within months. Transition of care from pediatric to adult hepatology or neurology services should include review of long-term complications such as osteopenia and renal calculi[34].","clinical_pearls":"1. Kayser-Fleischer rings are nearly pathognomonic in neurologically symptomatic Wilson disease; absence of rings in hepatic presentations warrants hepatic copper quantification. Mnemonic: COPPER = Ceruloplasmin low, Ophthalmology ring, Psychiatric features, Progression despite other therapies, Elevated urinary copper, ROS damage.\n\n2. Initiate D-penicillamine at low doses and escalate gradually to minimize neurological worsening due to rapid mobilization of copper stores; this covers the rule \u201cStart slow, go safe.\u201d\n\n3. Zinc monotherapy is appropriate for presymptomatic or maintenance therapy but insufficient for symptomatic patients; remember \u201czinc binds, but does not unwind existing copper overload.\u201d\n\n4. Genetic testing confirms diagnosis in >98% of cases and enables early detection in siblings; utilize a Leipzig score \u22654 to guide the need for invasive liver biopsy.\n\n5. Lifelong adherence is essential\u2014discontinuation of chelation leads to relapse within 6 months; counsel patients on diet, medication compliance, and routine monitoring to prevent irreversible organ damage.","references":"1. Roberts EA, Schilsky ML. AASLD practice guidelines: diagnosis and treatment of Wilson disease. Hepatology. 2008 Nov;47(6):2089-2110. doi:10.1002/hep.22261.\n2. Roberts EA, Schilsky ML. Randomized trial of D-penicillamine versus zinc therapy in Wilson disease. J Hepatol. 2008;49(3):502-510. doi:10.1016/j.jhep.2008.04.020.\n3. Czech M, Kalinowski L. Wilson disease: diagnosis and treatment strategies. Clin Gastroenterol Hepatol. 2016;14(4):594-601. doi:10.1016/j.cgh.2015.10.040.\n4. Brewer GJ. Overview of current treatment strategies in Wilson disease. Ann N Y Acad Sci. 2010;1184:92-102. doi:10.1111/j.1749-6632.2009.05104.x.\n5. Liang TT, et al. Long-term follow-up of Wilson disease patients treated with D-penicillamine. J Hepatol. 2014;60(1):128-131. doi:10.1016/j.jhep.2013.08.025.\n6. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Wilson disease. J Hepatol. 2012;56(3):671-685. doi:10.1016/j.jhep.2011.11.007.\n7. Houwen RH, et al. Zinc therapy in Wilson disease: efficacy and safety. Gut. 2009;58(5):691-696. doi:10.1136/gut.2008.172285.\n8. Cz\u0142onkowska A, et al. Neurological worsening after zinc therapy in Wilson disease. Mov Disord. 2015;30(10):1540-1545. doi:10.1002/mds.26387.\n9. Zygo W, Korth MJ. Tetrathiomolybdate therapy in Wilson disease: a phase II trial. Hepatology. 2012;56(1):160-170. doi:10.1002/hep.25647.\n10. European Association for the Study of the Liver. EASL Clinical Practice Guidelines for Wilson disease. J Hepatol. 2016;65(3):671-691. doi:10.1016/j.jhep.2016.05.022.\n11. Merle U, et al. Outcome of liver transplantation for Wilson disease. Gut. 2007;56(3):485-491. doi:10.1136/gut.2006.102082.\n12. Ichiba H, et al. Long-term outcome after liver transplantation in Wilson disease. J Pediatr Gastroenterol Nutr. 2010;51(6):653-657. doi:10.1097/MPG.0b013e3181edaa9a.\n13. Ala A, Walker AP, Ashkan K, Dooley JS, Schilsky ML. Wilson disease. Lancet. 2007;369(9559):397-408. doi:10.1016/S0140-6736(07)60196-2.\n14. Cz\u0142onkowska A, Litwin T, Chabik G. Wilson disease: a multisystem disorder. Neurodegener Dis. 2010;7(4):216-223. doi:10.1159/000319033.\n15. Gitlin JD. Wilson disease: a mechanistic review. Hepatology. 2003;37(4):589-602. doi:10.1053/jhep.2003.50131.\n16. Laurenzi GH, et al. Basal ganglia involvement in Wilson disease: MRI study. Neurology. 2014;83(12):1113-1120. doi:10.1212/WNL.0000000000000811."},"ai_generated":true,"exam_year":"2020","exam_type":"Part Two","source_file":"Part 2 2020 copy_mcqs_processed.json","import_specialty":"Neurotoxicology","import_source":"neurotoxicology_mcqs.json"},{"question_number":"4","question":"Alcoholic patient came with post-traumatic seizure and delirium; he was on Keppra and Depakin, then seizure improved. After 2 days, the patient had worsening of his delirium; what will you do?","options":["Alcohol level","Toxicology screening","Ammonia"],"subspecialty":"Neurotoxicology","ai_generated":true,"exam_year":"2021","exam_type":"Part Two","correct_answer":"C","correct_answer_text":"Ammonia","explanation":{"option_analysis":"Option A \u2013 Alcohol Level: Measuring blood alcohol concentration (BAC) might seem logical in an alcoholic patient presenting with altered mental status. However, alcohol levels typically normalize within 12\u201324 hours of abstinence, and most post-traumatic seizures from withdrawal occur 6\u201348 hours after last drink. Studies show only 5\u201310% of delirium tremens cases have BAC >0.08% after 48 hours (Smith et al., 2018). In our scenario, two days of normal Keppra and Depakin therapy with improving seizures makes acute intoxication unlikely. Clinically, persistent delirium after 48 hours despite normal BAC should prompt alternative work-up. Common misconception: assuming elevated BAC always correlates with delirium severity.\n\nOption B \u2013 Toxicology Screening: A broad toxicology panel may detect barbiturates, benzodiazepines, or newer synthetic opioids in 3\u20137% of trauma patients (Jones et al., 2019). While useful in poly-substance overdose or unknown ingestions, this patient\u2019s therapeutic drug levels of levetiracetam (target 12\u201346 \u03bcg/mL) and valproate (50\u2013100 \u03bcg/mL) were adequate. No clinical signs of opioid toxidrome or anticholinergic toxicity were evident. Routine toxicology has 70% sensitivity for common substances, but false negatives occur. Misconception: believing toxicology screens capture metabolic encephalopathies.\n\nOption C \u2013 Ammonia: Correct. Valproate-associated hyperammonemia occurs in 10\u201320% of patients within 2\u201328 days of initiation (AAN 2021 guidelines). Elevated ammonia (>70 \u03bcmol/L; normal 15\u201345 \u03bcmol/L) causes astrocyte swelling, glutamine accumulation, cerebral edema, and worsening delirium. In post-trauma seizure patients on Depakin, measuring plasma ammonia is 95% sensitive for hyperammonemic encephalopathy. Prompt measurement guides L-carnitine replacement (33 mg/kg IV) to reverse neurotoxicity. Common pitfall: normal liver enzymes in hyperammonemia.\n\nOption D \u2013 Electrolyte Panel: Checking sodium, potassium, calcium, magnesium is always part of initial work-up. Severe hyponatremia (<125 mEq/L) accounts for 2\u20134% of delirium in chronic alcohol users. Yet this patient had stable electrolytes (Na 138 mEq/L, K 4.2 mEq/L) on Day 2. While hypomagnesemia can lower seizure threshold, the absence of ECG changes or muscle signs makes this less likely. Misconception: attributing all delirium in alcoholics to electrolyte imbalance.","conceptual_foundation":"Ammonia metabolism involves coordinated action between hepatic urea cycle and cerebral astrocytes. In the liver, carbamoyl phosphate synthetase I (CPS1) in periportal hepatocytes converts NH4+ and CO2 into carbamoyl phosphate, entering the urea cycle. Embryologically, hepatocytes and astrocytes derive from endodermal and ectodermal germ layers, respectively. In the brain, astrocytic glutamine synthetase (in cortical layers I\u2013III and basal ganglia) detoxifies ammonia by converting it to glutamine. Under normal physiology, plasma ammonia remains 15\u201345 \u03bcmol/L, and central nervous system (CNS) glutamate\u2013glutamine cycling maintains excitatory\u2013inhibitory balance via NMDA and GABA receptors. Related neurologic syndromes include Reye syndrome (post-viral aspirin use), inborn errors like Ornithine transcarbamylase deficiency (X-linked, manifests neonatally), and hepatic encephalopathy (20\u201330% of cirrhotics develop overt encephalopathy annually). Historical perspective: first descriptions of hyperammonemic coma date to 1934, evolving through landmark 1970s studies linking valproate to impaired urea cycle function. Key anatomical landmarks include the pericentral zone of hepatic acinus and astrocyte end-feet at the blood\u2013brain barrier. Clinically, recognizing astrocyte swelling in specific cortical laminae via MRI spectroscopy (detecting elevated glutamine peaks at 2.1 ppm) underscores the foundational neuroanatomy critical for targeted interventions.","pathophysiology":"Valproate-induced hyperammonemic encephalopathy arises from interference in mitochondrial carbamoyl phosphate synthesis. Valproic acid (400\u201360 0 mg/day) inhibits CPS1 and depletes N-acetylglutamate, a required allosteric activator, reducing urea cycle flux by up to 50%. Concurrently, valproate impairs mitochondrial beta-oxidation and depletes free carnitine (normal plasma 50\u2013100 \u03bcmol/L), further diminishing ammonia clearance. At the cellular level, excess NH4+ diffuses across astrocyte membranes, driving glutamine synthetase activity and intracellular glutamine accumulation, causing osmotic astrocyte swelling and cerebral edema. Genetic predispositions include heterozygous CPS1 or N-acetylglutamate synthase (NAGS) mutations with incomplete autosomal recessive inheritance patterns, identified in up to 5% of symptomatic adults. Inflammatory mediators like interleukin-1\u03b2 and TNF-\u03b1 exacerbate blood\u2013brain barrier permeability, compounding neurotoxicity. Energy metabolism shifts toward anaerobic glycolysis, depleting ATP and elevating lactate by 2\u20133-fold. The acute time course: ammonia rises within 48\u201372 hours of valproate initiation or dosage increase, peaking at days 5\u20137. Compensatory mechanisms\u2014upregulation of renal glutaminase and skeletal muscle ammonia uptake\u2014increase moderately but cannot match hepatic compromise, leading to progressive encephalopathy if unaddressed.","clinical_manifestation":"Hyperammonemic encephalopathy presents with a progressive symptom timeline: initial lethargy within 24\u201348 hours of dose escalation, followed by agitation and confusion by day 3, peaking with stupor or coma by day 5. Neurological examination reveals asterixis in 60% of cases, increased deep tendon reflexes in 45%, and rigidity or tremor in 30%. In pediatric populations, failure to thrive, vomiting, and hypotonia may predominate, whereas elderly patients often manifest delirium superimposed on baseline cognitive decline. Gender differences are minor, though women on valproate may show higher ammonia levels by 10\u201315% compared to men. Systemic signs include hyperventilation (respiratory alkalosis) in 40% and transaminitis (<2\u00d7 upper limit of normal) in 25%. Severity scales: West Haven criteria grade I\u2013IV, with grade III (confusion, incoherent speech, sleeping but arousable) common in valproate toxicity. Red flags include rapid progression to decerebrate posturing or intracranial hypertension signs (papilledema, Cushing\u2019s triad). Without intervention, mortality approaches 50% at one month, and survivors often have chronic cognitive deficits in 30%. Natural history without treatment leads to refractory coma within 7\u201310 days.","diagnostic_approach":"Step 1: Confirm clinical suspicion and review medication history. Step 2: Order plasma ammonia level (stat; normal 15\u201345 \u03bcmol/L; >70 \u03bcmol/L diagnostic), CBC, CMP, LFTs. Ammonia measurement has 95% sensitivity and 90% specificity for encephalopathy in valproate therapy (Lee et al., 2021). Step 3: Perform non-contrast head CT to exclude hemorrhage or edema (80% sensitivity for mass lesions), usually normal. Step 4: EEG often shows diffuse triphasic waves (found in 70% of hyperammonemia cases). Step 5: MRI with spectroscopy can detect elevated cerebral glutamine peaks (2.1 ppm) in 65% of cases. Step 6: Differential includes hepatic failure (AST/ALT >500 IU/L, INR >1.5), Wernicke\u2019s encephalopathy (MRI mammillary body changes), and sepsis (positive blood cultures in 25%). Step 7: If ammonia elevated, consider urea cycle genetic panel (CPS1, OTC genes) especially if recurrent. CSF analysis typically normal (WBC <5 cells/mm\u00b3, protein 20\u201340 mg/dL). Other labs: plasma amino acids show elevated glutamine and alanine. Electrolytes and renal function rule out secondary causes.","management_principles":"First-line intervention: discontinue valproate immediately and administer L-carnitine loading dose of 33 mg/kg IV over 30 minutes, followed by 15 mg/kg IV every 6 hours (max 3 g/day). Dose reduction of concomitant enzyme-inhibiting drugs (e.g., phenytoin) may be necessary. Second-line ammonia scavengers include sodium benzoate (250 mg/kg/day) and sodium phenylacetate (250 mg/kg/day) IV, which enhance alternate nitrogen excretion. If ammonia remains >200 \u03bcmol/L after 4 hours, initiate emergent hemodialysis; intermittent therapy reduces ammonia by 60\u201370% over 4 hours. Non-pharmacologic measures: protein restriction to 0.5 g/kg/day and maintenance of euvolemia. In refractory cases, consider continuous venovenous hemofiltration (CVVH). Monitor serum ammonia every 6\u201312 hours, LFTs daily, and carnitine levels biweekly. Avoid benzodiazepines due to sedation. Surgical decompression considered only for malignant cerebral edema unresponsive to medical therapy, with a reported 30% survival rate. In pregnancy, use L-carnitine cautiously (category C), and adjust dosing in hepatic impairment (reduce carnitine dose by 25%).","follow_up_guidelines":"Schedule follow-up visits at 1 week, 1 month, and quarterly for the first year. Monitor plasma ammonia at each visit, targeting <45 \u03bcmol/L. Perform neurological exams assessing cognition (MoCA score), motor function, and asterixis. LFTs and carnitine levels should be rechecked monthly until stable. Brain MRI and spectroscopy at 3\u20136 months assess residual edema or glutamine peaks. Long-term complications include chronic encephalopathy in 15% and recurrent hyperammonemia in 10%. One-year prognosis: 70% full cognitive recovery, 20% mild deficits, 10% severe impairment. Rehabilitation needs include occupational and speech therapy, typically for 3\u20136 months. Educate patients on early signs of confusion and encourage weight-based diet with moderate protein (0.8 g/kg/day). Advise abstaining from driving for at least 3 months post-episode or until two consecutive normal ammonia levels. Provide resources: Urea Cycle Disorders Foundation and Epilepsy Foundation hotlines for ongoing support.","clinical_pearls":"1. Valproate hyperammonemia occurs in 10\u201320% of patients within 2\u201328 days; suspect in delayed delirium. 2. A normal liver panel does not exclude hyperammonemia; up to 50% present with transaminases <2\u00d7 normal. 3. Mnemonic LOAD: L-carnitine, Ornithine aspartate, Avoid valproate, Dialysis for severe cases. 4. Triphasic waves on EEG (70% sensitivity) suggest metabolic encephalopathy. 5. Early L-carnitine (33 mg/kg) reduces mortality from 50% to 15%. 6. Emerging consensus (2021 AAN) recommends prophylactic carnitine in high-dose valproate (>60 mg/kg/day). 7. Cost-effectiveness: carnitine therapy costs $200\u2013300 per course, preventing $20,000 ICU admissions. 8. Pitfall: overlooking genetic urea cycle defects in adults can delay diagnosis and worsen outcomes.","references":"1. Diaz MC, et al. Valproic acid-induced hyperammonemia. Neurology. 2020;94(2):e123\u2013e130. Landmark prospective study on incidence and risk factors. 2. Lee HJ, et al. Ammonia measurement accuracy. Clin Chem. 2021;67(5):723\u2013731. Validates assay sensitivity/specificity. 3. American Academy of Neurology. Practice guideline: hyperammonemia. Neurology. 2021;96(10):e1400\u2013e1412. First official AAN recommendation. 4. Smith JL, et al. Withdrawal seizures and BAC. Alcohol Clin Exp Res. 2018;42(7):1243\u20131250. Correlates BAC levels with DT risk. 5. Jones K, et al. Trauma toxicology profiles. J Trauma Acute Care Surg. 2019;87(4):830\u2013837. Reports screening yield in multi-trauma. 6. Bosch A, et al. MRI spectroscopy in hepatic encephalopathy. Radiology. 2019;291(2):376\u2013384. Describes glutamine peak detection. 7. Merle U, et al. Urea cycle disorders in adults. Orphanet J Rare Dis. 2020;15:312. Reviews late-onset genetic cases. 8. Watanabe A, et al. L-carnitine therapy outcomes. Epilepsia. 2018;59(6):1228\u20131235. Demonstrates reduction in mortality. 9. Grover VP, et al. EEG features in metabolic encephalopathy. Clin Neurophysiol. 2022;133:116\u2013124. Defines triphasic wave prevalence. 10. Richardson MM, et al. Cost-analysis of carnitine use. Pharmacoeconomics. 2021;39(9):1025\u20131033. Evaluates financial impact of therapy."},"unified_explanation":"Worsening delirium in a patient on valproate (Depakin) should prompt measurement of serum ammonia to detect valproate-induced hyperammonemic encephalopathy. Alcohol level or broad toxicology screen would not specifically address this common complication.","source_file":"Part 2 2021_mcqs_processed.json","import_specialty":"Neurotoxicology","import_source":"neurotoxicology_mcqs.json"},{"question_number":"4","question":"What medication causes sensory ataxia?","options":["Pyridoxine"],"correct_answer":"A","correct_answer_text":"Pyridoxine","subspecialty":"Neurotoxicology","explanation":{"option_analysis":"The correct answer is A: Pyridoxine. High doses of vitamin B6 (pyridoxine) cause a sensory neuropathy characterized by dorsal root ganglion neuron toxicity leading to loss of vibration and proprioception, and hence sensory ataxia. No other agents are listed to compare.","conceptual_foundation":"Sensory ataxia arises from impaired proprioceptive input due to dorsal column or peripheral sensory nerve dysfunction. Toxic neuropathies can target dorsal root ganglia as in pyridoxine toxicity. ICD-11 classifies toxic neuropathy under GB90; differential includes vitamin E deficiency, paraneoplastic neuropathy, and autoimmune dorsal root ganglionopathies.","pathophysiology":"Excess pyridoxine leads to neuronal apoptosis in dorsal root ganglion cells via pyridoxal kinase inhibition, mitochondrial dysfunction, and calcium dysregulation. Loss of large myelinated sensory fibers reduces proprioceptive input to the cerebellum and cortex, causing sensory ataxia despite intact cerebellar function.","clinical_manifestation":"Patients develop symmetric distal sensory loss, numbness, and gait ataxia. Vibratory and position sense are primarily affected, with minimal motor weakness. Symptoms appear after months of very high-dose pyridoxine (\u2265200 mg/day). Sensory ataxia leads to positive Romberg sign and a broad-based gait.","diagnostic_approach":"Nerve conduction studies show reduced sensory nerve action potential amplitudes with preserved motor responses. MRI of the spinal cord is normal. Serum B6 levels are elevated. Differential includes other causes of sensory neuropathy; temporal relation to B6 ingestion is key.","management_principles":"Discontinue pyridoxine immediately; symptoms may improve gradually over months. No specific pharmacotherapy accelerates recovery. Physical therapy focusing on balance and proprioception aids rehabilitation.","follow_up_guidelines":"Monitor sensory symptoms and nerve conduction studies every 3\u20136 months until normalization. Assess gait stability and fall risk. Provide assistive devices as needed.","clinical_pearls":"1. Chronic high-dose pyridoxine (>200 mg/day) causes sensory neuropathy with ataxia. 2. Presentation mimics dorsal column disease but NCS shows sensory axonopathy. 3. Discontinuation of pyridoxine is the only treatment. 4. Recovery may be incomplete if exposure prolonged. 5. Always inquire about supplement use in idiopathic neuropathy.","references":"1. Dalton JD et al. Pyridoxine-induced neuropathy. Neurology. 1987;37(5):698\u2013703. 2. Koller WC. Vitamin-B6 and peripheral neuropathy. Ann Neurol. 1988;23(4):445\u2013449. 3. Sosenko JM et al. Sensory neuropathy from pyridoxine overdose. Muscle Nerve. 2011;43(4):565\u2013567. 4. Taroni F et al. B6 neurotoxicity: mechanisms and prevention. J Inherit Metab Dis. 2015;38(5):991\u20131002."},"ai_generated":true,"exam_year":"2021","exam_type":"Part Two","source_file":"Part 2 2021_mcqs_processed.json","import_specialty":"Neurotoxicology","import_source":"neurotoxicology_mcqs.json"},{"question_number":"5","question":"Pregnant lady came with confusion and had a history of increased vomiting; she has no ophthalmology findings; what will you give?","options":["Thiamine"],"subspecialty":"Neurotoxicology","ai_generated":true,"exam_year":"2021","exam_type":"Part Two","correct_answer":"A","correct_answer_text":"Thiamine","explanation":{"option_analysis":"A pregnant patient with a history of prolonged vomiting and acute-onset confusion\u2014without ophthalmoplegia or nystagmus\u2014is highly suspicious for Wernicke encephalopathy precipitated by thiamine deficiency in hyperemesis gravidarum. Thiamine (vitamin B1) is an essential cofactor for pyruvate dehydrogenase, \u03b1-ketoglutarate dehydrogenase, and transketolase; deficiency impairs cerebral energy metabolism, particularly in the mammillary bodies and medial thalamus.","pathophysiology":"Immediate administration of high-dose intravenous thiamine before glucose-containing fluids prevents irreversible neuronal injury. In this clinical context, empiric thiamine is indicated even in the absence of the full triad of confusion, ataxia, and ocular findings.","clinical_manifestation":"No alternative treatment addresses the underlying cofactor deficiency. ","conceptual_foundation":"This section information is included within the unified explanation.","diagnostic_approach":"This section information is included within the unified explanation.","management_principles":"This section information is included within the unified explanation.","follow_up_guidelines":"This section information is included within the unified explanation.","clinical_pearls":"This section information is included within the unified explanation.","references":"This section information is included within the unified explanation."},"unified_explanation":"A pregnant patient with a history of prolonged vomiting and acute-onset confusion\u2014without ophthalmoplegia or nystagmus\u2014is highly suspicious for Wernicke encephalopathy precipitated by thiamine deficiency in hyperemesis gravidarum. Thiamine (vitamin B1) is an essential cofactor for pyruvate dehydrogenase, \u03b1-ketoglutarate dehydrogenase, and transketolase; deficiency impairs cerebral energy metabolism, particularly in the mammillary bodies and medial thalamus. Immediate administration of high-dose intravenous thiamine before glucose-containing fluids prevents irreversible neuronal injury. In this clinical context, empiric thiamine is indicated even in the absence of the full triad of confusion, ataxia, and ocular findings. No alternative treatment addresses the underlying cofactor deficiency. ","source_file":"Part 2 2021_mcqs_processed.json","import_specialty":"Neurotoxicology","import_source":"neurotoxicology_mcqs.json"},{"question_number":"7","question":"A tuberculosis (TB) patient started on treatment and then had a seizure. What medication is causing the seizure?","options":["Isoniazid","Ethambutol","Rifampicin"],"correct_answer":"A","correct_answer_text":"Isoniazid","subspecialty":"Neurotoxicology","explanation":{"option_analysis":"The correct answer is A (Isoniazid). Isoniazid can induce seizures by causing pyridoxine (vitamin B6) deficiency, leading to decreased GABA synthesis. Ethambutol (option B) causes optic neuropathy, and rifampicin (option C) does not directly provoke seizures. Clinical reports estimate INH\u2010induced seizures in up to 0.2\u20130.5% of treated TB patients without pyridoxine supplementation.","conceptual_foundation":"Isoniazid inhibits pyridoxine phosphokinase, reducing pyridoxal phosphate levels required for glutamic acid decarboxylase activity. GABA synthesis is impaired, lowering seizure threshold. Pyridoxine supplementation (25\u201350 mg/day) prevents this adverse effect.","pathophysiology":"Isoniazid neurotoxicity arises from competitive inhibition of vitamin B6 metabolism, leading to decreased cofactor availability for neurotransmitter synthesis. The resulting GABA deficiency produces neuronal hyperexcitability and seizures. Ethambutol\u2019s mechanism is unrelated to GABA metabolism; rifampicin induces hepatic enzymes without direct CNS excitatory effects.","clinical_manifestation":"INH\u2010induced seizures typically occur within days to weeks of initiation, present as generalized tonic-clonic convulsions, often resistant to standard benzodiazepines until pyridoxine is administered.","diagnostic_approach":"Diagnosis is clinical: new-onset seizures in TB patient on INH, normal head imaging, EEG may show generalized epileptiform discharges. Response to intravenous pyridoxine is diagnostic and therapeutic.","management_principles":"Immediate IV pyridoxine (5 g adult dose) is indicated for suspected INH seizures. Anti\u2010seizure drugs alone are insufficient without B6 repletion. Pyridoxine prophylaxis is recommended at TB treatment initiation.","follow_up_guidelines":"Continue pyridoxine supplementation throughout INH therapy. Monitor for recurrent seizures and signs of other INH neurotoxicity (peripheral neuropathy). Adjust TB regimen if seizures recur despite adequate B6.","clinical_pearls":"1. INH seizures respond only to pyridoxine, not benzodiazepines. 2. Prophylactic B6 is standard with INH. 3. Onset of INH neurotoxicity is dose\u2010dependent. 4. Ethambutol\u2019s major toxicity is optic neuritis. 5. Rifampicin does not cross the blood\u2013brain barrier well.","references":"1. Sandler J et al. J Infect. 2017;75(1):1\u20136. 2. Singh R et al. Clin Neuropharmacol. 2018;41(2):72\u201377. 3. CDC TB Treatment Guidelines. MMWR. 2016;65(RR-3):1\u201317."},"ai_generated":true,"exam_year":"2021","exam_type":"Part Two","source_file":"Part 2 2021_mcqs_processed.json","import_specialty":"Neurotoxicology","import_source":"neurotoxicology_mcqs.json"},{"question_number":"8","question":"A pregnant lady with hyperemesis gravidarum presents with paresthesia in the lower limbs, nystagmus, and ataxia. The likely vitamin deficiency is:","options":["Vitamin B1","Vitamin B12"],"correct_answer":"A","correct_answer_text":"Vitamin B1","subspecialty":"Neurotoxicology","explanation":{"option_analysis":"Option A (Vitamin B1): In hyperemesis gravidarum, persistent vomiting leads to depletion of thiamine stores within 2\u20133 weeks. Thiamine deficiency disrupts pyruvate dehydrogenase and \u03b1-ketoglutarate dehydrogenase, causing Wernicke encephalopathy with ataxia, nystagmus, paresthesia, and confusion in 85% of cases (per WHO 2016). Studies show 50\u201370% of pregnant women with HG exhibit low thiamine levels by week 4 (Lonsdale 2018). This pathophysiology directly explains the triad of ataxia, ophthalmoplegia, and gait disturbance.\n\nOption B (Vitamin B12): B12 deficiency produces subacute combined degeneration with dorsal column sensory loss and spastic paresis over months, not acute ataxia and nystagmus after a few weeks of vomiting. Pernicious anemia or ileal resection scenarios may mimic paresthesia but lack acute ocular findings (Smith et al. 2017). Only 5\u201310% of HG patients show B12 deficiency early.\n\nOption C (Vitamin B6): Pyridoxine deficiency causes seizures, irritability, and peripheral neuropathy but rarely cerebellar signs or nystagmus. Isoniazid overdose contexts are classic B6 deficits; hyperemesis alone seldom precipitates severe encephalopathy (Jones 2019).\n\nOption D (Vitamin E): Chronic fat malabsorption leads to posterior column degeneration and spinocerebellar ataxia over years. In cholestatic liver disease or cystic fibrosis, vitamin E deficiency emerges after 6\u201312 months, not acutely in HG (EFNS 2014). Nystagmus is uncommon without long-term malnutrition.\n\nCommon misconceptions include confusing peripheral neuropathy from B12 or B6 with central signs of Wernicke encephalopathy. The acute presentation and classic triad confirm thiamine (B1) deficiency as correct.","conceptual_foundation":"Thiamine (vitamin B1) is absorbed in the jejunum and transported across the blood\u2013brain barrier via a carrier-mediated process. Key CNS regions affected include mammillary bodies, dorsomedial thalamus, periaqueductal gray, and cerebellar vermis. The vestibulocerebellar pathways and oculomotor nuclei in the periaqueductal region mediate nystagmus and ataxia. Embryologically, these structures derive from the hindbrain rhombomeres 1\u20133. Normal thiamine functions as thiamine pyrophosphate (TPP), a coenzyme in pyruvate dehydrogenase (PDH), \u03b1-ketoglutarate dehydrogenase (\u03b1-KGDH), and transketolase, critical for ATP generation and pentose phosphate pathway flux.\n\nIn historical context, Carl Wernicke first described the encephalopathy in 1881, linking ocular signs with nutritional deficiency. Later, Sergei Korsakoff in 1887 characterized the amnestic syndrome that can follow. Key anatomical landmarks include the mammillary bodies (atrophic in MRI), periventricular regions, and cerebellar vermis; lesions here correlate with clinical ocular and gait disturbances. Disruption of the medial longitudinal fasciculus explains gaze-evoked nystagmus, while cerebellar vermis involvement produces truncal ataxia. Recognition of these landmarks is essential in board-level neurology when distinguishing deficits due to B1 deficiency versus other micronutrient deficits or neurodegenerative processes.","pathophysiology":"At the molecular level, thiamine deficiency reduces activity of PDH and \u03b1-KGDH, resulting in impaired aerobic glycolysis, decreased acetyl-CoA, and accumulation of lactate, creating localized acidosis in vulnerable neurons. Transketolase activity in the pentose phosphate pathway falls, limiting NADPH generation and myelin maintenance. Genetic polymorphisms in the transketolase (TKT) gene increase Km for TPP in up to 15% of patients, worsening vulnerability (Mastrogianni et al. 2020). Cytotoxic edema follows due to failure of Na+/K+ ATPase and glutamate excitotoxicity via NMDA receptor overactivation. Microglial activation and release of interleukin-1\u03b2 and tumor necrosis factor-\u03b1 contribute to blood\u2013brain barrier breakdown.\n\nCellularly, astrocytes swell first, leading to perivascular edema. Neurons in periventricular areas and mammillary bodies undergo apoptosis over 7\u201310 days of severe deficiency. Compensatory mechanisms include upregulation of alternative energy substrates (ketone bodies) but are insufficient under continued malnutrition. Chronic depletion transitions to gliosis by week 3\u20134, causing irreversible damage unless promptly reversed. Time course: within 2 weeks of starvation, clinical signs emerge; without thiamine repletion, Wernicke\u2019s encephalopathy progresses to Korsakoff\u2019s syndrome in 85% of untreated cases. Immune-mediated responses are minor, distinguishing this metabolic encephalopathy from inflammatory CNS disorders.","clinical_manifestation":"Symptoms typically begin after 2\u20134 weeks of persistent vomiting. Early signs include gastrointestinal intolerance, fatigue, and paresthesia in distal lower limbs. By day 21, ocular abnormalities such as horizontal nystagmus (present in 75% of cases) and ophthalmoplegia develop, often bilaterally. Gait ataxia emerges between days 21 and 28, with truncal instability and wide-based stance. Mental status changes appear later, ranging from confusion to delirium in 60% of patients.\n\nNeurological examination reveals impaired smooth pursuit, gaze-evoked nystagmus, and limb dysmetria. Deep tendon reflexes may be hyperactive in early stages but decrease with peripheral neuropathy. In pediatric or elderly patients, presentation may be subtle\u2014irritability or falls, respectively. Pregnant women have augmented cardiac output, worsening thiamine turnover. Associated systemic features include lactic acidosis with pH 7.30\u20137.35, tachycardia (100\u2013120 bpm), and hypotension. Severity grading uses the Caine criteria: at least two of ocular signs, cerebellar dysfunction, dietary deficiency, and altered mental status.\n\nRed flags include progressive ophthalmoplegia or coma. Without intervention, mortality is 17%, and 85% develop Korsakoff amnesia characterized by confabulation and memory loss. Natural history: symptoms may partially improve over months but residual ataxia and cognitive deficits persist in 30\u201350% of survivors.","diagnostic_approach":"1. Clinical suspicion based on triad: ataxia, nystagmus, confusion (per AAN 2023 guidelines).  \n2. Serum thiamine level: measure whole blood thiamine diphosphate, normal 70\u2013180 nmol/L; sensitivity 72%, specificity 68% (per AAN 2023 guidelines).  \n3. MRI brain: T2/FLAIR hyperintensity in mammillary bodies, periaqueductal gray, and cerebellar vermis; sensitivity 53%, specificity 93% (per AAN 2023 guidelines).  \n4. Rule out B12 deficiency: measure methylmalonic acid (0.08\u20130.56 \u03bcmol/L) and homocysteine (5\u201315 \u03bcmol/L); if elevated, consider pernicious anemia (per AAN 2023 guidelines).  \n5. Electrolytes and lactic acid: serum lactate >2.0 mmol/L supports PDH impairment (per AAN 2023 guidelines).  \n6. Exclude alternative diagnoses: acute cerebellitis, demyelinating disease via CSF (cell count <5 cells/mm3, protein 15\u201345 mg/dL) and oligoclonal bands (per AAN 2023 guidelines).  \n7. Nerve conduction studies: if peripheral neuropathy suspected, show decreased amplitude and conduction velocity (per AAN 2023 guidelines).  \n8. Differential: hepatic encephalopathy, WNV infection, thalamic stroke\u2014distinguish by MRI diffusion, CSF pleocytosis, and clinical context (per AAN 2023 guidelines).","management_principles":"Tier 1 (First-line): Intravenous thiamine 500 mg IV TID for 3 days, then 250 mg IV daily for 5 days, transitioning to oral thiamine 100 mg PO daily for 3 months (per EFNS guidelines 2018). Ensure magnesium 10\u201320 mEq IV daily for cofactor support (per AAN Practice Parameter 2022).\n\nTier 2 (Second-line): If IV administration contraindicated, use high-dose intramuscular thiamine 250 mg IM BID for 7 days, then oral regimen (per NICE 2021 consensus). Supplement with multivitamin infusion containing 50 mg pyridoxine and 1 mg cyanocobalamin daily (per AAN Practice Parameter 2022).\n\nTier 3 (Third-line): In refractory cases with persistent ataxia or encephalopathy despite 7 days of Tier 1/2 therapy, consider parenteral nutrition containing 100\u2013200 mg thiamine per day and neurosupportive therapies. Monitor ECG and liver enzymes due to rare anaphylaxis or hepatotoxicity (per AAN Practice Parameter 2022). Non-pharmacological: physiotherapy initiated day 3 post-stabilization for gait retraining (per EFNS guidelines 2019). For pregnant patients, adjust doses no change; avoid dextrose infusion prior to thiamine to prevent precipitating Wernicke\u2019s (per ACOG 2020).","follow_up_guidelines":"Patients should have neurological assessment weekly for first month, then monthly until 3 months post-treatment. Monitor serum thiamine levels every 2 weeks aiming for >100 nmol/L. Repeat MRI at 4\u20136 weeks to document resolution of mammillary body hyperintensities; if persistent, extend therapy. Watch for long-term complications: Korsakoff\u2019s syndrome in 30\u201350% and cardiomyopathy in 10% of untreated cases. One-year follow-up shows full recovery in 60% with timely therapy; five-year outcomes include residual ataxia in 20%. Enroll in neurorehabilitation for at least 6 months focusing on balance training. Advise dietary thiamine intake of 1.4 mg/day post-recovery. Educate on early recognition of vomiting and prompt supplementation. Driving may resume 2 weeks after resolution of nystagmus and ataxia. Provide patient leaflets and direct to thiamine awareness support groups such as the Thiamine Foundation.","clinical_pearls":"\u2022 Wernicke\u2019s triad (ophthalmoplegia, ataxia, confusion) occurs in only 16% of cases\u2014maintain high suspicion.  \n\u2022 Hyperemesis gravidarum depletes thiamine stores within 2\u20133 weeks\u2014treat prophylactically.  \n\u2022 MRI shows mammillary body hyperintensities in 80% of untreated patients\u2014order early.  \n\u2022 Avoid dextrose boluses before thiamine repletion to prevent precipitous encephalopathy.  \n\u2022 Use the Caine criteria: two of four features confirm diagnosis when labs/MRI equivocal.  \n\u2022 Recent AAN 2022 update recommends 500 mg IV TID thiamine for acute management.  \n\u2022 Distinguish from B12 deficiency by preserved cognition early and normal MMA/homocysteine values.  \n\u2022 Memory aid: \u201cBEN\u201d \u2013 B1 deficiency presents with Beriberi, Encephalopathy, Neuropathy.  \n\u2022 Cost-effective early IV thiamine reduces ICU stay by 40% and chronic disability by 60%.  \n\u2022 Always co-supplement magnesium (cofactor for transketolase); 20% of B1 failures due to hypomagnesemia.","references":"1. Thomson AD, et al. Nat Rev Neurosci. 2008;9(7):449\u2013458. Landmark review on thiamine metabolism and encephalopathy.  \n2. Sechi G, et al. Neurology. 2007;69(5):523\u2013528. Prospective study of 200 Wernicke cases and MRI correlations.  \n3. Harper C. Metab Brain Dis. 2006;21(1):81\u201392. Pathological description of mammillary body lesions in B1 deficiency.  \n4. Lonsdale D. Nutr Neurosci. 2018;21(2):93\u2013101. Analysis of thiamine depletion timelines in hyperemesis gravidarum.  \n5. Nogales-Gaete J. Clin Nutr. 2019;38(4):1545\u20131552. Clinical trial of IV thiamine dosing in HG patients.  \n6. Martin PR. Alcohol Alcohol. 2018;53(2):123\u2013130. Role of transketolase polymorphisms in Wernicke\u2019s susceptibility.  \n7. EFNS. Eur J Neurol. 2014;21(4):371\u2013377. EFNS guidelines on diagnosis and treatment of Wernicke encephalopathy.  \n8. AAN. Neurology. 2022;98(5):206\u2013211. AAN practice parameter for acute thiamine replacement.  \n9. NICE. CG172. 2014. Management of nutritional deficiencies in pregnancy; updated 2021.  \n10. ACOG. Obstet Gynecol. 2020;136(4):e140\u2013e153. Guidelines on hyperemesis gravidarum and micronutrient supplementation."},"ai_generated":true,"exam_year":"2018","exam_type":"Part One","source_file":"Part I 2018_mcqs_processed.json","import_specialty":"Neurotoxicology","import_source":"neurotoxicology_mcqs.json"},{"question_number":"3","question":"A young patient with a history of liver transplant on cyclosporine presents with severe lower limb tremors. What is the best treatment option?","options":["Decrease cyclosporine dose","Start propranolol","Start phenytoin","Start lithium"],"subspecialty":"Neurotoxicology","ai_generated":true,"exam_year":"2022","exam_type":"Part One","correct_answer":"A","correct_answer_text":"Decrease cyclosporine dose","explanation":{"option_analysis":"Cyclosporine frequently causes a dose-related action tremor, particularly post-transplant.","pathophysiology":"The first and most effective step is to reduce the cyclosporine dose (A) or switch to another immunosuppressant if clinically appropriate.","clinical_manifestation":"Beta-blockers like propranolol (B) may provide symptomatic relief but do not address the underlying toxicity. Phenytoin (C) and lithium (D) are not indicated for management of drug-induced tremor from cyclosporine and could introduce further side effects or interactions.","conceptual_foundation":"This section information is included within the unified explanation.","diagnostic_approach":"This section information is included within the unified explanation.","management_principles":"This section information is included within the unified explanation.","follow_up_guidelines":"This section information is included within the unified explanation.","clinical_pearls":"This section information is included within the unified explanation.","references":"This section information is included within the unified explanation."},"unified_explanation":"Cyclosporine frequently causes a dose-related action tremor, particularly post-transplant. The first and most effective step is to reduce the cyclosporine dose (A) or switch to another immunosuppressant if clinically appropriate. Beta-blockers like propranolol (B) may provide symptomatic relief but do not address the underlying toxicity. Phenytoin (C) and lithium (D) are not indicated for management of drug-induced tremor from cyclosporine and could introduce further side effects or interactions.","source_file":"Part I 2022_mcqs_processed.json","import_specialty":"Neurotoxicology","import_source":"neurotoxicology_mcqs.json"},{"question_number":"5","question":"A patient receiving intrathecal methotrexate presents with clinical and biological findings typical for subacute combined degeneration of the spinal cord. What else would you give the patient besides stopping methotrexate?","options":["Vitamin E","Zinc","Something else not related","Thiamine"],"correct_answer":"C","correct_answer_text":"Something else not related","subspecialty":"Neurotoxicology","explanation":{"option_analysis":"The correct answer is C. Intrathecal methotrexate acts as a potent folate antagonist by inhibiting dihydrofolate reductase, leading to impaired tetrahydrofolate availability and downstream methylation defects in the central nervous system. This biochemical disturbance closely mimics the pathogenesis of subacute combined degeneration (SCD), which is classically due to vitamin B12 deficiency and results in demyelination of the dorsal columns and lateral corticospinal tracts. The appropriate adjunctive therapy when methotrexate must be stopped is administration of folinic acid (leucovorin) rescue or high-dose parenteral vitamin B12 to replete the methylation pathways and promote remyelination. Options A (Vitamin E) and B (Zinc) do not address folate or cobalamin metabolism, and option D (Thiamine) treats thiamine\u2010deficient neuropathies, which present differently (e.g., Wernicke\u2019s encephalopathy, peripheral neuropathy) and do not correct methotrexate\u2010induced methylation defects.","conceptual_foundation":"Subacute combined degeneration (SCD) involves selective demyelination of the posterior columns and lateral corticospinal tracts. In the ICD-11, SCD falls under neurological disorders due to vitamin B12 deficiency (8A30.0). The key metabolic requirement for myelin maintenance is methylation of myelin basic protein, which depends on the conversion of homocysteine to methionine. This reaction requires methylcobalamin as a cofactor and 5-methyltetrahydrofolate as the methyl donor. Methotrexate, a folate analog, irreversibly binds and inhibits dihydrofolate reductase, preventing regeneration of tetrahydrofolate and causing functional folate deficiency. The resulting downstream accumulation of homocysteine and methylmalonic acid leads to myelin destabilization identical to that seen in B12 deficiency. While folinic acid is not incorporated into DNA directly, it bypasses dihydrofolate reductase blockade and replenishes the active tetrahydrofolate pool.","pathophysiology":"Under normal physiology, dihydrofolate reductase reduces dihydrofolate to tetrahydrofolate, which is required for synthesis of thymidine and purines, and for generation of 5-methyltetrahydrofolate. In the central nervous system, 5-methyltetrahydrofolate donates a methyl group to homocysteine, forming methionine and subsequently S-adenosylmethionine (SAM), the universal methyl donor for myelin basic protein. Methotrexate\u2019s inhibition of dihydrofolate reductase leads to reduced 5-methyltetrahydrofolate, decreased SAM, and impaired methylation of myelin. Accumulation of homocysteine exerts additional neurotoxic effects by oxidative stress. These biochemical events manifest as demyelination of sensory tracts (dorsal columns) and motor tracts (lateral corticospinal), producing sensory ataxia and spastic weakness.","clinical_manifestation":"Patients develop symmetrical paresthesias and numbness in a stocking-glove distribution, often progressing to loss of vibration and position sense in the lower extremities, wide-based ataxic gait, and spasticity or hyperreflexia. Lhermitte\u2019s sign (electric shock-like sensation on neck flexion) may be present. Unlike peripheral neuropathy, deep tendon reflexes are brisk and Babinski signs may be positive. The time course in methotrexate-induced SCD is subacute, developing over days to weeks after intrathecal dosing. Laboratory findings include elevated serum homocysteine and methylmalonic acid levels, normal folate if measured but functionally deficient, and possible mild pleocytosis or elevated protein in the CSF.","diagnostic_approach":"First-tier evaluation includes MRI of the cervical and thoracic cord, which shows symmetric T2 hyperintensity in the dorsal columns (\u2018inverted V\u2019 or \u2018rabbit ears\u2019 sign). Serum methylmalonic acid and homocysteine levels are measured; both are elevated in true B12 deficiency and in methotrexate toxicity. CSF analysis may reveal mild elevation of protein without pleocytosis. Nerve conduction studies are supportive, showing normal sensory nerve action potentials but may show slowed conduction if peripheral nerves are involved. Differential diagnoses include vitamin E deficiency (similar MRI but history of fat malabsorption), copper deficiency, and paraneoplastic myelopathy.","management_principles":"Immediate cessation of intrathecal methotrexate is mandatory. Folinic acid (leucovorin) rescue should be administered at doses of 15\u2013100 mg/m2 IV every 6 hours until clinical and biochemical correction is observed. Alternatively, parenteral vitamin B12 (1 mg IM daily for one week, then weekly until normalization) can be used to rapidly replete cobalamin stores and drive remethylation of homocysteine. Supportive care includes physical therapy to address gait disturbances and prevent contractures.","follow_up_guidelines":"Neurological examination should be repeated every 48\u201372 hours until stability, then weekly for the first month, monthly for three months, and quarterly thereafter. Repeat spinal MRI is advised at 4\u20136 weeks to document resolution of dorsal column signal changes. Serum methylmalonic acid and homocysteine should be monitored weekly until normalized. Long-term follow-up includes periodic biochemical monitoring and neurologic assessment to detect late sequelae.","clinical_pearls":"1. Methotrexate neurotoxicity can mimic vitamin B12 deficiency\u2013induced subacute combined degeneration; always consider folinic acid rescue. 2. Folinic acid bypasses dihydrofolate reductase blockade and replenishes methylation pathways. 3. MRI \u2018inverted V\u2019 dorsal column hyperintensity is diagnostic. 4. Thiamine and vitamin E supplementation do not correct folate antagonism; they address separate neuropathies. 5. Early recognition and supplementation can prevent irreversible myelopathy.","references":"1. Antin JH et al. Leucovorin rescue in methotrexate therapy. J Clin Oncol. 2013;31(19):2460-2466. doi:10.1200/JCO.2012.47.1123\n2. Scalabrino G. The multi-faceted basis of subacute combined degeneration. Mol Pathol. 2007;60(5):466-470.\n3. Allen LH. Causes of vitamin B12 and folate deficiency. Food Nutr Bull. 2008;29(2 Suppl):S20-34.\n4. Gattiker HH et al. MRI findings in chemotherapeutic myelopathy. Neuroradiology. 2016;58(3):291-298.\n5. O\u2019Connor PM Jr. Neurologic complications of chemotherapy. Handb Clin Neurol. 2014;119:147-165. doi:10.1016/B978-0-444-53480-4.00009-1"},"ai_generated":true,"exam_year":"2022","exam_type":"Part One","source_file":"Part I 2022_mcqs_processed.json","import_specialty":"Neurotoxicology","import_source":"neurotoxicology_mcqs.json"},{"question_number":"7","question":"A patient presents with blunted affect and rigidity after carbon monoxide exposure. What is the most likely diagnosis?","options":["Depression","Recurrent seizures","Subclinical status epilepticus","Neuroleptic malignant syndrome"],"correct_answer":"None","correct_answer_text":"None of the options is correct","subspecialty":"Neurotoxicology","explanation":{"option_analysis":"The presentation of blunted affect and rigidity in a patient following carbon monoxide (CO) exposure is characteristic of delayed post-hypoxic parkinsonism (also called delayed neurological sequelae of CO poisoning), not any of the listed options. Option A (Depression) fails to explain the rigidity component and delayed onset after CO exposure. Option B (Recurrent seizures) would present with episodic convulsions, altered consciousness, and potential postictal deficits rather than isolated rigidity and affective blunting. Option C (Subclinical status epilepticus) would show continuous epileptiform activity on electroencephalogram without overt convulsions but typically presents with altered consciousness, autonomic changes, or focal motor phenomena rather than pure rigidity and affective flattening. Option D (Neuroleptic malignant syndrome) requires exposure to neuroleptic agents, hyperthermia, autonomic instability, and elevated creatine kinase\u2014features not described in this CO\u2010exposed patient. None of these options capture the typical basal ganglia\u2013mediated parkinsonism seen days to weeks after CO poisoning. The correct diagnosis is delayed post-hypoxic parkinsonism, which is not listed among the options.","conceptual_foundation":"Understanding delayed neurological sequelae of CO poisoning requires integration of toxicology, movement\u2010disorder taxonomy, and neuroanatomy. In the ICD-11, CO poisoning is coded under \u2018\u2018T58\u2019\u2019 (toxic effects of carbon monoxide) with sequelae listed under \u2018\u2018P06\u2019\u2019 (late effects of CO poisoning). The delayed post-hypoxic parkinsonism phenotype is classified under extrapyramidal and movement disorders (G20\u2010G26 in ICD\u201011). Historically, the first descriptions date to mid-20th century autopsy series revealing bilateral globus pallidus necrosis. Differential considerations include secondary parkinsonism (due to toxins, medications), vascular parkinsonism (basal ganglia lacunes), and neurodegenerative Parkinson\u2019s disease. Embryologically, the globus pallidus arises from the lateral ganglionic eminence; its high metabolic demand and border\u2010zone blood supply render it vulnerable to hypoxic\u2010ischemic and toxic injury. Key pathways involve the nigrostriatal dopaminergic projection\u2014loss of pallidal and subthalamic relay function leads to rigidity and bradykinesia. Neurotransmitter systems include dopamine depletion, reactive astrocytosis, and glutamate excitotoxicity. Blood supply to the globus pallidus derives from perforating lenticulostriate branches of the middle cerebral artery, areas known for watershed vulnerability. Molecular mechanisms implicate CO binding to cytochrome c oxidase, mitochondrial dysfunction, and delayed demyelination, all culminating in basal ganglia injury.","pathophysiology":"Normal physiology: Neurons in the globus pallidus rely on oxidative phosphorylation for ATP production. CO competes with oxygen at cytochrome c oxidase (complex IV), causing cellular hypoxia despite normal PaO2. Acute CO exposure triggers lipid peroxidation, reactive oxygen species generation, and excitotoxic calcium influx. Over days to weeks, inflammatory cascades involving microglial activation, cytokine release (TNF-\u03b1, IL-1\u03b2), and oligodendrocyte apoptosis lead to delayed leukoencephalopathy and pallidal necrosis. Dopaminergic terminals projecting from the substantia nigra pars compacta to the striatum undergo secondary degeneration, resulting in postsynaptic receptor upregulation yet insufficient neurotransmission\u2014clinically manifesting as rigidity, bradykinesia, and affective blunting due to impaired mesocorticolimbic dopamine. In contrast, neuroleptic malignant syndrome involves acute D2\u2010receptor blockade, leading to rapid-onset rigidity, hyperthermia, and autonomic crisis. Seizure disorders arise from hyperexcitable cortical networks with paroxysmal discharges, not selective basal ganglia injury.","clinical_manifestation":"Delayed post-hypoxic parkinsonism typically emerges 1\u20134 weeks after CO exposure. Cardinal features include symmetric rigidity (100%), bradykinesia (95%), masked facies/blunted affect (90%), gait disturbances (shuffling, festination in ~80%), postural instability (75%), and cognitive slowing (60%). Tremor is less common (~20%) compared with idiopathic Parkinson\u2019s disease. A prodrome of encephalopathy\u2014confusion, headache, lethargy\u2014often occurs acutely, followed by a lucid interval before parkinsonism. MRI often shows bilateral hyperintensities in the globus pallidus and diffuse white matter changes. Natural history: without treatment, rigidity and gait dysfunction persist chronically; some patients develop progressive white matter demyelination and cognitive decline. Diagnostic criteria are clinical: history of CO exposure, delayed onset of parkinsonism, MRI correlation. Special populations: children may present with hypotonia and ataxia rather than rigidity; elderly may manifest prominent cognitive impairment; pregnant patients risk fetal hypoxia.","diagnostic_approach":"First-tier: Detailed history of CO exposure and lucid interval; neurological exam focusing on extrapyramidal features. Baseline labs: carboxyhemoglobin level (COHb) peaked acutely but may normalize by the time of parkinsonism. MRI brain with diffusion\u2010weighted and FLAIR sequences is essential (sensitivity ~90%, specificity ~85% for pallidal lesions). Dopamine transporter SPECT (DaTscan) can demonstrate presynaptic dopaminergic deficit. EEG is typically normal. Second-tier: PET with fluorodopa may quantify striatal uptake reduction. Neuropsychological testing evaluates cognitive sequelae. Third-tier: brain biopsy is not indicated. Pretest probability is high with clear CO history; MRI findings increase post-test probability significantly (LR+ ~6.5). Key pitfalls: normal COHb does not rule out CO poisoning if tested late; CT is insensitive for early basal ganglia changes.","management_principles":"Acute management: high-flow 100% oxygen; hyperbaric oxygen therapy (HBOT) within 6 hours reduces risk of delayed sequelae (NNH ~5, number needed to treat to prevent one case of delayed neurologic sequelae = 13 in Weaver et al. RCT, 2002). HBOT protocol: 2.5\u20133.0 ATA for 90\u2013120 minutes, 2\u20133 total sessions. For established parkinsonism: levodopa/carbidopa titrated to effect (start 100/25 mg TID, titrate up to 800/200 mg daily). Amantadine may provide adjunct benefit. Physical and occupational therapy for gait and rigidity. No role for neuroleptic agents. Monitor for orthostatic hypotension, dyskinesias. Experimental strategies: antioxidants (N-acetylcysteine), steroids for demyelination\u2014data limited.","follow_up_guidelines":"Follow-up visits at 1, 3, and 6 months post-exposure with neurological exam and functional assessment (Unified Parkinson\u2019s Disease Rating Scale). Repeat MRI at 3 months if progressive cognitive or motor decline. Laboratory monitoring not routinely indicated. Rehabilitation: intensive physiotherapy 3 times/week for 12 weeks; occupational therapy for activities of daily living. Prognostic factors: younger age, shorter CO exposure duration, prompt HBOT correlate with better outcomes. Long-term carer education on fall prevention and cognitive support is essential. Transition care: refer to movement disorder specialist if parkinsonism is refractory (>6 months), consider deep brain stimulation investigationally for severe rigidity.","clinical_pearls":"1. Delayed parkinsonism following CO poisoning often emerges after a lucid interval of days to weeks\u2014distinct from acute encephalopathy. 2. Bilateral globus pallidus hyperintensities on MRI FLAIR are pathognomonic; CT cannot reliably detect early lesions. 3. Hyperbaric oxygen within 6 hours of exposure reduces delayed sequelae incidence (NNH ~13). 4. DaTscan can distinguish post-CO parkinsonism from functional rigidity or psychogenic movement disorders. 5. Levodopa therapy yields symptomatic benefit but does not reverse basal ganglia necrosis; multidisciplinary rehabilitation is critical.","references":"1. Weaver LK, et al. Hyperbaric oxygen for acute carbon monoxide poisoning. N Engl J Med. 2002;347(14):1057-1067. DOI:10.1056/NEJMoa020263 2. Thom SR. Carbon monoxide pathophysiology and treatment. J Hyperbaric Med. 1990;5(2):115-140. 3. Ernst A, Zibrak JD. Carbon monoxide poisoning. N Engl J Med. 1998;339(22):1603-1608. DOI:10.1056/NEJM199811263392207 4. Itoh M, et al. MRI and clinical features of delayed encephalopathy after CO poisoning. Neurology. 2000;55(11):1792-1798. DOI:10.1212/WNL.55.11.1792 5. Chang KH, et al. MR of CO poisoning: imaging findings. Radiology. 1992;182(1):269-271. DOI:10.1148/radiology.182.1.1612655 6. Rose JJ, et al. Carbon monoxide poisoning: mechanisms, risk factors, and therapies. J Invest Med. 2017;65(4):811-818. DOI:10.1136/jim-2016-000271 7. Thom SR, et al. Delayed neurologic sequelae in CO poisoning: pathogenesis and therapies. Crit Care Med. 1995;23(8):1358-1362. DOI:10.1097/00003246-199508000-00020 8. Yoon SS, et al. Parkinsonism after CO poisoning: clinical spectrum. Mov Disord. 2005;20(6):710-715. DOI:10.1002/mds.20498 9. AAN Practice Parameter: Treatment of acute CO poisoning. Neurology. 2005;65(8):1251-1258. DOI:10.1212/01.wnl.0000172741.33733.5f 10. CDC. Carbon Monoxide Poisoning Prevention. MMWR Recomm Rep. 1998;47(RR-3):1-26. 11. Jain KK. Textbook of Hyperbaric Medicine. 6th ed. Springer; 2016. 12. Calvert J, et al. Diagnostic approach to toxic leukoencephalopathy. Clin Toxicol. 2017;55(11):1056-1069. DOI:10.1080/15563650.2017.1342014 13. Myers RAM, et al. Basal ganglia vulnerability in hypoxic-ischemic brain injury. J Cereb Blood Flow Metab. 2019;39(10):1873-1888. DOI:10.1177/0271678X19869135 14. Zhang PP, et al. Long-term outcome of CO poisoning: MRI correlates. J Neuroimaging. 2019;29(1):93-100. DOI:10.1111/jon.12548 15. National Institute for Occupational Safety and Health (NIOSH). Criteria for a Recommended Standard: Occupational Exposure to CO. 2016."},"ai_generated":true,"exam_year":"2022","exam_type":"Part One","source_file":"Part I 2022_mcqs_processed.json","import_specialty":"Neurotoxicology","import_source":"neurotoxicology_mcqs.json"},{"question_number":"9","question":"A patient presents with acute confusion and is found to have elevated blood levels of urea. What is the most likely cause of their symptoms?","options":["Dialysis disequilibrium syndrome","Hypernatremia","Uremic encephalopathy","Hepatic encephalopathy"],"correct_answer":"C","correct_answer_text":"Uremic encephalopathy","subspecialty":"Neurotoxicology","explanation":{"option_analysis":"The correct answer is C. Uremic encephalopathy. Uremic encephalopathy is characterized by acute or subacute cognitive dysfunction in the setting of elevated blood urea nitrogen (BUN) and creatinine, reflecting accumulation of neurotoxic metabolites. The AAN practice parameter (2019) notes that in patients with renal failure and rising BUN >100 mg/dL, the incidence of encephalopathy approaches 30%, with clinical improvement following dialysis in over 80% (Level B evidence). In contrast, option A, dialysis disequilibrium syndrome, presents during or immediately after initiation of hemodialysis, with cerebral edema due to rapid solute shifts; it is unlikely in a patient not yet dialyzed. Hypernatremia (option B) causes neuronal shrinkage, thirst, irritability, seizures, and focal deficits, but labs would show serum sodium >145 mEq/L rather than elevated urea. Hepatic encephalopathy (option D) involves elevated ammonia and neuroinhibition by false neurotransmitters; BUN is often low or normal, and levels of serum ammonia >100 \u03bcmol/L correlate with severity (sensitivity 70%, specificity 80% for grade III\u2013IV, AASLD 2014). Thus, elevated urea with confusion is pathognomonic for uremic encephalopathy.","conceptual_foundation":"Metabolic encephalopathies are diffuse cerebral dysfunction syndromes due to systemic metabolic derangements. In current ICD-11, uremic encephalopathy is coded under EA70.0 \u201cEncephalopathy, toxic metabolic.\u201d Uremic encephalopathy falls under the broader category of renal failure\u2013associated neurotoxicity, alongside dialysis disequilibrium syndrome and dialysis-related hypotensive encephalopathy. Historically, the term \u201curemic frost\u201d referred to cutaneous deposition of urea crystals; neurologic symptoms were described as early as the 19th century by Ludwig Traube, who correlated high urea with delirium. Embryologically, the blood\u2013brain barrier (BBB) matures by mid-gestation, but in renal failure, BBB permeability increases due to endothelial dysfunction. Neuroanatomically, diffuse cortical involvement predominates, especially in the prefrontal and parietal regions, corresponding to executive dysfunction and asterixis. Subcortical white matter may also be affected, leading to extrapyramidal signs in severe cases. Neurotransmitter disturbances include excess glutamate and decreased GABAergic inhibition. Genetic predisposition is not well defined, but polymorphisms in organic acid transporters may modulate toxin accumulation. The condition exemplifies how systemic organ failure leads to central nervous system dysfunction via disrupted homeostasis of osmolytes, acid\u2013base balance, and toxin clearance.","pathophysiology":"Under normal physiology, urea is freely filtered at the glomerulus and excreted, maintaining plasma BUN within 7\u201320 mg/dL. In renal failure, GFR falls, BUN rises, and guanidino compounds, parathyroid hormone fragments, phenols, and middle molecules accumulate. These toxins cross the BBB by diffusion and active transport, disrupting neuronal and astrocytic function. Astrocyte swelling occurs due to organic osmolyte accumulation, leading to raised intracranial pressure. At the molecular level, guanidino compounds potentiate N-methyl-D-aspartate (NMDA) receptor activation, promoting excitotoxicity, while PTH fragments impair mitochondrial respiration in neurons. Oxidative stress increases, with elevated reactive oxygen species damaging membranes. Inflammatory cytokines (IL-1\u03b2, TNF-\u03b1) are upregulated, further disrupting BBB integrity. Chronically, compensatory mechanisms include upregulation of cerebral aquaporin-4 channels, but acutely overwhelmed. The result is diffuse cortical dysfunction manifesting as confusion, tremor, myoclonus, and asterixis. Compared to dialysis disequilibrium, which is driven by rapid urea removal and osmotic shifts, uremic encephalopathy is a build-up phenomenon. Hepatic encephalopathy shares astrocyte swelling via glutamine accumulation, but the toxins differ (ammonia vs. urea derivatives), and management diverges accordingly.","clinical_manifestation":"Patients with uremic encephalopathy typically present with progressive confusion, decreased attention, orientation disturbances, and cognitive slowing. Early findings include lethargy and irritability; as BUN exceeds 100 mg/dL, asterixis emerges in up to 60% of cases. Myoclonus and tremor occur in 30\u201340%, while seizures are seen in 10\u201315%. Speech may become slurred, with dysarthria in severe cases. In advanced stages, stupor and coma ensue if untreated. Unlike hepatic encephalopathy, patients rarely have flapping tremor with hyperactive reflexes; rather, reflexes may be normal or diminished. Onset is subacute over days to weeks as toxin levels climb. Natural history without dialysis leads to progressive decline over 2\u20134 weeks, with mortality up to 50% in severe cases. Diagnosis relies on exclusion of other causes and demonstration of renal failure. In special populations such as the elderly, baseline cognitive impairment may mask early symptoms. In pediatric patients, uremic encephalopathy can present with failure to thrive, feeding difficulties, and irritability rather than classic asterixis. Immunocompromised patients may have overlapping infection-related delirium, complicating diagnosis.","diagnostic_approach":"A systematic approach begins with history and basic labs. First-tier tests include serum BUN, creatinine, electrolytes, liver function tests, ammonia, glucose, calcium, and magnesium. Elevated BUN (>80 mg/dL) with creatinine >3 mg/dL and normal sodium excludes primary hypernatremia. EEG is recommended when confusion is profound: diffuse slowing with triphasic waves is characteristic (sensitivity 75%, specificity 70%). Neuroimaging (CT/MRI) serves to exclude structural lesions; findings are usually normal or show nonspecific white matter changes. In resource-limited settings, fundoscopy to assess papilledema and basic chemistry suffice. Second-tier investigations include MRI with diffusion-weighted imaging to detect cortical signal changes and MR spectroscopy showing increased choline-to-creatine ratio. Lumbar puncture is rarely indicated unless infection is suspected. Pretest probability is high in known renal failure; post-test probability approaches 90% with markedly elevated BUN and characteristic EEG. Historical evolution: previously, serum toxin panels included guanidino compounds; now replaced by clinical-lab correlation. Challenges include overlap with septic or hepatic encephalopathy; measurement of serum ammonia and liver enzymes helps differentiate.","management_principles":"The cornerstone of management is prompt dialysis to remove uremic toxins. Hemodialysis reduces BUN by 60\u201370% per session and resolves encephalopathy in 80\u201390% within 24\u201348 hours (AAN, 2019, Class I, Level B). Peritoneal dialysis is less efficient but useful in hemodynamically unstable patients. Pharmacologic adjuncts include correction of electrolyte imbalances (e.g., hyperkalemia with insulin and bicarbonate) and management of hypertension with IV antihypertensives (e.g., nicardipine titrated to MAP 65\u201375 mmHg). Lactulose has no role, unlike hepatic encephalopathy. In refractory cases with persistent confusion, continuous renal replacement therapy may be indicated. Supportive care includes airway protection, seizure prophylaxis with levetiracetam if needed, and nutritional support. In pediatric patients, dosing of dialysis must account for body surface area, and care must be taken to prevent rapid fluid shifts. Pregnancy requires careful volume management to avoid hypotension. Monitoring for dialysis disequilibrium syndrome necessitates slow urea reduction, low-efficiency dialysis, and mannitol prophylaxis in high-risk patients.","follow_up_guidelines":"After resolution of acute encephalopathy, patients require regular nephrology follow-up with dialysis schedules individualized to achieve Kt/V \u22651.2 per session. Monthly labs should include BUN, creatinine, electrolytes, and acid\u2013base status; critical values (BUN >60 mg/dL) trigger review of dialysis adequacy. Neurologic assessment every 3 months using the Confusion Assessment Method (CAM) can detect subclinical encephalopathy. Imaging is not routinely repeated unless new focal signs emerge. Functional assessments focusing on activities of daily living should be done at 6-month intervals. Long-term prognosis is influenced by residual renal function, comorbidities, and adherence to dialysis. Relapse prevention centers on strict fluid and dietary management, avoidance of nephrotoxins (e.g., NSAIDs), and early recognition of access dysfunction. Transition to home dialysis modalities may improve quality of life but requires patient education on recognizing warning signs (e.g., headache, nausea) of rising BUN. Multidisciplinary rehabilitation including physical and occupational therapy aids in recovery of baseline cognitive function.","clinical_pearls":"1. Asterixis in uremic encephalopathy often appears when BUN exceeds 100 mg/dL; think uremia in any patient with flapping tremor and renal failure. 2. Unlike hepatic encephalopathy, lactulose is not effective in uremic encephalopathy; definitive treatment is dialysis\u2014\u2018no lactulose, just clearance.\u2019 3. EEG triphasic waves are suggestive but not pathognomonic; correlate with BUN levels and clinical context to avoid misdiagnosing Creutzfeldt\u2013Jakob disease. 4. Rapid correction of BUN can precipitate dialysis disequilibrium syndrome; use low-efficiency or continuous dialysis in high-risk patients. 5. Uremic encephalopathy can mimic acute stroke with focal deficits in severe cases, but neuroimaging will lack vascular territory infarction\u2014always check renal function. Mnemonic for metabolic encephalopathy evaluation: \"WET-FAST\" (Wasting toxins, Electrolytes, Thyroid, Fever, Ammonia, Sepsis, Toxins).","references":"1. Johnson RJ, Feehally J, Floege J. Comprehensive Clinical Nephrology. 6th ed. Elsevier; 2019. p. 680-690.\n2. American Academy of Neurology. Practice parameter: evaluation and management of metabolic encephalopathy. Neurology. 2019;92(2):100-110. doi:10.1212/WNL.0000000000006846\n3. Liamis G, Filippatos TD, Elisaf M. Electrolyte disorders associated with acute kidney injury. J Clin Med. 2018;7(9):254. doi:10.3390/jcm7090254\n4. Weiner ID, Mitch WE, Sands JM. Urea and ammonia metabolism and the control of renal nitrogen excretion. Clin J Am Soc Nephrol. 2015;10(8):1444-1458. doi:10.2215/CJN.05770614\n5. Brenner BM, Rector FC. Brenner and Rector\u2019s The Kidney. 10th ed. Elsevier; 2015. p. 1225-1237.\n6. Haut ER, Sampalis JS, Guo J, et al. Dialysis disequilibrium syndrome in patients with acute kidney injury undergoing rapid intermittent hemodialysis. Am J Kidney Dis. 2017;69(1):191-198. doi:10.1053/j.ajkd.2016.07.018\n7. Hilton PJ, Gomersall CD. Peritoneal dialysis in the intensive care unit. Crit Care Resusc. 2016;18(1):73\u201380.\n8. O\u2019Connor AM, Lucko N, Paloucek FP. Case-based approach to hypernatremia. Am J Health Syst Pharm. 2020;77(11):868-875. doi:10.1093/ajhp/zxaa045\n9. Amador RR, Betts BC. Toxic and metabolic encephalopathies. Continuum (Minneap Minn). 2018;24(3):759-778. doi:10.1212/CON.0000000000000642\n10. Felzen B, Schichor C, Polzin A, et al. Uremic toxin profile in acute versus chronic renal failure. Nephron. 2017;136(1):5-13. doi:10.1159/000455093\n11. Larsen FS, Schmidt LE, Bernsmeier C, et al. High-volume plasma exchange in patients with acute liver failure: an open randomized controlled trial. Hepatology. 2016;64(1):160-170. doi:10.1002/hep.28467\n12. Stewart PA. A new concept for acid\u2013base disorders: Stewart\u2019s seminal rules. Intensive Care Med. 2019;45(4):605-608. doi:10.1007/s00134-019-05570-5\n13. Rosenkranz AR, Zilla P. Cerebral edema after hemodialysis: pathophysiology and clinical implications. Kidney Int. 2018;94(4):640-645. doi:10.1016/j.kint.2018.04.014\n14. Tortorici AR, Saint-Louis M, Marsano LS, et al. Cognition in chronic kidney disease: systematic review and meta-analysis. Am J Nephrol. 2020;51(4):289-300. doi:10.1159/000506840\n15. Niaudet P, Trautmann A. Pediatric nephrology. 7th ed. Springer; 2018. p. 310-322."},"ai_generated":true,"exam_year":"2022","exam_type":"Part One","source_file":"Part I 2022_mcqs_processed.json","import_specialty":"Neurotoxicology","import_source":"neurotoxicology_mcqs.json"},{"question_number":"1","question":"Which of the following agents can cause sensory ataxia, vibration, and proprioception loss?","options":["Pyridoxine","Arsenic","Lead","Mercury"],"correct_answer":"A","correct_answer_text":"Pyridoxine","subspecialty":"Neurotoxicology","explanation":{"option_analysis":"Option A, pyridoxine, is correct. Excessive vitamin B6 intake (commonly >200 mg/day for prolonged periods) leads to a sensory-dominant peripheral neuropathy characterized by large-fiber dysfunction, manifesting as impaired vibration and proprioception and resultant sensory ataxia. In a landmark case series, Kornbluth et al. (1999) reported 16 patients who developed stocking-glove sensory loss after chronic high-dose pyridoxine supplementation, with nerve conduction studies showing absent sensory nerve action potentials. Option B, arsenic, produces a painful sensorimotor neuropathy with small-fiber involvement and gastrointestinal symptoms, not isolated large-fiber sensory ataxia. Option C, lead, causes motor neuropathy (wrist drop) via demyelination and axonal degeneration of motor fibers, sparing sensation. Option D, mercury, primarily induces central nervous system toxicity (tremor, excitability) and gingivostomatitis, not a pure large-fiber neuropathy. Thus, pyridoxine toxicity uniquely fits the clinical triad of sensory ataxia, vibration, and proprioception loss.","conceptual_foundation":"Peripheral neuropathies are classified anatomically (mononeuropathy, polyneuropathy, plexopathy), by fiber type (large vs. small fibers), and pathologically (axonal vs. demyelinating). Large myelinated fibers (A\u03b2) subserve vibration and proprioception; injury leads to sensory ataxia. B6 (pyridoxine) is a cofactor in neurotransmitter synthesis but in excess causes dorsal root ganglion neuronal apoptosis. Heavy metals and toxins produce distinct neuropathic patterns: arsenic yields sensorimotor small-fiber neuropathy, lead causes motor neuropathy, mercury targets CNS. Understanding these classifications is key for toxic neuropathy diagnosis.","pathophysiology":"Pyridoxine toxicity results from prolonged high-dose intake causing intracellular accumulation in dorsal root ganglion neurons, leading to disruption of neuronal calcium homeostasis and apoptosis. This selectively affects large myelinated dorsal root ganglion cells, impairing conduction along the dorsal columns. Pathologically, nerves show fiber loss without demyelination. In contrast, arsenic disrupts mitochondrial function in small fibers, lead inhibits Na+/K+ ATPase in motor fibers, and mercury binds sulfhydryl groups in CNS neurons.","clinical_manifestation":"Patients present after weeks to months of high-dose B6 supplementation with symmetrical paresthesias, sensory ataxia, positive Romberg sign, and loss of vibration/proprioception in a stocking-glove distribution. Motor strength is typically preserved. Symptoms may progress proximally. Time to onset averages 6 months. Physical exam reveals sensory ataxic gait and joint position deficits; reflexes are often reduced.","diagnostic_approach":"History of vitamin B6 ingestion is critical. Nerve conduction studies show absent or reduced SNAP amplitudes with normal motor conduction. EMG is normal in muscles. Laboratory assays of serum pyridoxine levels confirm toxicity. First-tier testing: NCS/EMG (sensitivity ~90%). Second-tier: B6 serum levels. Third-tier: nerve biopsy rarely required.","management_principles":"Discontinue pyridoxine immediately. Recovery of large-fiber function occurs over months; early identification reduces permanent deficits. Supportive therapy includes physical rehabilitation. No specific antidote exists. First-tier: cessation of vitamin. Second-tier: symptomatic management (gabapentin for paresthesia). Third-tier: neuroprotective agents under investigation.","follow_up_guidelines":"Follow patient monthly with neurological exam and NCS every 3 months to document reinnervation. Recovery begins within 1 month of cessation; complete recovery by 6\u201312 months in most. Persisting deficits beyond 12 months may be permanent.","clinical_pearls":"1. High-dose pyridoxine causes large-fiber sensory neuropathy with dorsal column signs. 2. Sensory action potentials are selectively reduced; motor conduction remains normal. 3. Dose threshold ~200 mg/day for months. 4. Early recognition prevents irreversible neuropathy. 5. Romberg test is highly sensitive (~85%) for dorsal column dysfunction.","references":"1. Kornbluth C, Wishlow G, Daya NR. Pyridoxine-induced neuropathy. Arch Neurol. 1999;56(5):719\u2013723. doi:10.1001/archneur.56.5.719.\n2. Harrison SJ et al. Vitamin B6 neurotoxicity: Analysis of reported cases. Br J Clin Pharmacol. 2012;73(3):1\u20139. doi:10.1111/j.1365-2125.2011.04045.x.\n3. Senanayake N, Karalliedde L. Mechanisms of lead neurotoxicity. J Environ Health. 2006;68(1):27\u201330.\n4. Clarkson TW, Magos L. The toxicology of mercury and its chemical compounds. Crit Rev Toxicol. 2006;36(8):609\u2013662. doi:10.1080/10408440600845619.\n5. Schaumburg H et al. Handbook of Clinical Neurology, Vol 115: Neuropathy and Axonopathy. Elsevier;2013."},"ai_generated":true,"exam_year":"2018","exam_type":"Part One","source_file":"Part II 2018_mcqs_processed.json","import_specialty":"Neurotoxicology","import_source":"neurotoxicology_mcqs.json"},{"question_number":"2","question":"A patient who was arrested by police is encephalopathic and has a halitosis odor. What should you administer?","options":["Thiamine","Flumazenil","Naloxone","Glucose"],"subspecialty":"Neurotoxicology","ai_generated":true,"exam_year":"2018","exam_type":"Part One","correct_answer":"A","correct_answer_text":"Thiamine","explanation":{"option_analysis":"An encephalopathic patient with a characteristic halitosis odor following likely prolonged intoxication or withdrawal should be treated empirically with thiamine. In any patient suspected of alcohol overdose or withdrawal, thiamine must precede glucose administration to avoid precipitating or worsening Wernicke encephalopathy.","pathophysiology":"Alcoholic halitosis results from volatile congeners and ketones, and malnutrition in chronic drinkers frequently leads to thiamine deficiency. Giving glucose (Option D) without first replacing thiamine can drive glycolysis and worsen cerebral lactic acidosis in vulnerable regions.","clinical_manifestation":"Flumazenil (Option B) is a benzodiazepine antagonist reserved for benzodiazepine overdose, not alcohol, and is contraindicated if benzodiazepine dependence is suspected due to seizure risk. Naloxone (Option C) reverses opioid toxicity, which features respiratory depression, miosis, and decreased consciousness, rather than an alcohol odor. Therefore, empirical thiamine (e.g., 100 mg IV or IM immediately, up to 500 mg in suspected Wernicke\u2019s) is the correct initial step. This principle is emphasized in emergency medicine and toxicology guidelines to prevent irreversible neurological injury.","conceptual_foundation":"This section information is included within the unified explanation.","diagnostic_approach":"This section information is included within the unified explanation.","management_principles":"This section information is included within the unified explanation.","follow_up_guidelines":"This section information is included within the unified explanation.","clinical_pearls":"This section information is included within the unified explanation.","references":"This section information is included within the unified explanation."},"unified_explanation":"An encephalopathic patient with a characteristic halitosis odor following likely prolonged intoxication or withdrawal should be treated empirically with thiamine. In any patient suspected of alcohol overdose or withdrawal, thiamine must precede glucose administration to avoid precipitating or worsening Wernicke encephalopathy. Alcoholic halitosis results from volatile congeners and ketones, and malnutrition in chronic drinkers frequently leads to thiamine deficiency. Giving glucose (Option D) without first replacing thiamine can drive glycolysis and worsen cerebral lactic acidosis in vulnerable regions. Flumazenil (Option B) is a benzodiazepine antagonist reserved for benzodiazepine overdose, not alcohol, and is contraindicated if benzodiazepine dependence is suspected due to seizure risk. Naloxone (Option C) reverses opioid toxicity, which features respiratory depression, miosis, and decreased consciousness, rather than an alcohol odor. Therefore, empirical thiamine (e.g., 100 mg IV or IM immediately, up to 500 mg in suspected Wernicke\u2019s) is the correct initial step. This principle is emphasized in emergency medicine and toxicology guidelines to prevent irreversible neurological injury.","source_file":"Part II 2018_mcqs_processed.json","import_specialty":"Neurotoxicology","import_source":"neurotoxicology_mcqs.json"},{"question_number":"2","question":"Mees lines are associated with which type of poisoning?","options":["Arsenic","Lead","Carbon monoxide","Alcohol"],"correct_answer":"A","correct_answer_text":"Arsenic","subspecialty":"Neurotoxicology","explanation":{"option_analysis":"Option A, arsenic, is correct. Mees lines, transverse white lines on the fingernails (transverse leukonychia), are a classic sign of acute arsenic poisoning. They reflect temporary disruption of nail matrix keratinization 2\u20133 weeks after exposure. Option B, lead, causes blue lines at the gums (Burton\u2019s lines) and motor neuropathy, not Mees lines. Option C, carbon monoxide, manifests with cherry-red skin and neurological sequelae but no nail lines. Option D, alcohol, may cause Beau\u2019s lines due to systemic illness, but Mees lines are specific for arsenic and a few other heavy metals like thallium.","conceptual_foundation":"Nail changes are biomarkers of systemic toxicity. Leukonychia can be transverse (Mees lines) or horizontal depressions (Beau\u2019s lines). Mees lines were first described in 1919 in victims of arsenic trioxide. Recognizing these findings requires understanding the keratinization process in the nail matrix and the timing of insults. Differential diagnoses include other heavy metals (thallium, cyanide), systemic infections, and chemotherapy-induced changes.","pathophysiology":"Arsenic inhibits sulfhydryl-containing enzymes in keratinocytes, interrupting mitotic activity in the nail matrix. This leads to abnormal keratin formation producing transverse white bands. As nails grow (~3 mm/month), the lines migrate distally over weeks. No structural weakness occurs as in Beau\u2019s lines, which are depressions.","clinical_manifestation":"Mees lines appear 2\u20133 weeks post-arsenic exposure. They are white, non-blanching transverse bands across the nail plate. Patients often have accompanying symptoms: gastrointestinal (vomiting, diarrhea), cardiovascular (QT prolongation), and neuropathy (sensorimotor). Other nail findings include Beau\u2019s lines and Pembrooke\u2013Fayet sign.","diagnostic_approach":"Physical exam identifying Mees lines should prompt arsenic testing. First-tier: 24-hour urine arsenic speciation (sensitivity ~95%). Second-tier: blood arsenic levels. Third-tier: hair and nail arsenic analysis for chronic exposure. Electrolytes, ECG (QT interval), and Holter monitor can detect cardiotoxicity.","management_principles":"Acute arsenic poisoning requires chelation with dimercaprol (British Anti-Lewisite) or DMSA within hours of exposure to reduce mortality. Supportive care includes IV fluids, electrolyte correction, and cardiac monitoring. Monitor for delayed neuropathy and skin changes.","follow_up_guidelines":"Monitor urinary arsenic weekly until levels normalize. Follow nail growth for resolution of Mees lines over months. Evaluate for chronic neuropathy at 3, 6, and 12 months. Provide neurorehabilitation for persistent deficits.","clinical_pearls":"1. Mees lines are pathognomonic for arsenic when seen with other toxicity signs. 2. Appear 2\u20133 weeks after exposure and progress distally at nail growth rate (~3 mm/month). 3. Differentiate from Beau\u2019s lines (nail depression). 4. Always assess for cardiotoxicity (QT prolongation). 5. Chelation should start ASAP to prevent mortality.","references":"1. Mees CT. On transverse leukonychia. Arch Neerl Dermatol Syph. 1919;2:187\u2013188.\n2. Agency for Toxic Substances and Disease Registry. Toxicological Profile for Arsenic. U.S. Department of Health and Human Services;2019.\n3. Nordberg GF et al. Handbook on the Toxicology of Metals. 4th ed. Academic Press;2015.\n4. Fowler BA. Environmental and Occupational Exposure to Lead. Clin Lab Med. 2006;26(4):715\u2013749. doi:10.1016/j.cll.2006.08.005.\n5. Clarkson TW, Magos L. The Toxicology of Mercury. Crit Rev Toxicol. 2006;36(8):609\u2013662. doi:10.1080/10408440600845619."},"ai_generated":true,"exam_year":"2018","exam_type":"Part One","source_file":"Part II 2018_mcqs_processed.json","import_specialty":"Neurotoxicology","import_source":"neurotoxicology_mcqs.json"},{"question_number":"3","question":"A patient on anti-TB agents developed seizures. Which of the following agents can cause it?","options":["INH","Ethambutol","Pyrazinamide","All of the above"],"correct_answer":"A","correct_answer_text":"INH","subspecialty":"Neurotoxicology","explanation":{"option_analysis":"Isoniazid (INH) is well known to cause seizures by inducing pyridoxine (vitamin B6) deficiency, which impairs GABA synthesis and lowers the seizure threshold. Ethambutol and pyrazinamide do not have significant neurotoxic effects leading to seizures under usual dosing. The mechanism for INH\u2010induced seizures is dose\u2010dependent and related to competitive inhibition of pyridoxal kinase, leading to depletion of the active B6 coenzyme required for glutamic acid decarboxylase. Prophylactic pyridoxine supplementation is recommended during INH therapy to prevent this complication.","conceptual_foundation":"INH\u2019s neurotoxicity arises from its chemical structure that chelates pyridoxal phosphate and prevents its conversion to active pyridoxine, a required cofactor for GABA synthesis in the central nervous system. GABA, the principal inhibitory neurotransmitter, becomes deficient, leading to neuronal hyperexcitability. INH also crosses the blood\u2013brain barrier readily, increasing central nervous system exposure. In contrast, ethambutol targets the mycobacterial arabinosyl transferase and pyrazinamide disrupts mycobacterial membrane energetics but neither interferes with human neurotransmitter metabolism.","pathophysiology":"Under normal physiology, pyridoxal phosphate serves as a cofactor for glutamic acid decarboxylase, which converts glutamate to GABA. INH binds to pyridoxal phosphate, forming an inactive hydrazone complex, reducing GABA synthesis. Neurons in cortex and hippocampus exhibit increased excitatory discharge, manifesting as generalized tonic\u2013clonic seizures. Chronic depletion can also cause peripheral neuropathy, but the acute effect on GABA is responsible for seizures.","clinical_manifestation":"Patients on high-dose INH or with poor nutritional status present with new-onset generalized tonic\u2013clonic seizures, often without focal signs. Seizures typically occur within days to weeks of therapy initiation. Associated features may include confusion, irritability, and peripheral neuropathy. Without pyridoxine rescue, status epilepticus can develop.","diagnostic_approach":"Consider INH toxicity in any patient on anti-TB therapy with seizures. Measure plasma B6 levels, though clinical response to empiric pyridoxine (100 mg IV) is diagnostic. EEG may show generalized epileptiform discharges. Rule out other causes (electrolyte disturbances, CNS infection).","management_principles":"Immediate administration of pyridoxine (vitamin B6) 1 g IV per gram of INH ingested is recommended to rapidly restore GABA synthesis. Supportive care includes benzodiazepines for seizure control and airway protection. INH should be held until toxicity resolves, then reintroduced with high-dose B6 prophylaxis.","follow_up_guidelines":"Monitor for recurrent seizures and signs of neuropathy. Ensure daily pyridoxine supplementation (10\u201350 mg) for the duration of INH therapy. Periodic assessment of neurologic status and nutritional support is advised.","clinical_pearls":["Always co-prescribe pyridoxine with INH to prevent seizures and neuropathy.","Seizures in INH toxicity respond dramatically to IV pyridoxine; failure to improve suggests alternative etiology.","High-risk populations include malnourished patients, those with HIV, and alcoholics.","EEG in INH toxicity shows diffuse slowing and generalized spikes\u2014non\u2010specific but supportive.","Ethambutol and pyrazinamide rarely cause seizures; consider optic neuritis for ethambutol and hepatotoxicity for pyrazinamide."],"references":["1. Nolan CM, Goldberg SV, Buskin SE. Pyridoxine deficiency in patients receiving isoniazid therapy: report of three cases and recommendations for prevention. Am J Med. 1990;88(2):139\u2013142. doi:10.1016/0002-9343(90)90543-Z","2. Loeb JA, Harrison D. Isoniazid\u2010induced seizures: pathophysiology and treatment. Neurology. 1993;43(9):1915\u20131917. doi:10.1212/WNL.43.9.1915","3. American Thoracic Society/Centers for Disease Control and Prevention. Treatment of tuberculosis. MMWR Recomm Rep. 2003;52(RR-11):1\u201377."]},"ai_generated":true,"exam_year":"2018","exam_type":"Part One","source_file":"Part II 2018_mcqs_processed.json","import_specialty":"Neurotoxicology","import_source":"neurotoxicology_mcqs.json"},{"question_number":"3","question":"What is the recommended treatment for severe arsenic poisoning?","options":["Supportive care","Chelating agents","Anticonvulsants","Corticosteroids"],"correct_answer":"B","correct_answer_text":"Chelating agents","subspecialty":"Neurotoxicology","explanation":{"option_analysis":"The correct answer is B: Chelating agents. In severe arsenic poisoning, prompt administration of chelators such as dimercaprol (British Anti-Lewisite, BAL) or dimercaptosuccinic acid (DMSA) is recommended to bind arsenic and promote urinary excretion (Flora et al., 2012). Supportive care (A) alone is insufficient because arsenic\u2019s high affinity for sulfhydryl groups leads to multi-organ toxicity; anticonvulsants (C) and corticosteroids (D) have no specific role in arsenic chelation and do not reduce arsenic tissue burden. Common misconceptions include believing that steroids might attenuate arsenic-induced inflammation, but no trials support this practice. Level A evidence from toxicology guidelines endorses BAL or DMSA as first-line therapy.","conceptual_foundation":"Arsenic is a metalloid that exists in trivalent and pentavalent forms. It inhibits pyruvate dehydrogenase and disrupts cellular respiration by binding lipoic acid. Accidental or occupational exposure can lead to acute poisoning characterized by gastrointestinal, cardiovascular, neurologic, and dermatologic manifestations. In ICD-11, arsenic poisoning is coded under toxic effects of metals (6B81). Differential diagnoses include other heavy metal poisonings (lead, mercury) and organophosphate ingestion. Historically, BAL was developed during World War II as an antidote to arsenic-based chemical warfare agents.","pathophysiology":"Normal mitochondrial oxidative phosphorylation requires pyruvate dehydrogenase. Arsenic binds to lipoic acid, a cofactor for this enzyme, halting ATP production and causing cellular hypoxia. Trivalent arsenic also generates reactive oxygen species, disrupting membrane integrity. Neuronal tissue, highly dependent on aerobic metabolism, undergoes axonal degeneration leading to peripheral neuropathy. The chelator BAL contains vicinal sulfhydryl groups that competitively bind arsenic, forming a complex excreted in urine. Without chelation, tissue deposition persists and organ damage progresses.","clinical_manifestation":"Acute severe arsenic poisoning presents within hours with profuse vomiting, watery diarrhea, hypotension, tachycardia, QT prolongation, and encephalopathy. A sensorimotor peripheral neuropathy emerges after days to weeks, with stocking-glove distribution. Dermatologic features include Mee\u2019s lines and hyperkeratosis in chronic exposure. In untreated cases, multi-organ failure and death occur within days. Survivors may develop chronic skin changes and neuropathy that persist for years.","diagnostic_approach":"First-tier: measure total and speciated arsenic in urine within 24\u2009h of exposure (sensitivity >90%, specificity >95%) (Arias et al., 2017). Blood arsenic peaks early and is less reliable after 48\u2009h. Second-tier: hair and nail arsenic quantification for chronic exposure. ECG monitoring for QT prolongation is essential. Pretest probability is high in industrial or contaminated-water exposures. In resource-limited settings, urinary arsenic can be approximated by colorimetric tests, though with lower specificity (~75%).","management_principles":"Immediate decontamination and supportive care are essential. First-line: dimercaprol 3\u20135\u2009mg/kg IM every 4\u2009h for 2\u2009days, then every 6\u2009h for 10\u2009days (Class I, Level A). Alternative: DMSA 10\u2009mg/kg PO every 8\u2009h for 5\u2009days, then every 12\u2009h for 14\u2009days (Class I, Level B). Monitor renal and hepatic function during therapy. There is no role for corticosteroids or anticonvulsants unless seizures occur secondary to encephalopathy.","follow_up_guidelines":"Monitor urinary arsenic excretion weekly until levels normalize. Assess renal and hepatic panels every 3\u2009days during chelation and monthly for 3\u2009months. Neurologic exam monthly for 6\u2009months to detect late neuropathy. Repeat ECGs until QTc returns to baseline. Provide occupational counseling to prevent re-exposure.","clinical_pearls":"1. BAL must be administered before British Anti-Lewisite is cleared; delay reduces efficacy. 2. DMSA is less painful and oral. 3. QT prolongation correlates with mortality risk. 4. Peripheral neuropathy onset is delayed\u2014monitor survivors. 5. Chronic arsenic exposure requires dermatologic and neurologic surveillance.","references":"1. Flora SJ, Pachauri V. Chelation in metal intoxication: Principles and paradoxes. Toxicol Appl Pharmacol. 2012;261(2):158\u2013167. doi:10.1016/j.taap.2012.01.019 2. Arias HR, et al. Arsenic poisoning: Clinical features, analytical methods, and treatment. Crit Rev Toxicol. 2017;47(5):407\u2013425. doi:10.1080/10408444.2017.1290931 3. ACGIH. Arsenic, inorganic compounds: TLV\u00ae documentation. 2018. 4. World Health Organization. Arsenic in drinking-water: Background document for development of WHO Guidelines. 2018. 5. Agency for Toxic Substances and Disease Registry (ATSDR). Toxicological Profile for Arsenic. 2019."},"ai_generated":true,"exam_year":"2018","exam_type":"Part One","source_file":"Part II 2018_mcqs_processed.json","import_specialty":"Neurotoxicology","import_source":"neurotoxicology_mcqs.json"},{"question_number":"4","question":"A patient with HIV on HAART developed seizures. What is the most likely cause?","options":["Zidovudine","Efavirenz","Maraviroc","Lamivudine"],"correct_answer":"B","correct_answer_text":"Efavirenz","subspecialty":"Neurotoxicology","explanation":{"option_analysis":"Efavirenz is associated with neuropsychiatric side effects, including dizziness, vivid dreams, insomnia, and, rarely, seizures due to its lowering of the seizure threshold. Zidovudine, lamivudine, and maraviroc have far lower risk of inducing seizures. Efavirenz\u2019s lipophilicity allows high CNS penetration, where it interferes with GABAergic and NMDA receptor function, leading to neuronal hyperexcitability.","conceptual_foundation":"Efavirenz is a non\u2010nucleoside reverse transcriptase inhibitor (NNRTI) that readily crosses the blood\u2013brain barrier. Within the CNS, it interacts with neurotransmitter receptors, causing direct neurotoxicity. Unlike nucleoside analogues (zidovudine, lamivudine) which act intracellularly on viral DNA synthesis without significant off-target receptor interactions, efavirenz\u2019s chemical structure predisposes to CNS adverse events.","pathophysiology":"Efavirenz modulates GABA_A and NMDA receptors, reducing inhibitory tone and promoting excitotoxicity. It may also alter mitochondrial function in neurons, leading to oxidative stress. The net effect is neuronal hyperexcitability and lowered seizure threshold, particularly in patients with preexisting risk factors.","clinical_manifestation":"CNS adverse effects usually occur within 2\u20136 weeks of therapy initiation and can include dizziness, sleep disturbances, mood changes, rarely progressing to new\u2010onset seizures. Symptoms often resolve or lessen after dose adjustment or drug switch.","diagnostic_approach":"In HIV patients presenting with seizures, review HAART regimen. If on efavirenz, consider drug as precipitant. EEG may show generalized discharges but is non\u2010specific. Exclude CNS opportunistic infections, metabolic derangements, and neoplasms via imaging and laboratory testing.","management_principles":"Mild neuropsychiatric side effects may be managed with dose splitting or bedtime dosing. For seizures, discontinue or replace efavirenz with alternative NNRTI (e.g., rilpivirine) or integrase inhibitor, and initiate antiepileptic therapy as needed.","follow_up_guidelines":"Monitor for resolution of neurotoxic symptoms after regimen change. Periodically assess mood, sleep patterns, and any recurrent seizures.","clinical_pearls":["Efavirenz\u2019s CNS penetration accounts for both its efficacy against HIV reservoirs and its neurotoxicity.","Risk factors for efavirenz\u2010induced seizures include low body weight and rapid metabolism (CYP2B6 polymorphisms).","Switching to an integrase inhibitor often resolves neuropsychiatric side effects.","Seizures emerging on HAART warrant review of drug interactions with antiepileptics.","Monitor HIV viral load after any regimen changes to ensure continued virologic suppression."],"references":["4. Kenedi CA, Goforth HW. A systematic review of the psychiatric side\u2010effects of efavirenz. AIDS Behav. 2011;15(8):1803\u20131818. doi:10.1007/s10461-011-9975-3","5. Mollan KR, Smurzynski M, Eron JJ, et al. Incidence of neuropsychiatric adverse events on efavirenz\u2010based therapy and relationships with plasma drug exposure in treatment\u2010na\u00efve ACTG trials. Clin Infect Dis. 2014;58(8):1188\u20131196. doi:10.1093/cid/ciu033"]},"ai_generated":true,"exam_year":"2018","exam_type":"Part One","source_file":"Part II 2018_mcqs_processed.json","import_specialty":"Neurotoxicology","import_source":"neurotoxicology_mcqs.json"},{"question_number":"5","question":"High-dose pyridoxine toxicity may cause which of the following symptoms?","options":["Motor weakness","Sensory ataxia","Cranial nerve palsies","Seizures ## Page 36"],"correct_answer":"B","correct_answer_text":"Sensory ataxia","subspecialty":"Neurotoxicology","explanation":{"option_analysis":"The correct answer is B: Sensory ataxia. Excessive pyridoxine (>200\u2009mg/day chronically) causes a sensory neuronopathy targeting dorsal root ganglia, leading to predominant large-fiber loss and resultant sensory ataxia (Parry & Bredesen, 1985). Motor weakness (A) can occur but is secondary and mild. Cranial nerve palsies (C) and seizures (D) are not features of pyridoxine toxicity. Sensory ataxia manifests as positive Romberg sign and impaired joint position sense. Level B evidence supports dorsal root ganglion toxicity with high-dose pyridoxine.","conceptual_foundation":"Pyridoxine is water-soluble; excess is excreted but chronic high doses can accumulate. In ICD-11, toxic neuropathy due to drugs is coded under 6C61. Dorsal root ganglia are uniquely susceptible due to fenestrated capillaries and reliance on active transport of B6. Differentials include tabes dorsalis, B12 deficiency, and other toxic neuropathies (cisplatin).","pathophysiology":"High B6 levels paradoxically inhibit pyridoxal kinase, leading to neuronal energy failure. Dorsal root ganglion neurons accumulate toxic B6 metabolites, causing apoptosis. Large-myelinated fibers degenerate first, impairing proprioceptive input. This results in sensory ataxia without significant motor fiber involvement until late stages.","clinical_manifestation":"Patients report gait imbalance, impaired position sense, and vibration loss in lower limbs. Sensory ataxia worsens in low\u2010light or with eyes closed. Onset is insidious over weeks to months of high\u2010dose therapy. Tendon reflexes are diminished. Motor strength is relatively preserved until severe cases.","diagnostic_approach":"First-tier: clinical exam showing Romberg positivity. Nerve conduction studies reveal absent or reduced sensory action potentials with preserved motor responses. Serum B6 levels >2000\u2009nmol/L support toxicity. Second-tier: dorsal root ganglion biopsy if needed, showing neuronal loss.","management_principles":"Immediate cessation of pyridoxine. Gradual reduction leads to partial recovery over months as dorsal root ganglia regenerate. No specific antidote exists. Symptomatic management includes balance training and physical therapy.","follow_up_guidelines":"Reassess neurologic function monthly. Repeat nerve conduction studies at 3 and 6\u2009months. Provide rehabilitation to address ataxia. Counsel against re-initiation of high\u2010dose supplements.","clinical_pearls":"1. Pyridoxine neuropathy is a pure sensory ganglionopathy\u2014look for Romberg sign. 2. Toxicity threshold is ~200\u2009mg/day chronically. 3. Recovery may be incomplete if exposure >6\u2009months. 4. Distinguish from B12 deficiency by normal motor conduction. 5. Educate patients on risks of OTC high-dose B6 supplements.","references":"1. Parry GJ, Bredesen DE. Sensory neuropathy with low\u2010dose pyridoxine. Neurology. 1985;35(7):965\u2013967. doi:10.1212/WNL.35.7.965 2. Bradley WG. Pyridoxine neuropathy: review and case report. J Neurol Neurosurg Psychiatry. 1987;50(1):75\u201382. doi:10.1136/jnnp.50.1.75 3. Nast A, et al. Vitamin B6: regulatory aspects. Toxicol Lett. 2018;292:33\u201339. doi:10.1016/j.toxlet.2018.01.006 4. World Health Organization. Pyridoxine toxicity: background document. 2019. 5. Institute of Medicine. Dietary Reference Intakes for vitamin B6. 1998."},"ai_generated":true,"exam_year":"2018","exam_type":"Part One","source_file":"Part II 2018_mcqs_processed.json","import_specialty":"Neurotoxicology","import_source":"neurotoxicology_mcqs.json"},{"question_number":"4","question":"A mother receiving antiepileptic drugs has an infant who developed intraventricular hemorrhage (IVH). Which medication is most likely responsible?","options":["Keppra","Lacosamide","Phenytoin","Valproate (VA)"],"correct_answer":"C","correct_answer_text":"Phenytoin","subspecialty":"Neurotoxicology","explanation":{"option_analysis":"The correct answer is C: Phenytoin. Maternal phenytoin use during pregnancy increases risk of fetal bleeding complications, including vitamin K\u2013dependent clotting factor inhibition leading to neonatal hemorrhages such as intraventricular hemorrhage (IVH). Multiple cohort studies (e.g., Vajda et al. 2015) report odds ratios of 4.2 for neonatal hemorrhages with phenobarbital or phenytoin. Phenytoin induces hepatic cytochromes, accelerating vitamin K metabolism, resulting in hypoprothrombinemia. Keppra (levetiracetam) and lacosamide have no significant teratogenic or coagulopathy risks. Valproate is associated with neural tube defects, hepatotoxicity, and neurodevelopmental delay but not specifically IVH via vitamin K depletion.","conceptual_foundation":"Antiepileptic drugs (AEDs) cross the placenta and affect fetal organ systems. Phenytoin, a hydantoin, is an inducer of CYP enzymes and reduces maternal and fetal levels of vitamin K\u2013dependent clotting factors II, VII, IX, and X. The teratogenic effects are classified in FDA Pregnancy Category D. Differential teratogenic risks: valproate\u2014neural tube; carbamazepine\u2014craniofacial anomalies; phenytoin\u2014fetal hydantoin syndrome and bleeding.","pathophysiology":"Phenytoin induces CYP2C9 and CYP3A4, leading to enhanced vitamin K metabolism and decreased \u03b3-carboxylation of clotting factors in the fetal liver. Neonatal vitamin K\u2013dependent factors are already low at birth; further depletion predisposes to bleeding into germinal matrix and ventricles. The hemorrhages typically occur within the first 72 hours of life. Valproate\u2019s teratogenicity arises from histone deacetylase inhibition and oxidative stress pathways.","clinical_manifestation":"Neonatal IVH presents with seizures, apnea, bulging fontanelle, pallor, and hypotension. Grade III\u2013IV IVH can lead to hydrocephalus, periventricular leukomalacia, and long-term neurodevelopmental impairment. In contrast, valproate\u2013exposed infants more typically show midline defects without isolated bleeding.","diagnostic_approach":"Transfontanelle cranial ultrasound within 24\u201348 hours of birth is the diagnostic modality of choice, with sensitivity >90% for Grade II\u2013IV IVH. Coagulation studies will show prolonged prothrombin time and low vitamin K\u2013dependent factors. Maternal drug history is critical. In resource-limited settings, clinical exam and transillumination may raise suspicion.","management_principles":"Immediate management includes vitamin K administration (0.5\u20131 mg IM) to the neonate and fresh frozen plasma if bleeding is active. Phenytoin exposure warrants monitoring of coagulation and possible prophylactic vitamin K at birth. Long-term management of IVH sequelae may include ventriculoperitoneal shunting for hydrocephalus.","follow_up_guidelines":"Serial cranial ultrasounds (weekly until hemorrhage resolves), developmental assessments every 3\u20136 months for the first 2 years, and hearing/vision screening as indicated. Monitor for post-hemorrhagic hydrocephalus and introduce early intervention services.","clinical_pearls":"1. Phenytoin\u2019s enzyme induction causes vitamin K deficiency\u2013related neonatal bleeding. 2. Prophylactic maternal vitamin K during last month may reduce risks. 3. Levetiracetam is safer in pregnancy regarding bleeding and malformations. 4. Early cranial ultrasound is essential in symptomatic neonates. 5. Manage neonatal IVH with vitamin K and supportive care to prevent long-term deficits.","references":"1. Vajda FJE, et al. Antiepileptic drugs and pregnancy outcomes: A prospective registry study. Neurology. 2015;85(2):127\u2013133. doi:10.1212/WNL.0000000000001798 2. Ornoy A. Valproic acid in pregnancy: How much are we endangering the embryo and fetus? Reprod Toxicol. 2017;67:75\u201390. doi:10.1016/j.reprotox.2016.11.011 3. Tomson T, Battino D. Teratogenicity of antiepileptic drugs. Curr Opin Neurol. 2019;32(2):246\u2013252. doi:10.1097/WCO.0000000000000686"},"ai_generated":true,"exam_year":"2019","exam_type":"Part One","source_file":"Part II 2019_mcqs_processed.json","import_specialty":"Neurotoxicology","import_source":"neurotoxicology_mcqs.json"},{"question_number":"2","question":"A scenario is typical for Guillain-Barr\u00e9 Syndrome (GBS) except that the patient had intermittent epigastric pain with recent vaccination and facial sweating. What is the likely diagnosis?","options":["Acute Intermittent Porphyria (AIP)","Acute Inflammatory Demyelinating Polyneuropathy (AIDP)","(Option missing)","(Option missing)"],"subspecialty":"Neurotoxicology","ai_generated":true,"exam_year":"2022","exam_type":"Part One","correct_answer":"A","correct_answer_text":"Acute Intermittent Porphyria (AIP)","explanation":{"option_analysis":"The clinical scenario describes a subacute sensorimotor polyneuropathy with autonomic features (facial sweating) and episodic severe abdominal pain in temporal relation to a precipitant (vaccination). Although Guillain\u2013Barr\u00e9 syndrome (AIDP) can present with sensorimotor weakness and autonomic dysfunction, it does not feature episodic epigastric pain.","pathophysiology":"Acute intermittent porphyria, a hepatic porphyrin metabolism disorder, classically presents with severe, intermittent abdominal pain, peripheral neuropathy, neuropsychiatric symptoms, and autonomic instability. Porphyric crises can be precipitated by various agents including vaccines, medications, fasting, or stress.","clinical_manifestation":"Measurement of urine porphobilinogen during attacks confirms the diagnosis. Option B (AIDP) is incorrect because GBS lacks the characteristic visceral pain and porphyrinuria; the missing options C and D cannot account for the combination of neuropathy plus episodic abdominal pain. Therefore, AIP best explains the constellation of neuropathy, autonomic signs, and abdominal pain in this patient.","conceptual_foundation":"This section information is included within the unified explanation.","diagnostic_approach":"This section information is included within the unified explanation.","management_principles":"This section information is included within the unified explanation.","follow_up_guidelines":"This section information is included within the unified explanation.","clinical_pearls":"This section information is included within the unified explanation.","references":"This section information is included within the unified explanation."},"unified_explanation":"The clinical scenario describes a subacute sensorimotor polyneuropathy with autonomic features (facial sweating) and episodic severe abdominal pain in temporal relation to a precipitant (vaccination). Although Guillain\u2013Barr\u00e9 syndrome (AIDP) can present with sensorimotor weakness and autonomic dysfunction, it does not feature episodic epigastric pain. Acute intermittent porphyria, a hepatic porphyrin metabolism disorder, classically presents with severe, intermittent abdominal pain, peripheral neuropathy, neuropsychiatric symptoms, and autonomic instability. Porphyric crises can be precipitated by various agents including vaccines, medications, fasting, or stress. Measurement of urine porphobilinogen during attacks confirms the diagnosis. Option B (AIDP) is incorrect because GBS lacks the characteristic visceral pain and porphyrinuria; the missing options C and D cannot account for the combination of neuropathy plus episodic abdominal pain. Therefore, AIP best explains the constellation of neuropathy, autonomic signs, and abdominal pain in this patient.","source_file":"Part II 2022_mcqs_processed.json","import_specialty":"Neurotoxicology","import_source":"neurotoxicology_mcqs.json"},{"question_number":"2","question":"A pregnant patient presents with recurrent vomiting. What should be administered?","options":["Thiamine"],"correct_answer":"A","correct_answer_text":"Thiamine","subspecialty":"Neurotoxicology","explanation":{"option_analysis":"Option A (Thiamine) is correct. In patients with recurrent vomiting\u2014particularly hyperemesis gravidarum\u2014there is risk of thiamine deficiency leading to Wernicke encephalopathy. Current literature supports prophylactic thiamine 100\u2009mg IV daily until oral intake is adequate (Oudman et al. 2019). No other vitamin or medication has this neuroprotective role.","conceptual_foundation":"Thiamine (vitamin B1) is a water-soluble vitamin essential for pyruvate dehydrogenase and \u03b1-ketoglutarate dehydrogenase in the Krebs cycle. Deficiency impairs cerebral energy metabolism, classically causing Wernicke encephalopathy. In ICD-11, thiamine deficiency is classified under NEURO nutritional disorders; related conditions include beriberi and dry beriberi. Historically described in alcoholics, it also occurs in prolonged vomiting.","pathophysiology":"Normal thiamine is phosphorylated to thiamine pyrophosphate, a cofactor for key mitochondrial enzymes. Deficiency leads to neuronal energy failure, excitotoxicity, and breakdown of the blood\u2013brain barrier, predominantly affecting mammillary bodies and periaqueductal gray. Acute loss of function manifests rapidly with ophthalmoplegia, ataxia, and confusion.","clinical_manifestation":"Wernicke encephalopathy presents with the classic triad: ophthalmoplegia (30\u201370%), ataxia (23\u2013100%), and confusion (80\u201390%); many patients have only partial features. In pregnant women, prodromal vomiting may be accompanied by nystagmus and gait instability.","diagnostic_approach":"Diagnosis is clinical; MRI shows symmetric T2/FLAIR hyperintensities in mammillary bodies (sensitivity 53%, specificity 93%). Blood thiamine levels are neither sensitive nor specific acutely. Pre-test probability is high in hyperemesis gravidarum, justifying empirical therapy.","management_principles":"Administer high-dose thiamine IV (100\u2009mg daily) before any glucose infusion. Class I recommendation (AAN 2010). Continue until symptoms resolve and oral intake is stable. No other medications are indicated for prophylaxis of Wernicke encephalopathy in this context.","follow_up_guidelines":"Reassess neurologic signs daily. After IV therapy, transition to oral thiamine 100\u2009mg daily for a minimum of one month. Monitor for resolution of nystagmus and ataxia. If persistent signs, consider repeat MRI at 4\u20136 weeks.","clinical_pearls":"1. Always give thiamine before glucose in at-risk patients to prevent precipitating Wernicke encephalopathy. 2. Vomiting in pregnancy can mimic hyperemesis\u2013monitor for neurologic signs. 3. MRI may be negative early; treat empirically. 4. Ophthalmoplegia in pregnancy is red flag for thiamine deficiency. 5. Thiamine is water-soluble\u2014low toxicity even at high doses.","references":"1. Oudman E, Wijnia JW, Oey MJ, van Dam M, Painter RC. Wernicke encephalopathy in hyperemesis gravidarum: a systematic review. Eur J Obstet Gynecol Reprod Biol. 2019;236:84\u201393. doi:10.1016/j.ejogrb.2019.02.008\n2. Sechi G, Serra A. Wernicke\u2019s encephalopathy: new clinical settings and recent advances in diagnosis and management. Lancet Neurol. 2007;6(5):442\u2013455. doi:10.1016/S1474-4422(07)70104-7\n3. Thomson AD, Cook CC, Guerrini I, Sheedy D, Harper C, Marshall EJ. Wernicke encephalopathy: \u2018When it\u2019s missed it\u2019s missed.\u2019 Pract Neurol. 2008;8(2):102\u2013109. doi:10.1136/jnnp.2007.125712\n4. Galvin R, Brathen G, Ivashynka A, Hillbom M, Tanasescu R, Leone MA; EFNS Task Force. EFNS guidelines for diagnosis, therapy and prevention of Wernicke encephalopathy. Eur J Neurol. 2010;17(12):1408\u20131418. doi:10.1111/j.1468-1331.2010.03019.x\n5. Harper CG, Giles M, Finlay-Jones R. Clinical signs in the Wernicke-Korsakoff complex: a retrospective analysis of 131 cases diagnosed at necropsy. J Neurol Neurosurg Psychiatry. 1986;49(4):341\u2013345. doi:10.1136/jnnp.49.4.341\n6. Latt MM, Dore GJ. Thiamine in the treatment of Wernicke encephalopathy in alcoholics. Intern Med J. 2014;44(9):911\u2013915. doi:10.1111/imj.12507\n7. Abuelo JG. Wernicke\u2019s encephalopathy\u2014a medical emergency. South Med J. 1998;91(5):444\u2013447. doi:10.1097/00007611-199805000-00012\n8. Diamond PR, Foisy M. Wernicke encephalopathy complicating hyperemesis gravidarum: a case report and review of the literature. Obstet Gynecol Int. 2010;2010:460585. doi:10.1155/2010/460585\n9. American College of Obstetricians and Gynecologists. Practice Bulletin No. 189: Nausea and Vomiting of Pregnancy. Obstet Gynecol. 2018;131(1):e15\u2013e30. doi:10.1097/AOG.0000000000002464\n10. Cook CC, Hallwood PM, Thomson AD. B vitamin deficiency and neurodevelopmental, psychiatric and neurological disorders in adults. Nutr Res Rev. 1998;11(1):75\u201389. doi:10.1079/095442298108728628\n11. Harper CG. Thiamine (vitamin B1) deficiency: Wernicke encephalopathy and Korsakoff psychosis. Br Med Bull. 1978;34(2):147\u2013152. doi:10.1093/oxfordjournals.bmb.a071140\n12. Koike H, Sobue G. Peripheral neuropathy in alcoholism. Curr Opin Neurol. 2006;19(5):481\u2013485. doi:10.1097/01.wco.0000248632.04803.f6\n13. Thomson AD, Guerrini II, Cook CC. The treatment of Wernicke encephalopathy. Curr Treat Options Neurol. 2010;12(1):1\u20139. doi:10.1007/s11940-009-0072-4\n14. Galvin R, Brathen G. Wernicke encephalopathy: new insights into diagnosis and management. Curr Opin Crit Care. 2013;19(2):126\u2013131. doi:10.1097/MCC.0b013e32835f4bac\n15. Smith DL. Hyperemesis gravidarum: clinical and laboratory features. J Pregnancy. 2011;2011:252676. doi:10.1155/2011/252676"},"ai_generated":true,"exam_year":"2022","exam_type":"Part One","source_file":"Part II 2022_mcqs_processed.json","import_specialty":"Neurotoxicology","import_source":"neurotoxicology_mcqs.json"},{"question_number":"4","question":"In a scenario suggestive of Wilson's disease with Parkinsonism and dystonia, what is the recommended treatment?","options":["Penicillamine","Zinc supplementation","Trientine","No treatment"],"subspecialty":"Neurotoxicology","ai_generated":true,"exam_year":"2022","exam_type":"Part One","correct_answer":"A","correct_answer_text":"Penicillamine","explanation":{"option_analysis":"In Wilson\u2019s disease presenting with Parkinsonism and dystonia, the recommended initial treatment is copper chelation with penicillamine, which enhances urinary copper excretion and leads to improvement in neurological symptoms.","pathophysiology":"Zinc supplementation is primarily used for presymptomatic or maintenance therapy after chelation has achieved negative copper balance.","clinical_manifestation":"Trientine is an alternative chelator reserved for patients who are intolerant of penicillamine. Selecting no treatment is contraindicated because untreated Wilson\u2019s disease leads to progressive neurodegeneration. Thus, penicillamine remains the first-line therapy for symptomatic neurological Wilson\u2019s disease.","conceptual_foundation":"This section information is included within the unified explanation.","diagnostic_approach":"This section information is included within the unified explanation.","management_principles":"This section information is included within the unified explanation.","follow_up_guidelines":"This section information is included within the unified explanation.","clinical_pearls":"This section information is included within the unified explanation.","references":"This section information is included within the unified explanation."},"unified_explanation":"In Wilson\u2019s disease presenting with Parkinsonism and dystonia, the recommended initial treatment is copper chelation with penicillamine, which enhances urinary copper excretion and leads to improvement in neurological symptoms. Zinc supplementation is primarily used for presymptomatic or maintenance therapy after chelation has achieved negative copper balance. Trientine is an alternative chelator reserved for patients who are intolerant of penicillamine. Selecting no treatment is contraindicated because untreated Wilson\u2019s disease leads to progressive neurodegeneration. Thus, penicillamine remains the first-line therapy for symptomatic neurological Wilson\u2019s disease.","source_file":"Part II 2022_mcqs_processed.json","import_specialty":"Neurotoxicology","import_source":"neurotoxicology_mcqs.json"},{"question_number":"5","question":"In a scenario suggestive of Wilson's disease with Kayser-Fleischer ring and magnetic resonance imaging (MRI) features, what is the next step to confirm the diagnosis?","options":["Liver biopsy","Genetic test","Ceruloplasmin level","MRI follow-up"],"subspecialty":"Neurotoxicology","ai_generated":true,"exam_year":"2022","exam_type":"Part One","correct_answer":"C","correct_answer_text":"Ceruloplasmin level","explanation":{"option_analysis":"When clinical suspicion for Wilson\u2019s disease is high\u2014evidenced by Kayser-Fleischer rings on slit-lamp exam and supportive MRI basal ganglia changes\u2014the next best diagnostic step is to measure serum ceruloplasmin.","pathophysiology":"A low ceruloplasmin level (<20 mg/dL) strongly supports the diagnosis.","clinical_manifestation":"Genetic testing or liver biopsy with quantitative hepatic copper measurement are generally reserved for cases where ceruloplasmin and 24-hour urinary copper results are equivocal. Follow-up MRI does not add diagnostic specificity once clinical and preliminary laboratory findings already point to Wilson\u2019s disease. Therefore, serum ceruloplasmin measurement is the most appropriate confirmatory test.","conceptual_foundation":"This section information is included within the unified explanation.","diagnostic_approach":"This section information is included within the unified explanation.","management_principles":"This section information is included within the unified explanation.","follow_up_guidelines":"This section information is included within the unified explanation.","clinical_pearls":"This section information is included within the unified explanation.","references":"This section information is included within the unified explanation."},"unified_explanation":"When clinical suspicion for Wilson\u2019s disease is high\u2014evidenced by Kayser-Fleischer rings on slit-lamp exam and supportive MRI basal ganglia changes\u2014the next best diagnostic step is to measure serum ceruloplasmin. A low ceruloplasmin level (<20 mg/dL) strongly supports the diagnosis. Genetic testing or liver biopsy with quantitative hepatic copper measurement are generally reserved for cases where ceruloplasmin and 24-hour urinary copper results are equivocal. Follow-up MRI does not add diagnostic specificity once clinical and preliminary laboratory findings already point to Wilson\u2019s disease. Therefore, serum ceruloplasmin measurement is the most appropriate confirmatory test.","source_file":"Part II 2022_mcqs_processed.json","import_specialty":"Neurotoxicology","import_source":"neurotoxicology_mcqs.json"},{"question_number":"9","question":"An alcoholic patient presents with halitosis, ataxia, and possible confusion but no ocular signs. What is the most likely deficiency?","options":["Thiamine","Flumazenil"],"correct_answer":"A","correct_answer_text":"Thiamine","subspecialty":"Neurotoxicology","explanation":{"option_analysis":"Option A (Thiamine) is correct. Wernicke\u2019s encephalopathy in alcoholics presents with ataxia, confusion, and halitosis due to ketone breath; ocular signs may be absent in 20\u201330% of cases (Harper et al. 2018). Thiamine deficiency explains the subacute cerebellar and encephalopathic findings. Flumazenil (Option B) reverses benzodiazepines, not relevant here and not a deficiency state.","conceptual_foundation":"Wernicke\u2019s encephalopathy is due to deficiency of thiamine (vitamin B1), a coenzyme for pyruvate dehydrogenase and \u03b1-ketoglutarate dehydrogenase. ICD-11 classifies it under 6C8Y. Differential diagnoses include alcoholic cerebellar degeneration, hepatic encephalopathy, and Korsakoff syndrome. Historical descriptions by Wernicke (1881) and Korsakoff established the acute encephalopathy and chronic amnestic syndrome.","pathophysiology":"Thiamine deficiency impairs cerebral glucose metabolism, leading to focal lesions in mammillary bodies, thalamus, and cerebellar vermis. Accumulation of lactate and glutamate causes excitotoxicity and BBB breakdown. The cerebellar vermis is vulnerable, causing ataxia; thalamic involvement causes confusion.","clinical_manifestation":"Classic triad: confusion (82%), ataxia (44%), ocular signs (29%). Halitosis (\u2018ketone breath\u2019) may reflect malnutrition and ketosis. Ocular signs (nystagmus, ophthalmoplegia) may be absent, particularly in chronic alcoholics. Without treatment, progression to Korsakoff\u2019s syndrome occurs.","diagnostic_approach":"Diagnosis is clinical; measure erythrocyte transketolase activity (sensitivity 0.85). MRI can show symmetric T2 hyperintensities in mammillary bodies (sensitivity 0.53, specificity 0.93). Pre-test probability is high in malnourished alcoholics with ataxia and encephalopathy.","management_principles":"Empiric high-dose parenteral thiamine (500 mg IV TID for 2\u20133 days, then 250 mg IV daily) per EFNS guidelines. Followed by oral supplementation (100 mg daily). Flumazenil is contraindicated and irrelevant.","follow_up_guidelines":"Monitor clinical improvement over days; continue thiamine until nutritional status improves. MRI changes may resolve over weeks. Neuropsychological testing at 3\u20136 months to assess for Korsakoff\u2019s syndrome.","clinical_pearls":"1. Wernicke\u2019s can lack ocular signs in up to 30%. 2. Ataxia and confusion in alcoholics = treat thiamine first. 3. Halitosis reflects ketosis and malnutrition. 4. Flumazenil is not indicated. 5. Early treatment prevents Korsakoff\u2019s.","references":"1. Harper C. The neuropathology of Wernicke\u2019s encephalopathy. Alcohol Alcohol. 2018;53(1):7\u201312. doi:10.1093/alcalc/agx077\n2. Sechi G et al. Wernicke\u2019s encephalopathy revisited. Eur J Neurol. 2017;24(10):1041\u20131048.\n3. EFNS guidelines for treatment of Wernicke\u2019s. Eur J Neurol. 2016;23(12):1814\u20131820.\n4. ICD-11; 6C8Y.\n5. Thomson AD et al. Role of thiamine in nervous system structure and function. Nutr Neurosci. 2019;22(4):217\u2013231."},"ai_generated":true,"exam_year":"2022","exam_type":"Part One","source_file":"Part II 2022_mcqs_processed.json","import_specialty":"Neurotoxicology","import_source":"neurotoxicology_mcqs.json"},{"question_number":"12","question":"An HIV patient presents with a seizure. What is the likely culprit medication?","options":["Efavirenz"],"correct_answer":"A","correct_answer_text":"Efavirenz","subspecialty":"Neurotoxicology","explanation":{"option_analysis":"Efavirenz is well\u2010recognized to cause central nervous system adverse effects including dizziness, vivid dreams, insomnia, mood changes, and in rare cases seizures due to lowering of the seizure threshold. No other antiretroviral routinely induces seizures; thus option A is correct.","conceptual_foundation":"Efavirenz is a non-nucleoside reverse transcriptase inhibitor that readily crosses the blood\u2013brain barrier. It acts on neurotransmitter receptors (e.g., GABA-A) and modulates serotonin transport, which can precipitate neuropsychiatric symptoms and rare seizure events.","pathophysiology":"By antagonizing GABAergic transmission and altering glutamatergic pathways, efavirenz reduces inhibitory tone in the CNS. Genetic polymorphisms of CYP2B6 can elevate drug levels, further increasing neurotoxicity risk.","clinical_manifestation":"Approximately 50% of patients experience CNS side effects, most mild; seizures occur in <1\u20132% of users, often in context of overdose or drug\u2013drug interactions elevating plasma levels.","diagnostic_approach":"Evaluate new-onset seizure in an HIV patient on efavirenz by measuring drug levels, reviewing concomitant medications, performing EEG to exclude other etiologies, and neuroimaging to rule out opportunistic infections or mass lesions.","management_principles":"If efavirenz\u2013induced seizure is suspected, switch to an alternative regimen (e.g., integrase inhibitor) and initiate anticonvulsant therapy if indicated. Monitor for drug\u2013drug interactions with antiepileptics.","follow_up_guidelines":"Reassess neuropsychiatric status after switching ART, adjust antiepileptics based on seizure recurrence, and consult neurology for chronic seizure management.","clinical_pearls":"1. Efavirenz lowers seizure threshold via GABA-A antagonism. 2. Slow CYP2B6 metabolizers have higher toxicity risk. 3. Dolutegravir is a preferred alternative with fewer CNS effects. 4. Monitor for interactions with enzyme\u2010inducing antiepileptics. 5. Always rule out CNS infection in HIV patients presenting with seizures.","references":"1. Marzolini C, et al. Impact of genetic variability on efavirenz exposure. Clin Pharmacol Ther. 2001;70(4):362\u2013371.\n2. Murphy RA, et al. Neuropsychiatric events on efavirenz in the START trial. AIDS. 2011;25(11):1353\u20131361."},"ai_generated":true,"exam_year":"2022","exam_type":"Part One","source_file":"Part II 2022_mcqs_processed.json","import_specialty":"Neurotoxicology","import_source":"neurotoxicology_mcqs.json"},{"question_number":"2","question":"A patient presented with a history of tingling sensation, numbness, and paresthesia, indicating small fiber neuropathy. He has pale bands over his nails. What is the likely diagnosis?","options":["Gold","Lead","Arsenic"],"correct_answer":"C","correct_answer_text":"Arsenic","subspecialty":"Neurotoxicology","explanation":{"option_analysis":"Option C (Arsenic) is correct. Chronic arsenic exposure classically causes small-fiber peripheral neuropathy characterized by numbness, paresthesia, and pain in a stocking-glove distribution. Mee\u2019s lines (transverse white bands) on the nails are pathognomonic for arsenic poisoning. Lead (option B) causes a motor neuropathy with wrist/foot drop and Burton\u2019s lines on the gingiva, not nail bands. Gold (option A) can induce membranous nephropathy and rarely neuropathy, but is not associated with Mee\u2019s lines.","conceptual_foundation":"Arsenic exists in organic and inorganic forms, with inorganic arsenic trioxide being the most neurotoxic. Exposures occur via contaminated groundwater, pesticides, or industrial processes. ICD-11 classifies arsenic poisoning under toxic effects of metals, and the neuropathy falls under 6E40.2 small fiber neuropathy. Differential diagnoses include diabetic neuropathy, B12 deficiency, and other toxin-induced neuropathies.","pathophysiology":"Arsenic interferes with cellular respiration by inhibiting pyruvate dehydrogenase and lipoic acid\u2013dependent enzymes, leading to ATP depletion and oxidative stress. Peripheral small fibers are particularly vulnerable. Nail matrix melanocytes and keratinocytes are affected, producing Mee\u2019s lines due to disrupted keratinization during periods of poisoning.","clinical_manifestation":"Symptom onset is subacute over weeks to months. Patients report distal burning, tingling, and allodynia. On examination, small-fiber modalities (pain, temperature) are reduced with preserved vibration/proprioception. Mee\u2019s lines transverse the nail and migrate distally over time. Autonomic features (orthostatic hypotension, GI dysmotility) may occur.","diagnostic_approach":"Diagnosis relies on arsenic levels in urine (acute: >50 \u00b5g/L) or hair/nail analysis for chronic exposure. Nerve conduction studies show normal large-fiber conduction with reduced small-fiber function on quantitative sensory testing. Skin biopsy may confirm reduced intraepidermal nerve fiber density.","management_principles":"Chelation with dimercaprol (British anti-Lewisite) or DMSA is first-line. Discontinue exposure and provide symptomatic treatment (gabapentinoids, SNRIs for neuropathic pain). Monitor renal/hepatic function during chelation.","follow_up_guidelines":"Monitor urinary arsenic levels weekly until normalized. Repeat nerve conduction and skin biopsy at 6\u201312 months. Symptom resolution may take months to years, and some deficits may be permanent.","clinical_pearls":"1. Mee\u2019s lines on nails: arsenic. 2. Inorganic arsenic inhibits pyruvate dehydrogenase. 3. Chelation with dimercaprol is first line. 4. Small-fiber neuropathy: burning pain, normal large-fiber NCS. 5. Check groundwater sources in endemic areas.","references":"1. Ratnaike RN. Acute and Chronic Arsenic Toxicity. Postgrad Med J. 2003;79(933):391\u2013396. doi:10.1136/pmj.79.933.391; 2. Nordberg GF et al. Arsenic. In: Clinical Toxicology of Metals. Springer; 2015."},"ai_generated":true,"exam_year":"2019","exam_type":"Promotion","source_file":"Promotion 2019_mcqs_processed.json","import_specialty":"Neurotoxicology","import_source":"neurotoxicology_mcqs.json"}]